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1 Introduction 
1.1 Skin as an interface and immunological organ 
The skin is the largest organ at the interface between the environment and the host. 
Consequently, the skin has a central role in host defense1. It continuously encounters 
signals from the environment, which may act as triggers of inflammation. Different 
functional compartments of the skin translate these signals into immune responses, 
both of the innate and the adaptive immune system2. The skin displays not only a 
protective function as a physiological barrier, but it is also a site of initial recognition 
of foreign substances, where decisions about the induction or inhibition of an immune 
response take place3. The skin’s innate immune system consists of three main 
components: anatomical/physical barrier (stratum corneum), cellular (antigen 
presenting cells, keratinocytes, mast cells, and PMNs) and secretory elements 
(antimicrobial peptides (AMPs), cytokines, and chemokines)4. It is now clear that the 
most effective anti-microbial response involves a balance between the innate and 
adaptive immune system5. 
The role of immune function of the skin is crucial, as immune dysfunction is 
implicated in the pathogenesis of a large variety of inflammatory skin disorders, 
including atopic and allergic contact dermatitis6,7. 
1.1.1 Atopic dermatitis is an inflammatory skin disease 
Atopic dermatitis (AD) is a chronic inflammatory skin disease. It affects at least 15% 
of children and is characterized by cutaneous hyperreactivity to environmental 
triggers6,8. Various studies indicate that AD has a complex etiology, with activation of 
multiple immunologic and inflammatory pathways. Complex interactions among 
susceptibility genes, the host’s environment, defects in skin barrier function and 
systemic and local immunologic responses contribute to the pathogenesis of AD8.  As 
AD has increasing prevalence rates especially in western countries, a ‘‘hygiene 
hypothesis’’ has been generated. According to this hypothesis increased hygiene 
standards with less infectious diseases during early years contributes to the 
development of AD and other allergic diseases because of the absence of pivotal 
immune priming inducing immune tolerance9,10. Detailed characterization of AD 
inflammation reveals a biphasic cutaneous cytokine milieu with an initial recruitment 
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of IL-4-producing Th2 cells followed by a more mixed phenotype in the chronic 
phase11-13. 
The skin of most patients with AD is colonized with Staphylococcus aureus (S. 
aureus). S. aureus can be isolated from clinically affected and unaffected skin, and 
both acute and chronic AD lesions are colonized. Staphylococcal colonization density 
is significantly lower in healthy individuals than in patients with AD and bacterial 
counts on unaffected skin are lower than on affected skin14. Staphylococcus aureus 
colonization is regarded as one of the most important initiating and exacerbating 
factors in AD15,16.  
Patients with AD have an increased propensity toward cutaneous viral infections. 
Infections by herpes simplex virus (HSV) referred to as eczema herpeticum17. 
Epidemiological data suggest that AD patients with more severe disease and with 
greater Th2 polarity are at greatest risk for skin infections with HSV or S. aureus17,18. 
1.1.2 Staphylococcus aureus as a skin pathogen 
Staphylococcus aureus is a frequent pathogen on the human host, where it colonizes 
mucosal and dermal surfaces. S. aureus is able to cause a broad spectrum of 
infectious diseases from superficial cutaneous infections to the severe systemic 
sepsis19. S. aureus has a wide repertoire of virulence factors. For example, cell-
surface proteins (including protein A) that promote adhesion to damaged tissue and 
to the surface of host cells20, which is a prerequisite for colonization and disease. 
Virulence factors are crucial for development of staphylococcal infections, which 
make them important targets for the host immune system in order to generate 
immune responses. Some of the most important inducers of such immune responses 
are lipoproteins (Lpp). They belong to one of the major classes of cytoplasmic 
membrane-anchored proteins. Lpp are functionally important at the interface between 
the membrane and the cell wall. Many of them are part of ABC transporters. They are 
involved in nutrient uptake, in mediating antibiotic resistance and some of them have 
a role in protein folding21. One predominant staphylococcal Lpp is SitC22, which is the 
binding component of the staphylococcal iron transporter SitABC. In immunological 
competent individuals, innate immune responses limit the establishment of the 
infectious disease, providing a rapid defense. Keratinocytes, which comprise 90-95% 
of the total epidermal cell population, play a pivotal role for the first defence. In 
addition to their function in the maintenance of the keratin barrier, they produce vast 
repertoire of cytokines, chemokines and AMPs3. Even a simple skin disruption or an 
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ultraviolet insult can initiate production of cytokines by keratinocyte23. The cytokines 
and chemokines further shape the local microenvironment by attracting and 
activating other immune cells. Both, keratinocytes and professional phagocytes such 
macrophages, neutrophils and dendritic cells, recognize S. aureus19. This recognition 
is managed by the binding of the bacterial surface of S. aureus to so called pattern 
recognition receptors (PRRs) on immune cells.  
 
1.2 Pathogen associated molecular patterns (PAMPs) and pattern-
recognition receptors (PPRs) 
PRRs recognize highly conserved molecular patterns common to many classes of 
pathogens, known as pathogen associated molecular patterns (PAMP)24. PAMP are 
nucleic acids, lipids, lipoproteins, carbohydrates or peptidoglycans from bacteria, 
fungi or protozoa. PRRs are expressed constitutively by the host and they are 
germline-encoded. Both the epithelial barrier cells and resident innate immune cells 
in the skin express PRRs7,25. These innate responses occur rapidly and are efficient 
at killing pathogens, therefore limiting pathogen-derived tissue injury. Indeed, in the 
early hours after infection, activation of PRRs results in fast killing of pathogens either 
directly by the cells of innate immune system such as macrophages or indirectly by 
induction of proinflammatory responses mediated by the release of cytokines and 
chemokines. There are several classes of PRRs: Toll like receptors (TLRs), NOD-like 
receptors (NLRs) and RIG-I-like receptors (RLRs).  
1.2.1 Toll-Like Receptors  
Among PRRs, Toll-like receptors (TLRs) are a well characterized family with distinct 
recognition profiles26. TLR1–10 are the best characterized human PRRs. The 
recognition of PAMPs by TLRs occurs in various cell compartments, including the cell 
surface (TLR1, 2, 4–6, 10) and endosomes (TLR3, 7–9). The TLR family members 
are expressed on the cell membranes of innate immune cells (DCs, macrophages, 
natural killer cells) and of adaptive immunity cells (T and B cells) and of non-immune 
cells (epithelial and endothelial cells)27. This fact emphasizes their function across 
the entire spectrum of innate and adaptive immunity. TLRs are believed to function 
as homo- or hetero-dimers. Most TLRs transduce a signal through the intracellular 
adapter molecule called myeloid differentiation factor 88 (MyD88), activating NF-B 
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and other transcription factors, which results in the induction of pro-inflammatory 
cytokine genes28.  
TLR2 has emerged as a principle receptor for Gram-positive bacteria, especially S. 
aureus29 and it is now known that staphylococcal Lpp are the major ligands for 
TLR221,30. Purified native staphylococcal Lpp, including SitC, were shown to induce 
cytokines through the TLR2-MyD88 signaling pathway31. The use of S. aureus 
mutants deficient in maturation of lipoproteins (lgt) and improved Lpp purification 
methods show that TLR2 is activated by Lpp29,30. In vivo, different murine infection 
models showed that mice, deficient in TLR2, display increased susceptibility to 
staphylococcal infections with severe disease course, higher bacterial loads in tissue 
and/or reduced inflammation32,33. When compared to other TLRs, TLR2 recognizes a 
remarkably broad range of PAMPs. These include bacterial lipopeptides from Gram-
positive bacteria and lipoarabinomannan from mycobacteria. This high diversity of 
ligand recognition by TLR2 comes possibly from its unique ability to homodimerize as 
well as heterodimerize with TLR1 and TLR634.  
1.2.2 TLR2 heterodimers and ligands  
Ozinsky et al.35 were the first to show, that TLR2, unlike other TLRs, has to form 
heterodimers with TLR1 or TLR6, to be able to initiate cell activation. Studies using 
knockout mice identified TLR1 as the coreceptor required for the recognition of 
bacterial triacylated lipoproteins such as Pam3Cys36,37. Diacylated components such 
as lipoprotein FSL-1 and Pam2Cys interact with TLR2/TLR6 heterodimers38,39. Using 
fluorescence resonance energy transfer (FRET) in human primary monocytes, 
Triantafilou et al.34 have shown that, a small preexisting population of TLR2 
heterodimers increases rapidly upon ligand treatment. Additionally it was shown, that 
TLR2/6 ligand binding reduced the percentage of preformed TLR2/1 heterodimers 
but not vice versa. Employing lipid raft-disrupting agents40, it was demonstrated that 
TLR2 heterodimers translocate to lipid rafts, depending on their interactions with 
specific ligands. The functional properties of S. aureus lipopeptides have been 
investigated in different cell types39,41,42. But data concerning functional 
consequences of activated different TLR heterodimers in vivo are sparse.  
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1.3 The adaptive immune response requires innate immune 
recognition  
Recognition of PAMPs by TLRs and other pathogen receptors on skin cells initiates a 
signaling cascade, leading to activation of transcription factors activator protein (AP)-
1 and nuclear factor (NF)-B, which ultimately results in the production of pro-
inflammatory cytokines, chemokines, AMPs and inducible enzymes in the skin. AMPs 
and chemokines have several effects. They repel infection by direct killing of the 
pathogen. Beside this, they are chemotactic for phagocytes and dendritic cells (DCs). 
Activation of phagocytes leads to triggering of the respiratory burst and killing of 
engulfed organisms43. DCs are the most important antigen presenting cells (APCs). 
Activated DCs migrate to skin draining lymph nodes and present antigens, captured 
in the skin, to antigen-specific T cells. This triggers the activation and proliferation of 
T cells44,45. Beside this, DCs direct the immune phenotypes of T cells, determining T 
cell polarization to the different Th subtypes. CD4+ T cells are capable of 
differentiating into at least 4 distinct functional phenotypes: IFN- producing Th1 
cells, IL-4 producing Th2 cells, IL-17 producing Th17 cells, and inducible regulatory T 
cells (Treg), which inhibit immune responses46. During this process DC-derived 
cytokines play the most important role. The differentiation of CD4+ T cells into Th1 
depends on IL-12, IL-4 induces Th2, whereas IL-23 together with IL-1, IL-6 and with 
or without TGF- induce Th17 cells. Furthermore, IL-10 is important for the inducible 
suppressive Tregs47. Activated T cells acquire effector functions and become effector 
T cells (Teff). They express new homing receptors, which direct their migration into 
the tissue where the antigen was detected. Once in this location, Teff cells produce 
cytokines that activate local cells, among them other immunological cells to control or 
eliminate the foreign material48.  
1.4 Mechanisms to limit inflammation 
Overactivation of TLRs leads to the generation of strong pro-inflammatory signals 
with persistence of proinflammatory cytokines, such as TNF and IL-649. Probably 
the best known example of a dangerous inflammatory reaction during infection is the 
sepsis syndrome, in which generalized inflammation induced by overproduction of 
cytokines leads to hypotension, intravascular coagulation, multiple organ failure, 
which finally could lead to death50. Thus, mechanisms to terminate and limit 
cutaneous inflammation need to be effective. These regulatory feed-back 
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mechanisms involve induction of tolerogenic DCs, apoptosis of effector T cells, 
release of anti-inflammatory cytokines or activation of Treg cells51. In recent years 
Myeloid-derived suppressor cells (MDSCs) have been appreciated as one of the 
main cell populations responsible for regulatory immune responses, both adaptive 
and innate. 
1.4.1 Myeloid-derived suppressor cells  
MDSCs are a heterogeneous group of myeloid cells comprised of hematopoietic 
progenitor cells and precursors of macrophages, DCs and granulocytes52. In mice, 
MDSCs express both the myeloid lineage differentiation antigens Gr-1 (Ly6G and 
Ly6C) and M integrin CD11b. In recent years several other markers have been used 
to describe specific subsets of these cells. Many MDSCs in tumor bearing mice 
coexpressed CD115 and CD12453. Macrophage marker F4/8054 and costimulatory 
molecule CD8055 have also been described on some subsets of MDSCs. 
MDSCs were originally described as a population of cells that accumulates in the 
blood and lymphoid organs of tumor-bearing mice52. Expansion of MDSCs has been 
detected in almost all tumor models. However, MDSCs have been shown to regulate 
immune responses during other pathological situations including bacterial and 
parasitic infection, autoimmune pathologies and inflammation. An expansion of 
MDSCs was observed during infections with different microorganisms, such as 
Salmonella typhimurium56, Trypanosoma cruzi57, Candida albicans58 or Toxoplasma 
gondii59. During a polymicrobial sepsis, MDSCs can induce the suppression and Th2-
polarization of the T cell response. Among others, this activation of MDSCs is based 
on MyD88, an adaptor protein on different TLRs60. The induction of MDSCs during 
chronic inflammation is dependent on secretion of different interleukins like IL-161 
and IL-662. 
A common feature for MDSCs is their high potential to suppress T cell responses. 
MDSCs from tumor-bearing animals have been shown to suppress CD8+ cells63. 
Multiple mechanisms could be involved in this process. T cell apoptosis is one such 
mechanism64. MDSCs can cause immune suppression through inhibition of activation 
of T cells65. This can be achieved by TCR  chain downregulation66,67 or by induction 
of peripheral tolerance63 or by changes in the pattern of cytokines secreted by T 
cells68. In most cases, the effective suppression requires close cell-cell-contact68. 
This suggests that the involved cells interact either through membrane-bound 
molecules and/or through the release of rapidly degradable soluble mediators.  
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Nitric oxide (NO) is one of the main suppressive factors produced by MDSCs68. Many 
experimental settings show that T cell suppression by MDSCs depends on NO57,69,70. 
The inducible NO-synthase (iNOS) and arginase can generate NO from the amino 
acid L-arginine. The inhibition of iNOS and arginase abolished suppression by 
MDSCs. The generation of NO by MDSCs also needs cell-cell-contact70. NO is 
known to block the IL-2 signal transduction cascade in T cells71. Apoptosis of T cells 
induced by NO was also described72. Nagaraj et al. demonstrated a nitration of TCR 
leading to anergy as one mechanisms of CD8+ T cell suppression by MDSCs73. 
Despite recent progress, the precise function of MDSCs in the context of 
inflammation and the mechanisms of MDSCs induction are not well-understood. 
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1.5 Aim of the thesis 
The skin harbors an active immune network playing a crucial role in host defense and 
in shaping immune responses. The aim of this work was to investigate how the 
constant interaction of the skin with bacteria impairs the immune system. In particular 
it was important to dissect the functional consequences of TLR2 activation in the 
skin. Using various in vivo mouse models of cutaneous inflammation we mimicked 
different immunological situations. Cutaneous application of bacterial substances, 
bacterial lysates or living bacteria was used to imitate the contact between the skin 
and microorganisms. Investigation of AD patients, where this intense interaction of 
bacterial substances and the cutaneous immune networks is part of disease 
pathogenesis, further completed this study, providing clinical data.  
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2 Results 
2.1 TLR2 ligands enhance Th2-mediated dermatitis 
To investigate the impact of TLR2 ligands on AD inflammation in the early phase of 
AD was the aim of S. Kaesler in her work “TLR2 ligands promote chronic atopic 
dermatitis through IL-4 mediated suppression of IL-10”. For this purpose a 
mouse model for acute AD inflammation was established. OVA-specific Th2 cells 
were adoptively transferred and activated in the skin of naive mice. In this model ear 
swelling correlates with antigen specific inflammation. Using IL4-/- cells and mice 
Kaesler et al. have shown that Th2-cell mediated dermatitis was dependent on IL-4, 
which is known as a dominant cytokine of human AD in the early phase of 
inflammation13,74. It is also known that S. aureus is a dominant trigger of AD15,16. 
Lipoproteins and lipoteichoic acid (LTA) were shown to be predominant 
staphylococcal TLR2 ligands30,75. Moreover, Travers et al demonstrated a correlation 
between the amount of LTA in AD lesions and AD aggravation75. Using LTA together 
with the lipoprotein Pam2 in the adoptive transfer experiments, the activation of TLR2 
in combination with IL-4 enhanced and sustained cutaneous inflammation. These 
data suggest that in the early phase of AD, where Th2-mediated inflammation 
predominates, TLR2 ligands (from pathogenic S. aureus) cause a transformation of 
the cutaneous inflammation from a transient into a chronic, persistent form.  
By experiments, where WT or Tlr2-/- Th2 cells were adoptively transferred into either 
WT or Tlr2-/- mice  Kaesler et al. have found that this enhancement of dermatitis was 
independent of TLR2 on T cells. This indicates that the predominant target cells of 
pro-inflammatory TLR2 signals are skin resident cells, most likely DCs, because 
these cells are the most important APC in the skin. Searching for the underlying 
mechanism Kaesler et al. discovered that the concerted activation of TLR2 and IL-4-
receptor on innate immune sentinels potently suppressed IL-10. IL-10 is the most 
important anti-inflammatory cytokine with immunomodulatory properties76. So we 
suggest that IL-10 suppression exacerbates Th2-mediated dermatitis and initiates the 
chronic phase of persistent inflammation.  
Taken together, these data show that TLR2 activation on skin resident cells 
aggravates cutaneous inflammation through the binding of ligands from pathogen 
bacteria. 
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2.2 Non-pathogenic bacteria alleviate cutaneous inflammation 
The skin is constantly colonized with bacteria, but detectable inflammation is rare in 
healthy individuals. This indicates that there must be mechanisms, which inhibit 
harmful inflammation. A recent double blind placebo controlled clinical trial, 
performed by the Department of Dermatology of the University of Tübingen, has 
given a hint about a possible mechanism. It demonstrated that the non-pathogenic 
microbe Vitreoscilla filiformis (Vf) abrogated cutaneous inflammation in AD patients 
when directly applied onto patients´ skin77. The aim of the study of T. Volz et al. 
“Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-
10-producing dendritic cells and regulatory Tr1 cells” was to investigate the 
underlying molecular mechanism of this inhibition. For our in vivo experiments we 
first utilized a mouse model of AD, in which mice of the NC/Nga strain were 
sensitized to the allergen and hapten fluorescein isothiocyanate (FITC). NC/Nga mice 
are a specific strain that has been shown to develop AD-like skin lesions and clinical 
features most closely resembling human AD78. In this model ear swelling also 
correlates with antigen specific inflammation. The addition of Vf lysate during several 
episodes of allergen contact showed significantly reduced ear swelling after allergen 
challenge, indicating a reduction of skin inflammation. Ex vivo antigen specific 
stimulation of draining lymph node revealed a reduction in T cell proliferation in Vf-
treated mice. Consistently, FITC-specific IFN- production by T cells, which is the 
hallmark cytokine of chronic AD13,74 was also significantly reduced. Beside this, only 
T cells from mice previously exposed to Vf displayed antigen specific production of 
IL-10, whereas control mice failed to do so. IL-10 is the most important anti-
inflammatory cytokine with multifunctional properties depending on cell types and 
settings76. It was known that IL-10 production by DCs contributes to the induction of 
tolerance79. In vitro investigations, conducted by T. Volz, further dissected the 
mechanism of this immune inhibition: Vf signals induced high levels of IL-10 and 
reduced the production of IL-12p70 in human and mouse DCs. Experiments with DC-
T cell co-cultures demonstrated that these IL-10+ DCs induced IL-10+ Treg cells, 
which efficiently suppressed effector T cells. Investigations of innate immune 
pathways, activated by Vf, revealed that IL-10 production by DCs was completely 
dependent on TLR2.  
Thus non-pathogenic bacteria could induce tolerogenic immune responses to resist 
the harmful inflammation. One may speculate that in the absence of a balance 
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between signals of non-pathogenic and pathogenic bacteria inflammation is induced 
due to functional dominance of signals of pathogenic bacteria. This situation could be 
true for inflammatory skin diseases such as AD.  
2.3 Staphylococcus aureus-derived lipoteichoic acid suppresses T 
cells 
As described before, Kaesler et al. found the aggravation of cutaneous inflammation 
by TLR2 ligand LTA. Interestingly, in another model of cutaneous inflammation we 
observed an opposite effect. In the model of contact hypersensitivity (CHS) to the 
weak hapten FITC, Chen et al. mimicked FITC-induced and T cell-mediated mild 
cutaneous inflammation described in the work “Staphylococcus aureus-derived 
lipoteichoic acid induces temporary T cell paralysis independent of TLR2”. The 
cutaneous inflammation of this mouse model resembles the immune situation in non-
lesional skin of AD patients. To our surprise, and in contrast to the work of S. 
Kaesler, additional exposure to LTA did not significantly amplify ear swelling. 
Therefore we investigated the dynamics of T cell cytokine expression in FITC CHS. 
Upon exposure to LTA, cutaneous IL-4 and IFN- mRNA expression was 
suppressed. Moreover, ex vivo T cell proliferation of draining lymph nodes was 
strongly inhibited. This indicated a possible direct effect of LTA on T cells. Therefore 
the properties of LTA were then further investigated in vitro in respect of their impact 
on T cell proliferation. We found that, in contrast to Pam2, LTA treatment led to 
significant suppression of T cell proliferation in vitro. This suppression was 
independent of the mode of T cell activation (antigen specific activation, unspecific 
activation by anti-CD3/28, activation by mitogen as PMA/Iono, activation by 
superantigen as SEB) and this suppression was found in both, mouse and human, T 
cells. Further experiments revealed that the LTA-exposed T cells were still viable and 
that the effect was not mediated by apoptosis. Moreover, the T cells remained fully 
responsive to subsequent stimulation. Interestingly, the effect was independent of 
TLR2 signaling.  
So we found two opposing functions of LTA: Kaesler et al. showed an aggravation of 
inflammation due to LTA (pro-inflammatory effect); in contrast, the work of K. Chen 
showed clearly that LTA suppress T cell proliferation (anti-inflammatory effect). 
Therefore in the next two experiments we wanted clarify the conditions, under which 
these effects could be relevant in vivo. To investigate the effect of LTA on T cells in 
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vivo, we needed a model with increased frequency of antigen-specific activated 
(effector) T cells. This was achieved by using donors for FITC specific T cells. Mice 
serving as donors were sensitized with FITC and draining lymph nodes and spleens 
of these mice were isolated. CD3+ T cells were then sorted and transferred into 
recipient mice, which were previously sensitized with FITC. The next day recipients 
were challenged with FITC or vehicle control and exposed to either LTA or PBS in 
addition. Interestingly, when challenged with vehicle only, in the absence of antigen, 
LTA elicited an ear swelling response, indicating direct pro-inflammatory effects of 
LTA. However, in the presence of antigen and T cell activation, LTA significantly 
reduced cutaneous inflammation (anti-inflammatory effect), possibly through direct 
inhibition of T cells.  
These data indicate that LTA may function as a TLR2 ligand on skin resident cells, 
activating the innate immune system and leading to inflammation. In contrast, LTA 
suppresses T cell proliferation directly in a TLR2 independent manner. So we further 
hypothesize that an early innate response is mediated by pathogen recognition 
receptors and results in inflammation in order to fight bacteria quickly. Whereas 
during the later immune responses, where the T cell-mediated immune response 
evolves, inflammation could be harmful and should be terminated, for example by 
LTA which controls T cell activation. The latter is transient to avoid prolonged periods 
of immune suppression. 
2.4 Cutaneous sensing of TLR2/6 ligands suppresses T cell 
immunity 
2.4.1 Cutaneous exposure to TLR2/6 but not to TLR2/1 ligands 
ameliorates T cell-mediated recall responses  
Further investigations of the role of TLR2/6 versus TLR2/1 ligands in immune 
response and in cutaneous immunity was one of the goals of the work of Skabytska 
et al. in “Cutaneous innate immune sensing of TLR2/6 ligands suppresses T 
cell immunity by inducing myeloid-derived suppressor cells”. In this work 
human AD and murine models were used to investigate the immune consequences 
of a cutaneous encounter with dominant PAMPs of Gram-positive bacteria. To 
investigate T cell-mediated cutaneous inflammation we used a mouse model of 
contact hypersensitivity to FITC. Mice were sensitized with FITC, and one week later, 
the subsequent encounter with FITC was complemented by cutaneous application of 
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the lipopeptide Pam2. The functional consequences of the combined antigen and 
Pam2 encounter were evaluated 5 days later by applying FITC to the ear’s skin. In 
FITC-sensitized control mice, the peak of T cell mediated CHS was determined by 
ear swelling thereafter. In contrast to our expectations, previous cutaneous exposure 
to the TLR2/6 ligands Pam2 and FSL-1 did not enhance, but almost completely 
abrogated FITC CHS and FITC-specific ex vivo T cell proliferation. Interestingly, and 
in contrast to Pam2, the TLR2/TLR1 ligand Pam3 failed to suppress FITC CHS and T 
cell proliferation. Next we wanted to know, whether bacterial lipopeptides from 
pathologically relevant bacteria have the same consequence for immune responses. 
Therefore we established a mouse model of epicutaneous bacterial colonization in 
the work of Wanke at al. “Staphylococcus aureus skin colonization is promoted 
by barrier disruption and leads to local inflammation“. This model is especially 
well suited for investigations of the natural route of skin colonization. In this mouse 
model the bacteria are not needed to be injected sub- or intra-cutaneously into the 
skin, but are applied onto the skin epicutaneously which resembles the natural way of 
skin infection. The integrity of the skin was previously affected by skin barrier 
disruption due to tape-stripping. This is also similar to the situation in AD, which is 
characterized by skin barrier defects6,80. The wild type (WT) mice were shaved and 
the skin was disrupted by tape-stripping of different strength (mild and strong), which 
however did not create wounds of the skin (confirmed by histological analysis). Living 
S. aureus bacteria were added to filter paper discs, placed onto the skin, and 
covered by Finn Chambers on Scanpor. Then the fixation was done by a stretch 
plaster. After overnight occlusion, Finn Chambers and plasters were removed to 
allow the mice to clean the skin and to ensure that the observed bacteria colonize the 
skin and are not only present on the skin surface. The analysis of colony-forming 
units (CFU) thereafter revealed that bacteria persist on the skin during at least 6 days 
(the longest observation time) and that the infection efficiency and the persistence of 
S. aureus was significantly higher in strongly tape stripped skin, compared to non- or 
mildly tape stripped skin. This suggests that epithelial barrier defects facilitate 
cutaneous S. aureus colonization, which is in accordance to further AD studies80. We 
also found an indication of enhanced cutaneous inflammation at the sites of S. 
aureus colonization: RT-PCR analysis of the infected skin revealed a significant 
elevation of all investigated cytokines (IL-1, IL-6, TNF-, IFN-) and induction of 
antimicrobial peptide (AMP) expression in comparison to non-infected skin. This 
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indicates that S. aureus application and persistence on barrier-disrupted skin induces 
an inflammatory cytokine response and that our model is suitable for investigation of 
cutaneous inflammation following bacterial colonization. Next we combined this 
model with the FITC CHS model to investigate whether living S. aureus on the skin 
also cause immune suppression. To clarify the role of lipoproteins in this process we 
additionally used lipoprotein-deficient S. aureus mutant (lgt) bacteria. Bacteria were 
applied during FITC re-exposure of FITC-sensitized mice. Similar to the TLR2/6 
ligands, wt bacteria, but not lipoprotein-deficient S. aureus caused immune 
suppression.  
These data show for the first time that cutaneous exposure to bacterial TLR2/TLR6 
ligands is sufficient to cause systemic immune suppression. 
2.4.2 Skin infection-induced immune suppression is mediated by 
Gr1+CD11b+ myeloid-derived suppressor cells 
Investigating the cells which could mediate the immune suppression following 
cutaneous TLR2/6 ligands exposure, we found a strong increase of splenic 
Gr1+CD11b+ cells only in these experimental conditions. Immature Gr1+CD11b+ cells 
are known as myeloid-derived suppressor cells (MDSCs) because of their ability to 
suppress T cell activation. Indeed, FITC specific ex vivo T cell proliferation was 
impaired in animals previously exposed to TLR2/6 ligands. We next investigated 
patients with AD as a model for massive cutaneous innate sensing of Gram-positive 
bacteria. In humans, MDSCs are typically described as CD11b+CD33+HLA-DR-CD14- 
cells52. Compared to healthy donors we observed a significant increase of MDSCs in 
the peripheral blood. Importantly, the upregulation of human MDSCs in peripheral 
blood was very impressive in patients with severe dermatitis and eczema herpeticum, 
which is a severe cutaneous viral infection resulting from immune suppression.  
In FITC CHS, T cells migrate to the skin and elicit FITC specific dermatitis. Therefore, 
we wondered whether MDSCs were also recruited to the skin. Indeed, 8 h after FITC 
application Gr1+CD11b+ cells were significantly increased in the skin of mice exposed 
to Pam2. Similarly, we investigated infected human skin and found a significant 
increase of MDSCs in AD in comparison to healthy skin, indicating that bacterial 
colonization and subsequent skin inflammation induces MDSCs accumulation in the 
skin also in humans.  
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2.4.3 Suppression of T cell activation by MDSCs induced by cutaneous 
innate immune sensing 
Recruitment of MDSCs to the skin suggested a MDSC-mediated suppression of T 
cell activation in the skin in vivo. Indeed, FACS-analysis of ear skin tissue following 
the final FITC-exposure revealed a significant decrease of CD3+ T cells and IFN--
production following Pam2 exposure. To better explore, how this MDSCs induced 
immune suppression is mediated, we isolated MDSCs 10 days after Pam2 exposure. 
MDSCs are known to be a very heterogeneous cell population with at least two cell 
subpopulations with different suppressive properties53,81,82. Monocytic Ly6C+ MDSCs 
have been described as more suppressive compared to granulocytic Ly6G+ 
MDSCs53,83. Therefore we isolated these two MDSCs populations and co-cultured 
them with naïve splenocytes at different ratios to prove their suppressive activity. 
Naïve splenocytes were activated with anti-CD3/CD28 and their proliferation was 
analyzed. Following co-culture with Ly6C+ MDSCs at a ratio of 2:1, almost complete 
suppression of T cell proliferation was observed, while Ly6G+ cells from our model 
were not suppressive. MDSCs´ immunosuppressive activity was reported to be a 
result of the activation of inducible NOS (iNOS) and arginase 1, leading to L-arginine 
depletion and increased production of NO68. Indeed, Ly6C+ MDSCs from Pam2-
exposed animals produced high levels of NO. NO production and T cell suppression 
by Ly6C+ MDSCs was completely abrogated in a transwell experiment, indicating that 
physical contact of MDSCs with T cells as it is likely happening in the skin and MDSC 
activation by T cells is a prerequisite for MDSC´s NO production and MDSC-
mediated immune suppression. To collect further evidence, we investigated PBMCs 
of AD patients and were able to detect a distinct iNOS+ population of CD11b+CD11c- 
cells which most likely are NO producing MDSCs. These cells were completely 
absent in healthy individuals. Moreover, using three color fluorescence 
immunohistology in AD skin samples, we also detected iNOS+CD11b+CD11c- cells. 
To investigate the evidence of MDSCs mediated immune suppression in humans, we 
then analyzed peripheral blood of AD patients and found T cell receptor  chain 
significantly down-regulated, which is known to be a general characteristic of immune 
suppression and one of the major features of MDSC-mediated T cell inhibition66,67. To 
further investigate whether human MDSCs were suppressive, we depleted CD11b+ 
cells from PBMCs and analyzed proliferation of T cells. In almost all healthy 
volunteers (7 of 8) CD11b depletion resulted in reduced T cell proliferation, on 
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contrary, this was only observed in one out of 7 AD patients. This finding 
demonstrates that MDSCs, which are present among the CD11b+ population in AD 
patients but not in healthy individuals, are immunosuppressive.  
These data, together with the findings of increased numbers of MDSCs in AD skin 
and elevated T cell proliferation following MDSCs depletion, indicate that MDSCs are 
not only increased in AD blood and skin, but also exert their suppressive activity 
allowing e.g. herpes viruses to spread. 
 
2.4.4 Pam2-induced immune suppression is dependent on cutaneous 
TLR2  
Since our data showed that cutaneously induced MDSCs are potent suppressors of T 
cell mediated immune responses, it was of major interest, to explore how innate 
immune sensing in the skin initiates MDSCs. Therefore, we next determined the role 
of TLR2. Tlr2-/- and wild type mice were treated with or without cutaneous Pam2 
exposure. Previous Pam2 exposure inhibited FITC CHS in wt mice. Conversely, 
Pam2 exposure in Tlr2-/- mice failed to inhibit FITC-specific CHS and T cell 
proliferation. Accordingly, MDSCs accumulation and systemic reduction of T cells 
was not detectable in Tlr2-/- mice previously exposed to Pam2. Cutaneous innate 
immune sensing through TLR2 may act through resident skin cells or recruited 
immune cells. Thus, mouse chimeras were generated to distinguish if TLR2 sensing 
is managed by skin resident or by recruited hematopoietic cells. Wild type mice 
reconstituted with wild type bone marrow (BM) (WT + WT-BM) and wild type mice 
that obtained Tlr2-/- BM (WT + Tlr2-/---BM) upregulated MDSCs following Pam2 
exposure. In contrast, Tlr2-/-- mice reconstituted with WT-BM (Tlr2-/- + WT-BM) failed 
to accumulate MDSCs, similar to control Tlr2-/-- mice with Tlr2-/-- BM (Tlr2-/-- + Tlr2-/--
BM). Thus, TLR2 expression on skin resident cells is necessary and sufficient for 
accumulation of MDSCs.  
2.4.5 IL-6 is required for Pam2-induced immune suppression 
Our previous experiments have shown that cutaneous Pam2 sensing through TLR2 
is sufficient to induce MDSCs and consecutive suppression of cutaneous recall 
responses. To identify the underlying mechanisms, we analyzed cutaneous mRNA 
expression following the application of FITC with or without Pam2 or Pam3 in 
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sensitized mice. Interestingly, both Pam2 and Pam3 unequivocally and moderately 
upregulated TNF and CXCL2 mRNA compared to FITC-only treated mice. Strikingly, 
upregulation of IL-6 mRNA in the skin was most pronounced following Pam2 
exposure. In comparison with skin following FITC-only or FITC-plus-Pam3 exposure, 
cutaneous Pam2 exposure induced a 400-fold upregulation of IL-6 mRNA. To 
regulate MDSC induction in the bone marrow, cutaneous IL-6 must reach the blood 
stream. Indeed, IL-6 concentrations in mouse sera strongly increased one day after 
cutaneous Pam2 exposure. These data suggest that IL-6 plays a crucial role in Pam2 
induced MDSC induction; therefore, IL6-/- mice were investigated. In contrast to WT 
mice, cutaneous Pam2 exposure in IL6-/- mice failed to reduce FITC-specific CHS, 
and no induction of MDSCs could be detected.  
Taken together, these data suggest a scenario in which Pam2 is sensed by TLR2 on 
skin-resident cells, leading to the expression and secretion of IL-6 in such high 
amounts that MDSCs expand and accumulate, causing systemic immune 
suppression, which leads to the inhibition of cutaneous recall responses. 
2.5 IL-4 abrogates T cell-mediated inflammation by the silencing of 
IL-23 
IL-4 is another pleiotropic cytokine, similar to IL-6. In the work described above, 
Kaesler et al. have found that IL-4 is a key cytokine for AD aggravation. On the other 
hand, Ghoreshi et al. has shown an improvement of cutaneous inflammation in 
humans in another skin disease (psoriasis) by IL-4 therapy84. This indicates a 
complex way of IL-4 function and its interaction with other cytokines in vivo. Recently 
it has become evident, that IL-17 is a key cytokine in the pathogenesis of 
psoriasis85,86. Therefore the hypothesis of the work of Guenova et al. “IL-4 
abrogates Th17 cell-mediated inflammation by selective silencing of IL-23 in 
antigen-presenting cells” was to ask, if IL-4 could affect IL-17 directly or indirectly 
for example by targeting the polarization of T cells. DCs and their cytokines 
determine the quality of an immune response45. In particular, they direct the 
phenotype of T cells87. In vitro experiments with DCs of E. Guenova have given a 
hint about the mechanism of IL-4-mediated suppression of T cell-mediated 
inflammation. They have shown that addition of IL-4 to different human DCs cultures 
caused a strong reduction of IL-23 with simultaneous induction of IL12p70, which 
was visible on RNA level as well as on protein level. IL-23 is crucial for the 
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polarization and maintenance of Th17 cells. Consequently the subsequent DC-T cell 
coculture revealed that IL-4 treated DCs failed to induce IL-17 producing Th17 cells. 
Instead, CD4+ T cells developed a highly polarized Th1 phenotype with high IFN- 
production. The analysis of human skin by histological staining and RT-PCR has 
detected a significant enhancement of both IL-23 and IL-17 in psoriatic skin. 
Consistent with in vitro data, the IL-4 therapy caused dose-dependent reduction of 
these cytokines. Simultaneously, IL-12 was induced. These data indicate that IL-4 
affected DCs change by re-programming their phenotype to low IL-23 and high IL-12 
producers with a reduction of Th17 cells as a consequence. These in vitro data had 
to be proven in an in vivo mouse model. We used the 2,4,6-trinitrochlorobenzene 
(TNCB)-induced delayed type hypersensitivity reaction (DTHR), a suitable model for 
investigation of IL-17-mediated cutaneous inflammation. Systemic administration of 
IL-4 to TNCB-sensitized mice reduced cutaneous inflammation (detected as ear 
swelling). An RT-PCR analysis of the inflamed tissue, following the IL-4 therapy, 
showed a strong reduction of IL23A and of IL17A in the ear tissues of mice 
challenged with TNCB. To directly test whether IL-4 prevented inflammation and the 
related DTHR primarily by suppressing IL-23, we treated sensitized mice with IL-4 
during a TNCB challenge, and one group of IL-4-treated mice was treated with 
recombinant mouse IL-23. The IL-4 therapy severely suppressed IL-23 levels and the 
DTHR almost to background levels. In sharp contrast, replacing the missing IL-23 
fully restored the cutaneous DTHR. 
The in vitro DC data and the results of the human study strongly suggested that DCs 
are the key cells, which are affected by IL-4. But we could not exclude that IL-4 also 
targets other cell types (for example T cells) in vivo. To find the mechanism of IL-4-
mediated immune regulation in vivo, we generated bone marrow (BM) chimeric mice, 
in which IL-4 signaling is selectively blocked in either T cells or DCs. We generated 
BM chimeric mice with hematopoietic cells consisting of Stat6-/- and T cell-/-cell mix 
(Stat6-/-/T cell-deficient mice). STAT6 is an important molecule for the IL-4R signaling 
pathway; therefore STAT6-deficient mice could be considered as IL-4 signaling 
deficient88. After transplantation those chimeric mice only harbored T cells that are 
deficient of STAT6 and therefore unresponsive to IL-4 therapy. When challenging the 
sensitized chimeric mice, we observed a comparable ear swelling in all the chimeric 
mice. This demonstrates that the beneficial effect of IL-4 in cutaneous inflammation is 
not mediated by T cells, but rather by DCs. To prove this, we generated BM chimeric 
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mice with hematopoietic Stat6-/-/MhcII-/- cell mix (Stat6-/-/MhcII-/- mice). Those mice 
have STAT6 negative DCs (MHC-II+), in which IL-4 signaling is impaired, whereas 
the STAT6+ T cells remained responsive to IL-4. When we treated the Stat6-/-/MhcII-/-  
mice with IL-4 during the challenge phase, cutaneous inflammation was significantly 
reduced to the levels comparable to non-treated mice. These data thus indicate that 
the anti-inflammatory effect of IL-4 is directly mediated via DCs and not by T cells. 
Taken together, the data of this study show that IL-4 inhibits inflammation by 
suppressing the capacity of DCs to produce IL-23. Depleted IL-23 levels then cause 
lower numbers of Th17 cells, which leads to increased skin inflammation and induce 
tissue damage in psoriasis. 
 
In conclusion, we identified that cutaneous TLR2 signaling has multifunctional 
consequences on skin immunity and systemic immune responses. TLR2 activation 
can cause both, an amplification of cutaneous inflammation and an immune 
suppression due to induction of IL-10 production, of regulatory T cells and of myeloid 
derived suppressor cells, which finally leads to suppression of dermatitis. In addition 
we identified how IL-4 regulates immune responses on the level of DCs. 
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3 Discussion 
The central aim of this work was to investigate the consequences of cutaneous TLR2 
activation. We have not found one definitive answer to this very complex question. 
Our data suggest that TLR2 ligands can both induce and aggravate inflammation, but 
also that innate immune sensing of TLR2 ligands can cause opposite effects of 
immune suppression or even tolerance. It seems to depend on the particular immune 
situation, the immune phase and the strength of cutaneous inflammation, the 
combination with cytokines, the cell types activating and interacting and many other 
yet unknown factors. Therefore we used different in vivo and in vitro models to mimic 
various immune situations. These experimental settings were necessary to dissect 
the wide consequences of interactions between the host and microorganisms on the 
skin interface. 
3.1 TLR2 signaling causes aggravation or alleviation of AD 
S. aureus has been suggested as one important AD trigger and TLR2 ligands, 
lipoproteins and LTA, are its predominant components16,75. The work of S. Kaesler et 
al. confirmed this hypothesis and demonstrated how the aggravation of cutaneous 
inflammation due to S. aureus occurs: the combination of the early AD cytokine IL-4 
and activation of TLR2 on skin resident cells caused an inhibition of anti-inflammatory 
IL-10 and consequently the aggravation and chronification of AD. Interestingly and 
intriguingly T. Volz et al. found that TLR2-dependent activation of DCs by 
components of non-pathogenic microbe Vitreoscilla filiformis resulted in an opposite 
effect. In this context IL-10 is not suppressed but induced and serves as key cytokine 
in alleviating cutaneous inflammation. Both effects are confirmed by clinical studies 
with AD patients. Staphylococcal TLR2 in AD lesions have been shown to correlate 
with AD severity75. The beneficial effect of non-pathogenic bacteria is well-known9,10 
and cutaneous applicated Vitreoscilla filiformis has been found to ameliorate AD77. 
Thus, what makes the difference? The first obvious difference of these two studies is 
the pathogenicity of the investigated bacteria. It is known that non-pathogenic 
bacteria induce tolerance10,89 and some bacteria have evolved tolerance induction as 
evasion strategy90,91. But it is still enigmatic how the same innate signaling via TLR2 
results in even opposing immune consequences. As, in a complex, physiological, 
immune situation, the innate immune system does not only recognize one single 
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TLR2 ligand, but it is rather a constellation of sensing via multiple PPRs, i.e., LPS 
and TLR4, RNA and TLR3, CpG DNA motifs and TLR9, etc. and thus their 
combination may be determining the outcome. It should also not be excluded that 
xenogeneic signals (delivered through a currently undefined mechanism) might 
synergize with microbial exposure for these effects. Another explanation could be 
that the strength of the innate immune signaling plays a role. A constant mild 
inflammation could be interpreted from the host immune system as a stimulus to 
counteract, similar to the phenomenon of T cell anergy due to a low affinity antigen.  
The other difference between these two works is the immune situation investigated. 
S. Kaesler et al. analyzed an early AD phase with predominant IL-4, whereas the 
subject of T. Volz` work is rather advanced cutaneous inflammation, where IFN- is a 
key cytokine. Thus, the interaction of different cytokines with TLR2 ligands during 
immune sensing could represent another level of immune regulation.  
Overall, these data suggest that the imbalance of non-pathogenic and pathogenic 
bacteria on AD skin contributes to skin inflammation. Non-pathogenic 
microorganisms tend to induce tolerance in healthy skin, thus avoiding harmful 
inflammation.  
3.2 Lipoteichoic acid has opposing immunological functions  
Interestingly, we identified one substance which displays opposing immunological 
functions depending on the target cell type. As described above, S. Kaesler et al. 
showed pro-inflammatory function of LTA on APCs, most likely on DCs. The anti-
inflammatory function of this substance was shown by K. Chen et al. who 
investigated the function of LTA on T cells. T cells are the dominant cells in the 
adaptive immune system and they mediate cutaneous inflammation in the later phase 
of defense against bacteria19. Unexpectedly K. Chen found that LTA suppressed T 
cell proliferation is independent of TLR2. A similar function of LTA was shown in 
platelets where it inhibited platelet aggregation92 It has also been reported that 
bacterial components from S. aureus inhibited fibroblast proliferation in vitro93 and 
one in vivo study also reported inhibitory properties of LTA94. Several non-pathogenic 
microorganisms such as Staphylococcus epidermidis also contain LTA. Therefore the 
anti-inflammatory function of LTA could be explained as an evasion mechanism 
evolved by pathogens during the evolution. In addition, our in vivo experiments 
suggested another possible explanation for LTA functions. We hypothesize that in 
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the early phase of inflammation sensing of LTA by the innate immune system is 
beneficial to the host, acting pro-inflammatory to fight the bacterial invasion. In the 
later stage, where the inflammation is rather harmful, LTA acts on T cells as an anti-
inflammatory agent, helping to terminate ongoing immune responses. 
 
3.3 TLR2 heterodimers show functional differences 
As mentioned before, the immune responses to microorganisms are very divers and 
complex, partially because of the presence of a large variety of PAMPs. In the work 
of Skabytska et al. we have taken advantages of some microbial derived molecules, 
which are exclusively bound by one specific TLR2 heterodimer. The result of this 
work is, that different TLR2 heterodimers differ in their immunological functions in 
vivo. Cutaneous exposure to TLR2/TLR6 but not TLR2/TLR1 ligands induced 
systemic immune suppression. With these data we have shown for the first time such 
distinct functional differences for ligands of the two TLR2 heterodimers in vivo. This 
suggests that the presence of certain TLR ligands, the ratio of different TLRs within a 
cell or a possible interaction between TLR2 and TLR1 or TLR6 defines the nature of 
consecutive immune responses. Variety of receptor specificity achieved by 
combination of different TLR receptors could be beneficial to the host cell, as, the 
structure of bacterial Lpp is not constant in each bacterium. It was shown recently, 
that the degree of Lpp-acylation depends on environmental factors and growth 
phase. Lipoprotein SitC was triacylated when S. aureus was in the exponential 
growth phase at neutral pH and diacylated in the post exponential phase at low pH95. 
At the situation on the skin, where pH is low and chronic S. aureus colonization 
(which is almost always found in AD) is present, a post exponential growth phase of 
S. aureus can be assumed. Consequently, Lpp from S. aureus on the skin are more 
diacylated. Based on our data, we hypothesize that diacylation of Lpp could have 
immune suppressive effects as a consequence. Further, one can also assume that 
pathogenic and non-pathogenic skin microflora may have different acylation 
properties and therefore different compositions of TLR2 ligands and thus overall differ 
in their immune consequences.  
Our data further create a more detailed understanding about mechanisms functional 
in MDSC induction driven by infections. Signaling through MyD88 was described to 
be required for the complete expansion of MDSCs, however the exact cascade of 
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events was not investigated60. Data from our chimera experiment indicate that TLR2 
predominantly on skin resident cells and not on hematopoietic cells is necessary and 
sufficient for the accumulation of MDSCs in the spleen and induction of systemic 
immune suppression. This underlines the decisive key role of the skin for systemic 
immune regulation.  
3.4 Myeloid-derived suppressor cells mediate immune suppression 
in severe AD 
We have shown for the first time a significant increase of MDSCs in the blood and 
skin of AD patients. This result and our further experiments with CD11b depletion of 
PBMCs and the presence of iNOS expressing CD11c negative cells in AD patients 
suggested a disease-specific induction as well as a suppressive activity of MDSCs in 
AD. We propose that severe AD causes an increase in the frequency of 
immunosuppressive MDSCs as an attempt to stop severe inflammation. This results 
in temporary immune suppression and increases the susceptibility for secondary 
infection. Indeed, immune suppression in response to strong cutaneous inflammation 
is a well known phenomenon in patients with AD17,18. These patients suffer from 
spreading of herpes viruses like in eczema herpeticum. So we contributed to the 
understanding of the complex clinical presentation of AD showing that MDSCs are 
responsible for immune suppression in this disease. Based on our findings, detection 
of MDSCs in peripheral blood could also be further developed as biomarker for 
immune suppression in severe AD. As perspective new therapeutic options may be 
developed that include the depletion (apheresis) or transfer of autologous MDSCs to 
regulate immune responses. 
3.5 IL-6 and IL-4 have pleiotropic roles in cutaneous inflammation 
IL-6 is a multifunctional cytokine with a broad spectrum of biological activities 
including immune regulation, hematopoiesis and inflammation96. Overproduction of 
IL-6 has been shown to play a pathological role in inflammatory autoimmune 
diseases such as rheumatoid arthritis97. And Il6-/- mice have shown impaired 
inflammatory responses98. But there are also reports about an anti-inflammatory role 
of IL6. In some settings IL-6 orchestrates down-regulation of pro-inflammatory 
cytokines as well as up-regulation of anti-inflammatory molecules99. We also 
identified IL-6 in its anti-inflammatory role, as a key factor for MDSC accumulation 
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following skin infection and induced immune suppression. However, we classify this 
mechanism rather as a negative feed-back-loop in severe inflammation, secondary to 
its pro-inflammatory function. Our data suggest that Pam2 activates TLR2/TLR6 on 
resident skin cells, which causes production of IL-6 by skin resident cells. The level of 
this cytokine (and a risk of dangerous tissue damage) is so high that a negative feed-
back mechanism is induced, leading to the MDSC accumulation and subsequent 
immune suppression. 
Cutaneous innate immune cells100, keratinocytes and even melanocytes101-103 are all 
capable of producing IL-6. It is especially evident in AD, where keratinocytes act as a 
critical first line of defense against microbial infection. Early IL-6 production was 
described after a direct contact of keratinocytes with S. aureus104. Moreover, IL-6 was 
found to be increased in AD skin105 and especially in AD skin lesions75, where the 
amount of IL-6 correlated with bacterial burden75. Genome wide association studies 
recently also identified an IL-6 receptor (IL-6R) variant as a new risk factor for AD106 
and a small case series with three patients demonstrated therapeutic efficacy of an 
IL-6R blockade by tocilizumab, an IL-6R antibody107.  
Immune suppression after increased IL-6 may be a common mechanism, because 
IL-6 has also been implicated in the progression of established tumors, a condition in 
which MDSCs suppress anti-tumoral immune responses62,108.  
Thus, these data highlight that IL-6, next to its well characterized pro-inflammatory 
properties, is also crucial for anti-inflammatory responses by orchestrating negative-
feed-back-loops through MDSCs.  
IL-4 is another well characterized cytokine with known pleiotropic functions. As 
shown above, S. Kaesler et al. has identified IL-4 as a key cytokine responsible for 
aggravation of cutaneous inflammation in early AD. We have clearly shown in human 
and mouse data potent immunosuppressive properties of IL-4 in another 
inflammatory skin disease, psoriasis, in the work of E. Guenova et al. . Interestingly, 
both works revealed that IL-4 affects APCs, most likely DCs, to exert these opposing 
effects. DCs and their cytokines determine the outcome and quality of immune 
responses, for example through polarization of T cells45. Consequently, the alteration 
of DC functions has profound impact on the quality of immune responses, not only 
during initiation but also for ongoing immune responses. Which of these effects 
predominates depends on the immunologic networks in a given immune situation. IL-
4 acts as an APC modifier, directly instructing APCs to change their cytokine 
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repertoire. This includes the depletion of IL-23, one most important maintenance 
factors of Th17 response. At the same time IL-12p70 is upregulated, promoting the 
replacement of a Th17 response by a Th1 response, which proved to be of 
therapeutic use in psoriasis. Interestingly, psoriasis is characterized by the absence 
of IL-4, and both Th1 and Th17 cells prevail in the skin85,86. In configurations of the 
immune system, in which IL-10 is a dominant regulator, the APC modifier IL-4 shuts 
down IL-10 production, instructing an increase and persistence of inflammation. This 
was shown for AD, which, in the early phase, is dominated by a Th2 immune 
response and high IL-4 levels.  
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4 Summary 
The skin plays a major protective role against pathogens, not only as physical barrier, 
but also as site of first recognition of exogenous substances and as orchestrator of 
consecutive immune responses. Moreover, it is known that immunological crosstalk 
between skin resident cells and immune cells is required for effective immune 
responses. The skin is constantly in contact to Gram-positive bacteria and 
consequently to different TLR2 ligands. We identified cutaneous TLR2 activation as a 
multifaceted pathway with various and in part opposing consequences on immune 
responses. In the early Th2-dominated phase of atopic dermatitis (AD), TLR2 ligands 
contributed to aggravation and persistence of cutaneous inflammation due to IL-4-
mediated suppression of IL-10 in APC during ongoing inflammation. In contrast, a 
study with non-pathogenic bacterial lysates (Vitreoscilla filiformis) revealed that TLR2 
activation suppressed AD due to induction of IL-10 and IL-10 producing regulatory T 
cells pointing to an anti-inflammatory role of TLR2 activation. Functional analyses of 
TLR2 ligands revealed that cutaneous exposure to diacylated TLR2/6 ligands, but not 
to triacylated TLR2/1 ligands inhibited subsequent cutaneous T cell-mediated recall 
responses. This was due to a systemic induction of Gr1+CD11b+ myeloid-derived 
suppressor cells (MDSCs) directly suppressing T cells. Investigating AD patients, 
where TLR2 ligands accumulate, we detected a significant increase of MDSCs in the 
peripheral blood and skin of AD patients in comparison to healthy individuals. 
Interestingly, signals through TLR2 on skin cells, but not on hematopoietic cells, as 
well as cutaneous IL-6 induction were necessary and sufficient for the expansion of 
MDSCs and their immunomodulatory effect in this context. Investigating the 
underlying mechanism of IL-4-mediated therapy of psoriasis we found that IL-4 
predominantly suppressed the IL-23/Th17 immune axis in this disease. These 
investigations demonstrate that the same signaling molecules within a complex 
immune network can be involved in the signaling of opposite immune reactions like 
inflammation or suppression of inflammation. Thus, single linear activation pathways 
have to be integrated in a network to understand the final immune outcome. This 
consideration of the whole signaling network is not only necessary to understand the 
pathogenesis of immunological diseases and their therapeutic strategies, but also to 
unravel possible side effects and restrictions of current immune therapies.  
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5 Zusammenfassung  
Unsere Haut ist ständig Bakterien und Antigenen der Umwelt ausgesetzt. Deswegen 
hat das Immunsystem der Haut die Aufgabe, nicht nur die Fremdsubstanzen zu 
erkennen, sondern auch die darauf entsprechenden Immunantworten zu generieren 
und deren Verlauf zu steuern. Vor allem ist die Haut mit Gram positiven Bakterien 
und somit mit TLR2-Liganden im ständigen Kontakt. Wir fanden unterschiedliche und 
zum Teil gegensätzliche Auswirkungen der kutanen TLR2-Aktivierung auf das 
Immunsystem. In der frühen Th2-dominierenden Phase der atopischen Dermatitis 
(AD) führten TLR2-Liganden zu einer Verschlechterung und Chronifizierung der 
Hautentzündung. Die wurde durch die Hemmung der IL-10-Produktion in den APCs 
durch IL-4 bewerkstelligt. Eine weitere Arbeit mit den Lysaten von nicht-pathogenen 
Vitreoscilla filiformis zeigte dagegen, dass die Aktivierung von TLR2 zu einer 
Hemmung der kutanen Entzündung und somit zu einer Besserung der AD führte. Der 
hierfür zugrundeliegende Mechanismus war die Induktion von IL-10 und IL-10-
produzierenden regulatorischen T-Zellen. Funktionale Analysen von TLR2-Liganden 
ergaben, dass eine kutane Applikation von TLR2/6- und nicht TLR2/1-Liganden in 
einer systemischen Immunsuppression der T-Zell-Antworten resultierte. Wir 
identifizierten weiter, dass Gr1+CD11b+ myeloide Suppressorzellen (MDSCs) diese 
Wirkung vermittelten. Untersuchungen bei AD Patienten zeigten einen höheren Level 
an MDSCs im Blut im Vergleich zu Kontrollgruppen. Interessanterweise war die 
Präsenz der TLR2 Rezeptoren auf den Hautzellen und nicht auf den 
hämatopoetischen Zellen notwendig und ausreichend für die MDSC-Induktion. 
Darüber hinaus identifizierten wir kutanes IL-6 als das Schlüsselzytokin für die 
MDSC-vermittelte Immunsuppression. Auf der Suche nach dem Mechanismus der IL-
4-Therapie in Psoriasis fanden wir, dass IL-4 überwiegend die IL-23/Th17-Achse in 
dieser Erkrankung hemmt. Diese Ergebnisse zeigen, wie ein komplexes 
immunologisches Netzwerk, wie es in der Haut vorherrscht, durch teilweise 
überlappende Signale so eingestellt und verändert werden kann, dass es zu völlig 
unterschiedlichen Immunantworten kommt. Um das finale Ergebnis der 
Immunantwort zu verstehen, müssen nicht nur einzelnen Signalwege, sondern deren 
Interaktion betrachtet werden. Diese Betrachtungsweise hilft bei dem Verständnis der 
Pathogenese der immunologischen Erkrankung sowie bei der Entwicklung 
therapeutischer Ansätze.  
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6 Abbreviations 
AD  atopic dermatitis 
AMPs  antimicrobicidal peptides  
APC   antigen presenting cells 
BM   bone marrow 
CHS   contact hypersensitivity model  
CFU   colony forming units 
DC  dendritic cells 
FITC  fluorescein isothiocyanate 
IL   interleukin 
Lgt  diacylglyceryl transferase gene  
Lpp   lipoproteins  
NO   nitric oxide 
LTA  lipoteichoic acid  
MAMPs microorganism-associated molecular patterns 
MDSC myeloid-derived suppressor cells 
MyD88  myeloid differentiation factor 88 
Pam3Cys  tri-palmitoyl cysteinyl lipopeptide (Pam3CSK4) adapted from the 
Escherichia coli Braun’s lipoprotein  
Pam2Cys  di-palmitoyl cysteinyl lipopeptide – Pam2Cys as well as Pam3Cys mimic 
the proinflammatory properties of bacterial lipoproteins 
PAMPs  pathogen-associated molecular patterns 
PPRs  pattern recognition receptors 
SitC   predominant lipoprotein in Staphylococcus, part of the iron transporter 
SitABC;  
S.  Staphylococcus 
TCR  T cell receptor  
Teff  effector T cells 
TLR  Toll-like receptor 
Treg  regulatory T cells  
Vf lysate lysate of the non-pathogenic bacterium Vitreoscilla filiformis. 
WT   wild type 
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Running Title: Skin infection-induced MDSCs suppress T cell immunity 29 
 2 
Summary  30 
Skin is constantly exposed to bacteria and antigens, and cutaneous innate immune sensing 31 
orchestrates adaptive immune responses. In its absence, skin pathogens can expand, entering 32 
deeper tissues leading to life-threatening infectious diseases. To characterize skin-driven 33 
immunity better, we applied living bacteria, defined lipopeptides, and antigens cutaneously. 34 
We found suppression of immune responses due to cutaneous infection with Gram-positive S. 35 
aureus, which was based on bacterial lipopeptides. Skin exposure to toll-like receptor 36 
(TLR)2-6- but not TLR2-1-binding lipopeptides potently suppressed immune responses 37 
through induction of Gr1+CD11b+ myeloid-derived suppressor cells (MDSCs). Investigating 38 
human atopic dermatitis, in which Gram-positive bacteria accumulate, we detected high 39 
MDSC amounts in blood and skin. TLR2 activation in skin resident cells triggered 40 
interleukin-6 (IL-6), which induced suppressive MDSCs, which are then recruited to the skin 41 
suppressing T cell-mediated recall responses such as dermatitis. Thus, cutaneous bacteria can 42 
negatively regulate skin-driven immune responses by inducing MDSCs via TLR2-6 43 
activation. 44 
 3 
Introduction  45 
The skin is the largest organ at the interface between the environment and the host. The skin 46 
plays a major protective role not only as physical barrier but also as the site of first 47 
recognition of microbes and orchestrates consecutive immune responses (Naik et al., 2012; 48 
Swamy et al., 2010; Volz et al., 2011).  49 
Staphylococcus aureus (S. aureus) is one of the most potent skin pathogens and is found to 50 
colonize skin of about 30 to 50% of healthy adults, among them 10-20% persistently (Lowy, 51 
1998). Coming from the skin S. aureus can infect any tissue of the body and cause life-52 
threatening diseases, particularly because of the widespread occurrence of antibiotic-resistant 53 
strains, known as methicillin-resistant Staphylococcus aureus (MRSA) (Saeed et al., 2014). In 54 
atopic dermatitis (AD) patients, there is an approximately 200-fold increase of S. aureus 55 
colonization with more than 90% of AD patients displaying S. aureus in comparison to the 56 
healthy skin (Leung and Bieber, 2003). 57 
Microbes are first sensed by the innate immune system through pattern recognition receptors 58 
(PRRs), which recognize microbe-associated molecular patterns (MAMPs) (Kawai and Akira, 59 
2010). Both epithelial cells and resident innate immune cells in the skin express PRRs 60 
(Kupper and Fuhlbrigge, 2004; Lai and Gallo, 2008). Among PRRs, Toll-like receptors 61 
(TLRs) are a well-characterized family with distinct recognition profiles (Kawai and Akira, 62 
2010). TLR2 has emerged as a dominant receptor for Gram-positive bacteria, especially S. 63 
aureus (Biedermann, 2006; Lai and Gallo, 2008; Mempel et al., 2003). Among TLR2 ligands, 64 
lipoproteins seem to be especially important because the lipoprotein diacylglyceryl transferase 65 
(lgt) deletion mutant of S. aureus induces much less proinflammatory cytokines in human cell 66 
lines (Stoll et al., 2005) and less TLR2-MyD88 adaptor protein-mediated inflammation in a 67 
mouse model of systemic infection (Schmaler et al., 2009). It is now established that there are 68 
different classes of lipopeptides that all bind TLR2 (Müller et al., 2010; Schmaler et al., 69 
2009). However, how these TLR2 ligands differ in regard to functional consequences has not 70 
 4 
been thoroughly investigated. TLR2 is known to form heterodimers with TLR1 and TLR6 to 71 
interact with this broad spectrum of ligands (Kang et al., 2009). TLR1 is required as a co-72 
receptor for recognition of triacylated lipopeptides, such as Pam3Cys (Buwitt-Beckmann et 73 
al., 2006; Jin et al., 2007), while diacylated lipopeptides, such as FSL-1 or Pam2Cys, interact 74 
with TLR2-TLR6 heterodimers (Mae et al., 2007; Mühlradt et al., 1997). Functional 75 
properties of S. aureus lipopeptides in respect to TLR2 heterodimers have been investigated 76 
in several cell types (Buwitt-Beckmann et al., 2006; Hajjar et al., 2001), but evidence 77 
demonstrating specific functional consequences for the activation of different heterodimers in 78 
vivo is lacking. 79 
Sustained activation of TLRs causes persistent production of proinflammatory cytokines, such 80 
as tumor necrosis factor (TNF) or interleukin-6 (IL-6), leading to tissue damage (Kawai and 81 
Akira, 2010; Kupper and Fuhlbrigge, 2004; Lai and Gallo, 2008). Consequently, to 82 
reconstitute the integrity of the surface organ, mechanisms to limit cutaneous inflammation 83 
must be effective (Lai et al., 2009). In recent years Gr1+CD11b+ myeloid-derived suppressor 84 
cells (MDSCs) have been identified as one cell population responsible for modulating 85 
immune responses (Bronte, 2009; Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and 86 
Sinha, 2009). The most characteristic functional property of MDSCs is to suppress T cell 87 
responses (Gabrilovich et al., 2001; Kusmartsev et al., 2000). In the context of inflammation 88 
the precise function of MDSCs and the mechanisms of MDSC induction are not well-89 
understood; but in a sepsis model with Gram-negative bacteria their induction has been shown 90 
to depend on TLR4-MyD88 activation (Delano et al., 2007), and in tumor models, different 91 
innate cytokines, such as IL-6, induce MDSC accumulation (Bunt et al., 2007; Chalmin et al., 92 
2010). However, the suppression of IL-6 also increases susceptibility to bacterial and fungal 93 
infections, indicating pleiotropic effects of IL-6 (Hoetzenecker et al., 2011).  94 
In this study we have identified a pathway of immune regulation that operates in the skin. We 95 
mimicked intense cutaneous contact to bacteria in different in vivo mouse models by using 96 
 5 
living bacteria and lipopeptides. We investigated AD as a model for massive cutaneous 97 
immune sensing of Gram-positive bacteria in humans. We found that cutaneous infection with 98 
S. aureus caused immune suppression. The exposure to TLR2-6 ligands was sufficient to 99 
cause an almost complete reduction of consecutive cutaneous recall responses. This skin 100 
exposure induced accumulation of MDSCs, allowing MDSC recruitment to the skin, and 101 
suppression of T cell-mediated recall responses. Signals through TLR2 on skin resident cells 102 
but not on recruited hematopoietic cells, as well as cutaneous IL-6 induction, were necessary 103 
and sufficient for the expansion of MDSCs and consecutive immune suppression. These data 104 
demonstrate that cutaneous recognition of TLR2-6 ligands orchestrates a unique pathway of 105 
cutaneous immune modulation mediated by MDSCs, indicating a yet unknown level of 106 
immune counter-regulation. 107 
 6 
Results  108 
Cutaneous Staphylococcus aureus induces immune suppression. 109 
We aimed to characterize the consequences of intense cutaneous innate immune sensing as in 110 
the case of colonization or infection with Gram-positive bacteria. We established a mouse 111 
model of epicutaneous colonization with pathologically-relevant S. aureus (Wanke et al., 112 
2013). Mimicking S. aureus skin infection by applying living S. aureus bacteria onto the skin 113 
with disrupted skin barrier we found a distribution of the bacteria not only in the skin, but also 114 
in the internal organs (spleen and kidney) (Figure 1A), indicating the importance of the skin 115 
as an effective defense immune organ with the potential to impact the whole immune system. 116 
To investigate how bacterial infection influences consecutive immune responses, we 117 
combined this model of bacterial colonization and the murine T cell-mediated contact 118 
hypersensitivity (CHS) to FITC, in which bacteria were applied epicutaneously during FITC 119 
re-exposure of FITC-sensitized mice (see protocol in Figure S1A). The application of FITC 120 
onto the ear led to FITC-specific dermatitis as determined by ear swelling which 121 
corresponded to the strength of the FITC-specific immune response. The cutaneous 122 
application of S. aureus 7 days previous to the FITC challenge did not enhance, but 123 
significantly reduced ear swelling and immune cell infiltration (Figure 1B, C). This immune 124 
suppression was completely dependent on immune sensing of bacterial lipoproteins, as 125 
lipoprotein-deficient S. aureus mutant (lgt) (Stoll et al., 2005) failed to induce immune 126 
suppression. Injecting S. aureus into the subepithelial dermis (intracutaneous route) also 127 
induced consecutive immune suppression, which, however, tended to be weaker compared to 128 
effects of S. aureus application onto the epithelium (Figure S1B). To identify underlying 129 
mechanisms of S. aureus-induced cutaneous immune suppression we analyzed skin-draining 130 
lymph nodes. Only exposure to wild-type (WT) S. aureus bacteria and not the lipoprotein-131 
deficient lgt S. aureus reduced ex vivo FITC-specific T cell proliferation (Figure 1D). In the 132 
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spleen, CD4+ and CD8+ T cells were also reduced in mice cutaneously exposed WT S. aureus 133 
but not in mice exposed to lipoprotein-deficient lgt S. aureus (Figure 1E). Only in mice 134 
displaying suppressed T cells we detected a strong increase of Gr1+CD11b+ so called 135 
myeloid-derived suppressor cells (Figure 1E). In contrast to this, accumulation of 136 
Gr1+CD11b+ was not detected in the liver (Figure S1D). At d3 after FITC challenge, MDSCs 137 
were also slightly increased in draining lymph nodes due to cutaneous WT S. aureus 138 
infection, corresponding the decrease of proliferating Ki67+ T cells (Figure S1E). Further 139 
experiments investigating other suppressive cell populations showed no alterations in the 140 
number of regulatory T (Treg) cells and IL-10 producing cells (Figure S1F); the numbers of 141 
Langerhans cells (LC, defined as CD11cloCD205hi) and CD11c+MHC-II+ cells were also 142 
unchanged, dermal dendritic cells (dDCs, defined as CD11chiCD205lo) were slightly increased 143 
(Figure S1E). These data indicate that MDSCs function independent of Treg cells and do not 144 
inhibit migration of DCs into lymph nodes. 145 
In order to further emphasize the functional and clinical relevance of these findings, we 146 
investigated atopic dermatitis (AD) patients. AD is a perfectly suited model disease for 147 
investigations on immune consequences of skin exposure to bacteria, as AD is an 148 
inflammatory skin disease that is nearly always covered with and triggered by Staphylococci. 149 
In humans, MDSCs are typically described as CD11b+CD33+HLA-DR-CD14- cells 150 
(Gabrilovich and Nagaraj, 2009). We observed a significant increase of MDSCs in the 151 
peripheral blood mononuclear cells (PBMCs) of AD patients (Figure 1F). The upregulation of 152 
human MDSCs was especially consistent in patients, in which severe AD was complicated by 153 
eczema herpeticum, which is a severe cutaneous viral infection resulting from immune 154 
suppression (Figure 1F, red squares) (Beck et al., 2009; Wollenberg et al., 2003), suggesting 155 
suppressive properties of MDSCs also in AD patients. 156 
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These data show that cutaneous S. aureus is sufficient to induce MDSCs and to cause immune 157 
suppression. 158 
 159 
Cutaneous exposure to TLR2-6 but not to TLR2-1 ligands ameliorates T cell-mediated 160 
recall responses  161 
Next, we investigated the intriguing finding that lipoprotein-deficient S. aureus failed to 162 
induce immune suppression in our model (Figure 1B). As lipoproteins are sensed by different 163 
TLR2 heterodimers (Henneke et al., 2008), we have taken advantage of microbial-derived 164 
molecules which are exclusively bound by one specific TLR2 heterodimer. We selected three 165 
lipopeptides for our studies: TLR2-6 ligands diacyl lipopeptides FSL-1 and Pam2Cys and the 166 
triacylated lipopeptide Pam3Cys that is often used as a reference compound for TLR2-1 167 
activation. As in our previous model, lipopeptides were applied to the skin during re-exposure 168 
of FITC-sensitized mice to FITC (see protocol Figure S1A). Similarly to the living S. aureus, 169 
the cutaneous exposure to TLR2-6 ligand FSL-1 almost completely abrogated consecutive 170 
FITC-specific recall responses (Figure 2A, B), FITC-specific ex vivo T cell proliferation 171 
(Figure 2C) and orchestrated splenic reduction of CD4+ and CD8+ T cells together with 172 
MDSC accumulation (Figure 2D). This result was confirmed with another TLR2-6 ligand, 173 
Pam2Cys (Figure 2E-H). In contrast to Pam2Cys, the TLR2-TLR1 ligand Pam3Cys failed to 174 
suppress FITC-specific dermatitis and T cell proliferation (Figure 2E-G). Accordingly, no 175 
reduction of CD4+ and CD8+ T cells and no induction of Gr1+CD11b+ cells could be detected 176 
(Figure 2H). 177 
These data show that cutaneous exposure to bacterial TLR2-TLR6 ligands is sufficient to 178 
cause immune suppression and that activation of TLR2-TLR6 heterodimers differs in regard 179 
to functional consequences from activation of TLR2-TLR1 heterodimers. 180 
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Further, in order to control whether the presentation of the antigen FITC is directly influenced 181 
by Pam2Cys exposure, we analyzed the number of FITC positive DCs 14 hours after 182 
cutaneous FITC application and Pam2Cys exposure. There were no differences in the 183 
numbers of FITC positive CD11c+MHC-II+ cells and other dendritic cell populations (dDC, 184 
LC) in draining lymph nodes (Figure S1G). Similarly, the analysis of other cell populations at 185 
this early stage of the response revealed comparable numbers of T cells (CD4+, CD8+), 186 
activated T cells (CD4+CD25+) and proliferating cells (Ki67+) (Figure S1H), IL-10 producing 187 
cells and Treg cells (Figure S1I) in both mouse groups. The treatment of mice with 188 
cyclophosphamide for Treg cell depletion failed to reverse Pam2Cys-induced immune 189 
suppression (Figure S1J-L), further indicating that Treg cells are not involved in this type of 190 
immune suppression.  191 
 192 
Skin infection-induced immune suppression is mediated by Gr1+CD11b+ myeloid-193 
derived suppressor cells 194 
Next, as proof of concept that MDSCs are the responsible cells for the observed immune 195 
suppression upon cutaneous Pam2Cys exposure, we depleted Gr1+ cells. This depletion 196 
caused an abrogation of immune suppression (Figure 3A right). Inversely, the adoptive 197 
transfer of MDSCs, isolated from mice previously exposed to Pam2Cys, resulted in reduction 198 
of both FITC-specific dermatitis and T cell proliferation (Figure 3B,C). To investigate 199 
whether human MDSCs in AD patients with intense cutaneous exposure to lipoproteins were 200 
suppressive, we depleted CD11b+ cells from PBMCs and analyzed proliferation of activated T 201 
cells. The CD11b+ population among PBMCs consists of antigen presenting cells and, in 202 
addition, contains MDSCs in AD but not healthy individuals. Consequently, in 7 of 8 healthy 203 
volunteers CD11b depletion resulted in reduced T cell proliferation (Figure 3D, left). On the 204 
contrary, this was only observed in one out of 7 AD patients (Figure 3D, right).). These 205 
results demonstrate that MDSCs, which are present among the CD11b+ population in AD 206 
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patients but not in healthy individuals, are immunosuppressive. Indeed, T-cell receptor -207 
chain was significantly down-regulated in AD patients (Figure 3E), which is known to be one 208 
of the major features of MDSCs-mediated T cell inhibition (Zea et al., 2005) 209 
Taken together, these data revealed that skin infection-induced immune suppression is 210 
mediated by MDSCs. 211 
 212 
Myeloid-derived suppressor cells are recruited to the skin in mice and humans 213 
Detecting MDSCs in human blood and mouse spleen following cutaneous innate immune 214 
sensing indicates systemic MDSC expansion. Therefore, we next monitored the kinetics of 215 
MDSC induction in mice a) in the bone marrow (BM), its primary source (Figure 4A, left), 216 
and b) in one site of MDSC enrichment, the spleen (Figure 4A, right) at different time points 217 
after cutaneous Pam2Cys exposure. Starting on day 2, Gr1+CD11b+ cells in the bone marrow 218 
increased and peaked at day 7 with about 75% of cells being Gr1+CD11b+. In the spleen, both 219 
CD4+ and CD8+ T cells were strongly reduced. Gr1+CD11b+ cells increased starting at day 4 220 
with up to 7-fold induction on day 11 following cutaneous Pam2Cys exposure (Figure 4A).  221 
In FITC-CHS, T cells migrate to the skin and elicit dermatitis. Therefore, we analyzed 222 
whether MDSCs were also recruited to the skin. Indeed, 8 h after FITC challenge 223 
Gr1+CD11b+ cells were significantly increased in the skin of mice previously exposed to 224 
Pam2Cys (Figure 4B). Similarly, we compared healthy skin with lesional skin from AD 225 
patients colonized or infected with S. aureus. Flow cytometry analysis confirmed a significant 226 
increase of MDSCs in the skin of AD patients compared to healthy skin (Figure 4C), 227 
indicating that presence of bacteria and subsequent skin inflammation induce MDSC 228 
accumulation in the skin also in humans.  229 
 230 
Suppression of T cell activation by MDSCs is induced by cutaneous innate immune 231 
sensing 232 
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Recruitment of MDSCs to the skin suggested MDSC-mediated suppression of T cell 233 
activation in the skin in vivo. As first indication we found that the depletion of CD11b+ cells 234 
of isolated skin cells caused a stronger T cell proliferation following stimulation with anti-235 
CD3-D28 in comparison to cells not depleted of CD11b+ cells (Figure S2A), confirming a 236 
suppressive function of skin MDSCs ex vivo.  Moreover, flow cytometry analysis of ear skin 237 
tissue following the FITC challenge revealed a significant decrease of CD3+ T cells (Figure 238 
5A, right) and IFN- production (Figure 5A, left) in previously Pam2Cys-exposed mice. 239 
Expression analysis of other cytokines revealed a significant decrease of the Th2 cell cytokine 240 
IL-4 (a target for a systemic AD treatment (Beck et al., 2014)), IL-10 and a tendency for IL-241 
17 inhibition (Figure 5B). The investigation of cutaneous chemokines in the skin showed a 242 
down-regulation of most analyzed chemokines (CCL2, CCL3, CCL4, CCL5, CCL11, CCL13, 243 
CCL17, CCL20, CCL27). Only T cell attracting CCL22 (a CCR4 ligand) and CCL28 (CCR3 244 
and CCR10 ligand) were significantly upregulated (Figure 5C). The corresponding 245 
chemokine receptors were expressed on the MDSCs in the skin, blood and bone marrow 246 
(Figure 5D), which further indicates that MDSCs are attracted to the site (and by similar 247 
mechanism) of T cell migration.  248 
To explore the mechanisms mediating MDSC-induced immune suppression, we isolated 249 
MDSCs 10 days after Pam2Cys exposure. Flow cytometry analysis revealed the presence of 250 
both Ly6C+ and Ly6G+ MDSCs. Morphological evaluation of isolated MDSCs confirmed that 251 
Ly6G+ MDSC were granulocytic, whereas Ly6C+ MDSCs were monocytic (Figure S2B). In 252 
the skin Gr1+CD11b+ cells were further characterized as CD11c-, CD15-, MHC-II-, B220-253 
negative and positive for CD16-32, partly positive for F4-80 (Figure S2C) and splenic Ly6C+ 254 
cells had a similar phenotype (Figure S2C). Next, we isolated Gr-1dimLy6G-Ly6C+CD11b+ 255 
(Ly6C+) and Gr-1highLy-6G+CD11b+ (Ly6G+) MDSCs from Pam2Cys-exposed mice and co-256 
cultured them with naïve splenocytes (responder cells) activated with anti-CD3-CD28 257 
antibodies (Abs) at different ratios. Following co-culture with Ly6C+ MDSCs at a ratio of 2:1, 258 
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almost complete suppression of T cell proliferation was observed, while Ly6G+ cells were not 259 
suppressive (Figure 5E, left). Investigating the suppressive activity more thoroughly revealed 260 
that Ly6C+ MDSCs inhibited Th0 CD4+ T cells as well as of Th1-, Th2- and Th17-polarized 261 
cells (Figure S2D). MDSCs´ immunosuppressive activity is reported to be a result of the 262 
activation of inducible NOS (iNOS), leading to increased production of nitric oxide (NO) 263 
(Gabrilovich et al., 2001). Indeed, we found an increased iNOS expression in the skin after 264 
FITC challenge in Pam2Cys-exposed mice (Figure S2E) and Ly6C+ MDSCs from Pam2Cys-265 
exposed animals produced high concentration of NO (Figure 5E, middle). NO production and 266 
T cell suppression by Ly6C+ MDSCs was completely abrogated in a transwell experiment 267 
(Figure 5E middle, Figure S2F), indicating that MDSC activation is a prerequisite for MDSC 268 
NO production and MDSC-mediated suppression. Flow cytometry analysis of the co-culture 269 
confirmed higher expression of iNOS by Ly6C+ cells (with a very low expression of arginase 270 
and IL-10 by both MDSC subsets) (Figure S2G). In addition, the inhibition of iNOS by L-271 
NMMA or L-NIL completely abrogated MDSC-mediated suppression of T cell proliferation 272 
(Figure 5E, right). Similarly, in PBMCs of AD patients we detected a distinct iNOS+ 273 
population of CD11b+CD11c- cells. These cells were completely absent in healthy individuals 274 
(Figure 5F). Importantly, we also detected iNOS+CD11b+CD11c- cells in AD skin (Figure 5G, 275 
Figure S2H).  276 
All together, the above results indicate that skin infection-induced MDSCs are present in the 277 
skin in mice and humans, where they inhibit T cell proliferation by means of cell-to-cell 278 
contact and iNOS. 279 
 280 
Pam2Cys-induced immune suppression is dependent on cutaneous TLR2  281 
Next, we investigated underlying mechanisms how innate immune sensing in the skin initiates 282 
MDSCs. Therefore we determined the role of TLR2. Tlr2-/- and WT mice were treated as 283 
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shown in Figure S1A with or without cutaneous Pam2Cys exposure. In contrast to WT mice 284 
(Figure 6A left), Tlr2-/- mice failed to inhibit FITC-specific CHS (Figure 6A right) and T cell 285 
proliferation (Figure 6B) and no reduction of CD4+ and CD8+ T cell numbers and 286 
accumulation of MDSCs (Figure 6C) was observed following Pam2Cys exposure. Cutaneous 287 
innate immune sensing through TLR2 may act through skin resident cells or recruited 288 
circulating blood immune cells. Thus, mouse chimeras were generated to distinguish between 289 
TLR2 sensing of skin resident or recruited hematopoietic cells, as depicted in Figure S3A. 290 
Chimerism was confirmed by PCR of bone marrow cells (Figure S3B). The percentage of 291 
MDSCs was analyzed following the protocol shown in Figure S1A. WT mice, reconstituted 292 
with WT BM (WT + WT-BM) and WT mice, that obtained Tlr2-/- BM (WT + Tlr2-/--BM), 293 
upregulated MDSCs following Pam2Cys exposure (Figure 6D, top). In contrast, Tlr2-/- mice 294 
reconstituted with WT BM (Tlr2-/- + WT-BM) failed to accumulate MDSCs, similar to 295 
control Tlr2-/- mice with Tlr2-/- BM (Tlr2-/- + Tlr2-/--BM) (Figure 6D, bottom). Thus, TLR2 296 
expression on skin resident cells, which next to keratinocytes includes radiation resistant skin 297 
resident Langerhans or mast cells, is necessary and sufficient for MDSC accumulation. 298 
Next, we investigated a functional role of TLR2 on MDSCs. Chimeric mice were generated 299 
by reconstitution with 50% CD45.1 WT and 50% CD45.2-Tlr2-/- BM (Figure S3C). 300 
Following Pam2Cys exposure, approximately 20% of spleen cells were MDSCs irrespective 301 
whether WT CD45.1 or Tlr2-/-CD45.2 cells were analyzed (Figure S3D), demonstrating that 302 
TLR2 is dispensable on MDSC precursor cells for MDSC induction and accumulation.  303 
 304 
Cutaneous IL-6 is critically required for MDSC induction 305 
Our previous experiments showed that cutaneous Pam2Cys sensing through TLR2 is 306 
sufficient to induce MDSCs and consecutive suppression of cutaneous recall responses. To 307 
identify underlying mechanisms we first analyzed which cells in the skin could be responsible 308 
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for sensing Pam2Cys. Immunofluorescence staining of TLRs after exposure of mice to 309 
Pam2Cys or Pam3Cys showed an upregulation of the corresponding TLR on keratinocytes 310 
(Figure 7A). Similar analyses of human skin samples showed pronounced TLR2 expression in 311 
human skin  albeit at lower amount in AD compared to healthy skin (Figure S4A), as known 312 
from other studies (Kuo et al., 2013). Next, we analyzed the functional consequences of the 313 
TLR upregulation. We exposed mice to different TLR ligands (Pam2Cys, Pam3Cys, CpG and 314 
LPS) and analyzed cutaneous mRNA expression of cutaneous cytokines. All TLR ligands 315 
moderately upregulated TNF and the chemokine CXCL-2 was most dominantly induced by 316 
Pam2Cys and Pam3Cys (Figure 7B). Upregulation of IL-6 mRNA in the skin was most 317 
pronounced only after Pam2Cys exposure. In comparison to skin following FITC-only or 318 
FITC-plus-other TLR-ligands exposure, cutaneous Pam2Cys exposure induced a 400-fold 319 
upregulation of IL-6 mRNA (Figure 7B, right). On the protein level we detected increased IL-320 
6 production by CD45 negative cells (which were also MHC-II negative, Figure S4B) (Figure 321 
7C). To confirm these data, we stimulated primary human keratinocytes with TLR ligands 322 
and detected upregulation of IL-6 production exclusively following Pam2Cys treatment 323 
(Figure 7D).  324 
To regulate MDSC induction in the bone marrow (Figure 4A), cutaneous IL-6 needs to reach 325 
the blood stream (Chalmin et al., 2010). Indeed, IL-6 concentrations in mouse sera strongly 326 
increased one day after cutaneous Pam2Cys exposure (Figure 7E). These data suggest that IL-327 
6 plays a crucial role in Pam2Cys-induced MDSC induction; therefore, Il6-/- mice were 328 
investigated. In contrast to WT mice, cutaneous Pam2Cys exposure in Il6-/- mice failed to 329 
suppress FITC-CHS (Figure 7F), and no induction of MDSCs could be detected (Figure 7G). 330 
Consequently, the injection of IL-6 into the mice caused an increase of MDSCs in the spleen 331 
(Figure S4C, D), suggesting that IL-6 is responsible for MDSC induction and expansion. To 332 
investigate whether IL-6 plays a role in MDSC migration to the skin, we applied anti-IL-6 333 
antibody shortly before challenge and analyzed MDSC numbers in the skin. We found a 334 
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significant and unequivocal increase of Gr1+CD11b+ cells in both conditions (Figure S4E) 335 
and the adoptive transfer of MDSCs into Il6-/- mice showed a suppression of immune 336 
responses, comparable to what is observed in WT mice (Figure S4F). To investigate whether 337 
IL-6 plays a role for MDSC development, we analyzed MDSCs generation in vitro. BM-338 
derived MDSCs (see suppl. Methods) were treated with IL-6 during development and their 339 
suppressive function was investigated in a suppression assay with responder cells. As shown 340 
in Figure 7H, the exposure of MDSCs to IL-6 during generation enhanced their suppressive 341 
function. These data indicate that IL-6 supports induction and development of suppressive 342 
MDSCs, but not their migration to the skin. 343 
Taken together, these data suggest a scenario in which Pam2Cys is sensed by TLR2 on skin 344 
resident cells, leading to the expression and secretion of IL-6 in such high amounts that 345 
MDSCs expand and accumulate, leading to the inhibition of cutaneous recall responses.  346 
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Discussion  347 
In this study we found that cutaneous exposure to bacteria and bacterial substances known to 348 
act as potent MAMPs induced a strong immune suppression mediated by MDSCs. These 349 
findings highlight that certain classes of bacterial molecules are able to orchestrate unique 350 
pathways that, even after limited cutaneous exposure, are sufficient to induce immune 351 
suppression. We found that cutaneous exposure to TLR2-TLR6 but not to TLR2-TLR1 352 
ligands induced MDSCs and consecutive cutaneous immune suppression. Bacteria differ in 353 
the acylation patterns of their lipoproteins (Kurokawa et al., 2012b). Our results suggest that 354 
they may differ in their potential to activate different TLR2 heterodimers and to regulate 355 
immune responses as well. Consequently, acylation properties may characterize bacteria as 356 
pathogens or commensals. It was shown recently, that the degree of lipoprotein-acylation 357 
depends on environmental factors and growth phase. Lipoprotein SitC was triacylated when S. 358 
aureus was in the exponential growth phase at neutral pH and diacylated in the post 359 
exponential phase at low pH (Kurokawa et al., 2012a). At the situation on the skin, where pH 360 
is low and chronic S. aureus colonization (which is almost always found in AD) is present, a 361 
post exponential growth phase of S. aureus can be assumed. Consequently, lipoproteins from 362 
S. aureus on the skin are more diacylated. Based on our data, we hypothesize that diacylation 363 
of lipoproteins induces acute inflammation followed by immune suppression as a 364 
consequence. Further, one can also assume that pathogenic and non-pathogenic skin 365 
microflora may have different acylation properties and therefore different compositions of 366 
TLR2 ligands and thus overall differ in their immune consequences.  367 
Previous data using a systemic sepsis model with Gram-negative bacteria derived from the 368 
gut described the MyD88 and TLR4 pathway to be most relevant for MDSC expansion 369 
(Delano et al., 2007). However, the exact cascade of events was not investigated (Arora et al., 370 
2010; Delano et al., 2007). Our data investigating the common route of cutaneous infection 371 
with Gram-positive bacteria show that TLR2 activation on skin resident cells mediates MDSC 372 
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accumulation and consecutive immune suppression. Induction of MDSCs by activation of 373 
cutaneous TLR2-6 most dominantly involves IL-6. Cutaneous innate immune cells (Blander 374 
and Medzhitov, 2004), keratinocytes and even melanocytes (Stadnyk, 1994; Takashima and 375 
Bergstresser, 1996) are all capable of producing innate cytokines, such as IL-6. Indeed, in 376 
AD, where keratinocytes act as a critical first line of defense against microbes, early IL-6 377 
production has been described after direct contact of keratinocytes with S. aureus (Sasaki et 378 
al., 2003). Moreover, IL-6 has been found to be increased in AD skin (Fedenko et al., 2011) 379 
and especially in AD skin lesions (Travers et al., 2010), in which the amount of IL-6 380 
correlates with bacterial burden (Travers et al., 2010). Genome wide association studies 381 
recently also identified an IL-6 receptor (IL-6R) variant as a risk factor for AD (Esparza-382 
Gordillo et al., 2013) and a small case series with three patients has demonstrated therapeutic 383 
efficacy of an IL-6R blockade by tocilizumab, an IL-6R antibody (Navarini et al., 2011). 384 
These observations confirm the importance of IL-6 production by skin cells in response to 385 
microbes; however the precise immune consequences of cutaneous IL-6 induction had not 386 
been elucidated. Our data allow to propose a model, how the cutaneous innate immune 387 
network functions: diacylated lipopeptides activate TLR2-TLR6 on skin resident cells 388 
followed by marked IL-6 production leading to the MDSC accumulation, which is a 389 
prerequisite of subsequent immune suppression by MDSCs. Our data also indicate that these 390 
TLR2-6-induced MDSCs are prototypic MDSCs as characterized in other settings. Moreover, 391 
our data further has identified that skin infection-induced MDSCs suppressed immune 392 
responses in mice and humans. 393 
In conclusion, our study reveals a consequence of cutaneous innate immune sensing for 394 
adaptive immune functions. The presence of certain lipoproteins on the skin may serve not 395 
only as danger signal for the initiation of effective immune responses, but may also be able to 396 
counter-regulate inflammation and potently control and suppress immune responses.  397 
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Experimental Procedures 398 
Animals 399 
Specific-pathogen-free, WT BALB/c mice were purchased from Charles River (Sulzfeld, 400 
Germany). Tlr2-/- mice (C57BL/6) were from C. Kirschning (Institute of Medical 401 
Microbiology, University Duisburg-Essen) and were backcrossed to BALB/c for 10 402 
generations. Il6-/--BALB/c mice were from Dr. M. Kopf (Swiss Federal Institute of 403 
Technology, Switzerland). All mice were kept under specific pathogen-free conditions in 404 
accordance with FELASA (Federation of European Laboratory Science Association) in the 405 
University of Tübingen. The experiments were performed with the approval of the local 406 
authorities (Regierungspräsidium Tübingen HT1/10, HT3/11, HT7/11, HT5/13, HT8/13). 407 
Age-matched female mice were used in all experiments. 408 
Epicutaneous mouse skin infection model  409 
The experimental model is based on epicutaneous application of the S. aureus on shaved skin 410 
of mice (Wanke et al., 2013). Mice were sensitized with FITC following the protocol as 411 
shown in Figure S1A. At days 7 and 10 3x108 WT or lgt-mutant S. aureus Newman in 30µl 412 
PBS or PBS control were added to filter paper discs placed onto the prepared skin and 413 
covered by Finn Chambers on Scanpor (Smart Practice, Phoenix, USA). Before application to 414 
the skin, barrier was disrupted by tape-stripping.  415 
FITC contact hypersensitivity and exposure to TLR2 ligands 416 
Mice were sensitized by administration of 80 µl of a 0.37% FITC solution (dissolved in 1:1 417 
acetone:dibutyl phthalate, Sigma Aldrich, Taufkirchen, Germany) on the shaved abdomen on 418 
days -8, -7. TLR2 ligands were applied intracutaneously together with the second 419 
epicutaneous application of FITC on days -1 and 0 (Figure S1A) in the following 420 
concentrations per mouse: Pam2Cys: 2 µg, Pam3Cys: 4 µg, FSL-1: 40 µg. Control mice 421 
obtained PBS instead of TLR2 ligands. At d7 mice were challenged by epicutaneous 422 
 19 
application of 0.37% FITC solution on both sides of the ears. Ear thickness was measured 423 
with a micrometer (Oditest®, Kroeplin, Germany) as previously described (Volz et al., 2014), 424 
and data are expressed as change in ear thickness compared to thickness before treatment. In 425 
some experiments mice were treated with 0.3µM CpG 1668 (0.2µM, Eurofins Genomics, 426 
Ebersberg, Germany), 1µg/mouse LPS (from Salmonella minnesota R595, Alexis 427 
Biochemicals, Lausen, Switzerland), cyclophoshamide (2mg/mouse, Sigma-Aldrich, 428 
Taufkirchen, Germany), 20µg/mouse rmIL-6 (20µg/mouse) or 50µg/mouse anti-IL-6 429 
(Biolegend, San Diego, USA). 430 
Human MDSCs 431 
The study was approved by the local ethics committee of the University of Tübingen, 432 
Germany, and written informed consent was obtained from all subjects (project number 433 
344/2011BO2, 345/2011BO2, 396/2011BO2, 040/2013BO2, 180/2013BO2). PBMCs were 434 
obtained from heparinized blood by centrifugation (800g for 30min) using Ficoll-Histopaque 435 
(Biochrom, Berlin, Germany). MDSCs in the blood or skin of either healthy volunteers or 436 
non-AD-controls or atopic dermatitis patients were analyzed by flow cytometry and 437 
characterized as CD11b+CD33+HLA-DR-CD14- cells.  438 
Bone marrow chimeras 439 
Recipient mice were lethally irradiated at 7.0 cGy and next day bone marrow cells (106 cells 440 
per recipient) were i.v. injected into recipient mice. To confirm the chimerism of mice, 441 
genotyping of bone marrow cells by PCR for the WT and the mutated Tlr2 gene was 442 
conducted (Figure S3B).  443 
Depletion of CD11b+ cells  444 
CD11b+ cells were depleted from PBMCs using the CD11b+ Beads (Miltenyi Biotech, 445 
Bergisch Gladbach, Germany) according to manufacturer’s protocol. 446 
Statistical analysis 447 
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Unless otherwise stated, quantitative results are expressed as means +/- standard deviations 448 
and differences were compared by unpaired, two-tailed Student’s t-test (p < 0.05 was 449 
regarded as significant).  450 
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Figure legends 668 
 669 
Figure 1. Cutaneous Staphylococcus aureus induces immune suppression in mice and 670 
humans. (A-E) FITC-sensitized wild-type (WT) mice were treated following the protocol in 671 
Figure S1A (with living WT or lipoprotein mutant (lgt) S. aureus). Bacterial load as colony 672 
forming units (CFU) (mean +/- standard deviation SD, n=5) (A), ear swelling (mean +/- SD, 673 
n=5) (B), histology (H&E staining) (C), proliferation of skin-draining lymph node (LN) cells 674 
stimulated ex vivo with FITC (detected as counts per minute (cpm) of 3H-thymidine 675 
incorporation) (mean +/- SD of triplicates) (D), and the percentage of cell populations in the 676 
spleen (mean +/- SD, n=5) (E) were investigated. *: P < 0.05. (F) PBMCs from atopic 677 
dermatitis (AD) patients (n=33) and healthy volunteers (n=30) were analyzed for MDSCs, 678 
defined as CD11b+CD33+HLA-DR-CD14- cells. The dots represent individual values and the 679 
horizontal bar is the group mean. Red squares represent MDSCs of patients with severe AD 680 
and eczema herpeticum. *: P < 0.05 (Mann-Whitney test). Data are representative of at least 681 
two independent experiments. See also Figure S1. 682 
 683 
Figure 2. Cutaneous exposure to TLR2-6 but not TLR2-1 ligands ameliorates T cell-684 
mediated recall responses of the skin. WT mice were treated following the protocol shown 685 
in Figure S1A. Mice were cutaneously exposed to FSL-1 in (A-D) and Pam2Cys or Pam3Cys 686 
in (E-H). Ear swelling response (mean +/- SD, n=5) (A, E), histology (H&E staining) (B, F), 687 
proliferation of skin-draining LN cells stimulated ex vivo with FITC (mean +/- SD of 688 
triplicates) (C, G) and the percentage of cell populations in the spleen (mean +/- SD, n=5) (D, 689 
H) are shown. Data are representative of at least two independent experiments. Experiments 690 
shown in (A) were performed with FSL-1 from two different providers. *: P < 0.05.  691 
 692 
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Figure 3. Myeloid-derived suppressor cells are responsible for skin infection-induced 693 
immune suppression. (A) WT mice were treated with FITC with or without cutaneous 694 
Pam2Cys exposure following the protocol in Figure S1A. The mice were additionally treated 695 
with Gr1 depleting (right) or with an isotype control antibody (left) at day 2 and 4. Ear 696 
swelling response (mean +/- SD, n=5, left) was evaluated. Data are representative of two 697 
independent experiments. (B-C) WT mice were treated following the protocol shown in 698 
Figure S1A (without Pam2Cys exposure). One group of mice received Ly6C-Ly6G positive 699 
cells from donors that were sensitized with FITC and exposed to Pam2Cys. The control group 700 
received spleen cells from naïve mice. The ear swelling response (mean +/- SD, n=5) (B) and 701 
the FITC-specific proliferation of LN cells (as cpm, mean +/- SD of triplicates) (C) were 702 
evaluated. (D) CD11b+ cells of PBMCs from healthy volunteers (n=8, left) and AD patients 703 
(n=7, right) were depleted, stimulated with anti-CD3-CD28-mAbs and analyzed for 704 
proliferation. *: P < 0.05 (Mann-Whitney test). (E) PBMCs from healthy donors (n=8) and 705 
AD patients (n=7) were analyzed for TCR -chain expression (mean fluorescence intensity, 706 
MFI, CD3+ Gate of living cells) by intracellular flow cytometry. Each dot represents an 707 
individual value, the horizontal bar is the group mean. *: P < 0.05 (Mann-Whitney test). See 708 
also Figure S2. 709 
 710 
Figure 4. Skin infection-induced MDSCs accumulate in the skin in mice and humans.  711 
(A) WT mice were treated following the protocol in Figure S1A. The percentage of CD4+, 712 
CD8+ or Gr1+CD11b+ cells in Pam2Cys-exposed mice were analyzed by flow cytometry at 713 
indicated time points after Pam2Cys exposure in bone marrow (left) and spleen (right) (mean 714 
+/- SD, n=3). Asterisks show significant differences compared with t=0 determined by one-715 
way analysis of variance (ANOVA) followed by Dunnet’s post test. *: P < 0.05 Data are 716 
representative of two independent experiments. (B) Cells from ear skin, isolated 4 h or 8 h 717 
after FITC challenge, were analyzed by flow cytometry (gate: living cells). A representative 718 
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flow cytometry plot (left), means +/- SD (n=5) (middle), and total numbers of Gr1+CD11b+ 719 
cells (mean +/- SD, n=5) (right) are shown. Data are representative of three independent 720 
experiments. (C) Cells isolated from skin samples of AD patients (n=9) and non-AD-controls 721 
(n=9) were analyzed by flow cytometry (gate: living cells) for MDSCs, defined as 722 
CD11b+CD33+HLA-DR-CD14- cells. A representative flow cytometry plot with the gating 723 
strategy first for CD11b+CD14- (top) and then CD33+HLA-DR+ (bottom) and the percentage 724 
of the CD11b+CD33+HLA-DR-CD14- cells (left) and cumulative analysis (right) is shown. 725 
Each of the dots represents an individual value and the horizontal bar the group’s mean. *: P 726 
< 0.05 (Mann-Whitney test). n.s., not significant. 727 
  728 
Figure 5. Skin infection-induced MDSCs suppress T cell activation through mechanisms 729 
requiring NO production. (A) WT mice were treated following the protocol in Figure S1A. 730 
24 h (A, B) or 8 h (C, D) after FITC challenge ear tissue cells were analyzed. (A) Flow 731 
cytometry for CD3+ cells (top) and IFN- production (bottom). A cumulative result (means 732 
+/- SD, n=5) is shown. (B-C) Quantitative RT-PCR analysis for cytokines (B) or chemokines 733 
(C) (normalized to housekeeping genes -actin-APDH) and means +/- SEM (n=5) are shown. 734 
Expression of the skin of FITC only-exposed mice was set as 1. *: P < 0.05. (D) Cells isolated 735 
from bone marrow, blood and skin of Pam2Cys-treated mice were analyzed for chemokine 736 
receptor expression by flow cytometry (gate: Gr1+CD11b+ of living cells), shown as 737 
percentage of Gr1+CD11b+ (means +/- SD, n=5). (E) Spleen cells were co-cultured in vitro 738 
with Ly6C+ or Ly6G+ MDSCs as indicated, stimulated by anti-CD3-CD28-mAbs and 739 
analyzed for proliferation (left); supernatants (ratio 2:1) were analyzed for NO production by 740 
Griess reaction (mean +/- SD of experimental triplicates) (middle), iNOS inhibitors L-NMMA 741 
and L-NIL were added to the co-culture (right). Significant differences between experimental 742 
conditions were assessed by one-way ANOVA followed by Tukey’s post-hoc test (*: P < 743 
0.05). Data are representative of at least two independent experiments. (F) PBMCs from 744 
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healthy donors and AD patients were analyzed by intracellular flow cytometry (iNOS+ in 745 
CD11b+CD11c-Gate of living cells). A representative result out of 7 individuals is shown. (G) 746 
Skin tissue of AD patients was analyzed by immunofluorescence. Arrows indicate cells 747 
positive for CD11b and iNOS and negative for CD11c. Scale bar represents 25 m. See also 748 
Figure S2. 749 
 750 
Figure 6. Pam2Cys-induced immune suppression is dependent on TLR2. (A-C) WT and 751 
Tlr2-/- mice were treated following the protocol shown in Figure S1A and ear swelling (mean 752 
+/- SD, n=5) after FITC challenge (A), proliferation of lymph node cells after FITC 753 
stimulation ex vivo (mean +/- SD of triplicates) (B), and the percentage of spleen cell 754 
populations (mean +/- SD, n=5) (C) were analyzed. (D) WT mice or Tlr2-/- were irradiated 755 
and reconstituted with WT or Tlr2-/- bone marrow cells (see Figure S3A). 7 weeks later, the 756 
chimeric mice were treated following the protocol shown in Figure S1A and their spleen cells 757 
were analyzed by flow cytometry. The percentage of Gr1+CD11b+ cells is shown (mean +/- 758 
SD, n=5). Data are representative of three independent experiments. *: P < 0.05, n.s., not 759 
significant. See also Figure S3. 760 
 761 
Figure 7. IL-6 is required for induction of Gr1+CD11b+ cells and Pam2Cys-induced 762 
immune suppression. (A-C) WT mice were treated following a protocol similar to that 763 
shown in Figure S1A. 24 h after cutaneous exposure to TLR ligands or PBS (control), 764 
immunoflourescence for TLR2 (red), TLR6 or TLR1 (blue) and nuclei (green) was done in A, 765 
a representative picture (n=3) is shown. Scale bar represents 30 m (B) The skin was 766 
evaluated for the expression of TNF, CXCL-2, and IL-6 mRNA by quantitative RT-PCR 767 
analysis (normalized to housekeeping gene -actin). Expression in the skin of untreated mice 768 
(naïve) was set as 1 (mean +/- SD, n=5). (C) Skin cells were isolated and analyzed for IL-6 769 
production by intracellular flow cytometry, a cumulative analysis (mean +/- SD, n=5) is 770 
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shown. (D) Primary human keratinocytes were isolated, treated with TLR ligands for 24h and 771 
the production of IL-6 was measured by ELISA (mean +/- SD of triplicates). (E) WT mice 772 
were treated following a protocol similar to that shown in Figure S1A and IL-6 concentrations 773 
in the sera were analyzed by ELISA (mean +/- SD of triplicates). (F, G) WT and Il6-/- mice 774 
were treated following the protocol shown in Figure S1A and ear swelling (mean +/- SD, n=5) 775 
(F) and the percentage (mean +/- SD, n=5) of Gr1+CD11b+ cells (G) were analyzed. (H) Bone 776 
marrow-derived MDSCs were treated with IL-6 (in indicated concentrations) during 777 
generation and their suppressive activity was measured in a co-culture with activated spleen 778 
cells (responder cells) in ratio 1:4. Proliferation of responder cells without MDSCs was set as 779 
100%. Data are representative of two independent experiments. *: P < 0.05. See also Figure 780 
S4. 781 
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Toll-like receptor 2 ligands promote chronic atopic
dermatitis through IL-4–mediated suppression of IL-10
Susanne Kaesler, PhD,a* Thomas Volz, MD,a* Yuliya Skabytska, MSc,a Martin K€oberle, PhD,a Ulrike Hein, MD,a
Ko-Ming Chen, MD,a Emmanuella Guenova, MD,a,b Florian W€olbing, MD,a Martin R€ocken, MD,a and
Tilo Biedermann, MDa,c T€ubingen and Munich, Germany, and Zurich, Switzerland
Background: Atopic dermatitis (AD) is a T cell–mediated
inflammatory skin disease, with TH2 cells initiating acute flares.
This inflamed skin is immediately colonized with Staphylococcus
aureus, which provides potent Toll-like receptor (TLR) 2
ligands. However, the effect of TLR2 ligands on the
development of TH2-mediated AD inflammation remains
unclear.
Objective: We investigated the progression of TH2
cell–mediated dermatitis after TLR2 activation.
Methods: Using models for acute AD with TH2 cells initiating
cutaneous inflammation, we investigated the consequences of
TLR2 activation. Dermatitis, as assessed by changes in ear skin
thickness and histology, was analyzed in different BALB/c and
C57BL/6 wild-type and knockout mouse strains, and immune
profiling was carried out by using in vitro and ex vivo cytokine
analyses.
Results: We show that TH2 cell–mediated dermatitis is
self–limiting and depends on IL-4. Activation of TLR2
converted the limited TH2 dermatitis to chronic cutaneous
inflammation. We demonstrate that the concerted activation of
TLR2 and IL-4 receptor on dendritic cells is sufficient for this
conversion. As an underlying mechanism, we found that the
combinatorial sensing of the innate TLR2 ligands and the
adaptive TH2 cytokine IL-4 suppressed anti-inflammatory IL-10
and consequently led to the exacerbation and persistence of
dermatitis.
Conclusion: Our data demonstrate that innate TLR2 signals
convert transient TH2 cell–mediated dermatitis into persistent
inflammation, as seen in chronic human AD, through
IL-4–mediated suppression of IL-10. For the first time, these
data show how initial AD lesions convert to chronic
inflammation and provide another rationale for targeting
IL-4 in patients with AD, a therapeutic approach that is
currently under development. (J Allergy Clin Immunol
2014;134:92-9.)
Key words: Staphylococcus aureus, Toll-like receptor 2, innate
immunity, IL-4, TH2, atopic dermatitis, IL-10
Atopic dermatitis (AD) is a frequent inflammatory skin disease
characterized by reduced skin barrier function, intracutaneous
T-cell activation, itchy dermatitis, and susceptibility to cutaneous
microbial and viral infections, and its prevalence has markedly
increased during the past 3 decades. AD is thought to be based on
(1) the genetic trait causing susceptibility and (2) environmental
factors.1-5 A detailed characterization of AD inflammation has
revealed a biphasic cutaneous cytokine milieu with initial
recruitment of IL-4–producing TH2 cells, followed by a mixed
phenotype in the chronic phase.6,7 Although cutaneous barrier
dysfunction also contributes to TH2 cell polarization, the TH2
cell cytokine IL-4 further reduces the cutaneous barrier. Addition-
ally, IL-4 suppresses antimicrobial peptide production and
immune function, allowing cutaneous microbes to expand and
persist.2,8-10 Next to this prominent communication between the
epithelium and T cell–derived cytokines, professional antigen-
presenting cells, especially activated dendritic cells (DCs), are
also found in AD lesions and are thought to promote AD initiation
and persistence by recruiting and activating T cells.11
In contrast to the cascade of steps driving adaptive immunity
during AD, much less is known about the role of innate immune
activation. In the skin rapid activation of innate sentinels drives
the first-line response to microbes. The key event in this process is
the recognition of microbial pathogen-associated molecular
patterns (PAMPs) by specific receptors, such as Toll-like
receptors (TLRs), on sentinel cells.12 After activation by innate
immune signals, immune sentinels, such as DCs, orchestrate
adaptive immune responses during infections, autoimmunity,
allergy, and tolerance.13,14 To this end, pathogen recognition
receptors on DCs recognize a broad spectrum of different
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Abbreviations used
AD: Atopic dermatitis
DC: Dendritic cell
IL-4R: IL-4 receptor
LTA: Lipoteichoic acid
OVA: Ovalbumin
Pam2: Pam2Cys
PAMP: Pathogen-associated molecular pattern
TLR: Toll-like receptor
WT: Wild-type
PAMPs.13 These innate immune sentinels detect more than 1
signal at a time, but only recently has it been appreciated that
the combination of incoming signals is crucial for the outcome
of immune responses.15 This is of special interest in the context
of AD because AD skin lesions are heavily colonized with
gram-positive Staphylococcus aureus and PAMPs from S aureus
predominantly bind TLR2.2,16 Interestingly, levels of cutaneous
TLR2 ligands strongly correlate with AD severity.17 Increased
understanding of combinative innate immune sensing is required
to comprehend the pathogenesis of chronic inflammatory diseases
at interface organs, and studying such diseases can serve as a
model to establish general mechanisms of innate inflammation.
In the present work we analyzed the consequences of innate
immune sensing through TLR2 for TH2 cell–mediated cutaneous
inflammation. We used TH2 cell–mediated dermatitis models
because IL-4–producing TH2 cells are found in early AD lesions
when the skin encounters increasing innate TLR2 signals derived
from S aureus. We found that a single exposure to TLR2 ligands
converts TH2-mediated transient dermatitis to chronic persistent
cutaneous inflammation. These findings mimic the development
of skin lesions in patients with AD. As the underlyingmechanism,
we demonstrated that the concerted activation of TLR2 and IL-4R
on innate immune sentinels potently suppressed IL-10, thereby
exacerbating TH2-mediated dermatitis and initiating chronic
inflammation. The most important immune skin sentinels are
DCs, and we show that the concerted activation of TLR2 and
IL-4R on DCs is sufficient to convert limited dermatitis into
aggravated and persisting inflammation. Thus the combined
sensing of innate immune signals together with the hallmark
adaptive cytokine of early inflammation, IL-4, determined the
outcome of this chronic immune response in patients with AD.
For the first time, these data show how initial AD lesions are
converted to chronic inflammation. In addition, these findings
also provide another rationale for targeting IL-4 in patients with
AD, a therapeutic approach that is currently under development.
METHODS
Mice
BALB/c, C57BL/6, DO11.10, OT-II, and signal transducer and activator of
transcription 6 (Stat6)–deficient mice were purchased from Charles River
(Sulzfeld, Germany) or the Jackson Laboratory (Bar Harbor, Me). Tlr22/2
BL/6 mice were provided by C. Kirschning (Duisburg, Germany) and
backcrossed to the BALB/c background, MHCII2/2 mice were provided by
L. Klein (Munich, Germany), and Il4ra2/2 mice were provided by A.
Gessner (Erlangen, Germany). All mice were kept and bred under specific
pathogen-free conditions in accordance with the guidelines of the Federation
of European Laboratory Science Association. All animal experiments were in
compliancewith both European Union and German law andwere approved by
local authorities (Regierungspr€asidium T€ubingen, HT4/03, HT2/11, HT9/13).
Ovalbumin sensitization and adoptive T-cell
transfer
Ovalbumin (OVA)–specific T cells were obtained from transgenic mice
(DO11.10, OT-II) or fromOVA-sensitized mice.18 CD41 T cells were isolated
with microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and
expanded in vitro. For adoptive transfer, 1 3 106 OVA-specific TH2 cells
with or without 5 mg of OVA protein (Hyglos, Regensburg, Germany) or
1.5 mg of OVA323-339 peptide (EMC, T€ubingen, Germany) were intracutane-
ously injected into the ear. S aureus lipoteichoic acid (LTA; 10 mg; obtained
from T. Hartung, Konstanz, Germany) or Pam2Cys (Pam2; 2 or 4 mg; EMC)
were included, where stated. DCswere exposed to 10mg/mLPam2 for 5 hours,
washed twice with PBS, pulsed with 1 mg/mL OVA peptide for 1 hour, and
washed twice with PBS. Controls were only pulsed with OVA. Where stated,
DCs were incubated with 10 mg of IL-4/mL over night before Pam2 exposure.
A total of 23 105 DCs were applied intradermally together with 13 106 TH2
cells. For IL-10 supplementation in Il4ra knockout mice, 2 mg of IL-10
(PeproTech, Heidelberg, Germany) was added, and an additional 2 mg was
injected 6 and 24 hours later. Control animals received PBS. For induction
of endogenous OVA-specific TH2 cells, DO11.10 mice were sensitized as pre-
viously described19 and challengedwithOVAprotein, followedbyPam2 injec-
tion. Ear thickness was measured with a micrometer (Kroeplin, Schl€uchtern,
Germany) and expressed as a change in ear thickness after treatment.
Cell culture
T-cell culture was performed, as previously described.20 OVA-specific TH2
cellswere expandedby the addition of 1.5 ng/mL IL-4 (PromoCell, Heidelberg,
Germany) and 10mg of OVA or 2.5mg/mLOVA323-339 peptide. For TH pheno-
typing, T cells were stimulated with 0.5mg/ml phorbol 12-myristate 13-acetate
(Sigma, Taufkirchen, Germany) and 1 mmol/L ionomycin (Sigma). Bone
marrow–derived DCs were generated and cultured, as previously described,21
and stimulated with 10 mg of Pam2/mL or 10 mg of S aureus LTA/mL with
or without 10 ng of IL-4/mL. Quantification of IL-4, IFN-g, IL-10, IL-12p70
(BD PharMingen, Heidelberg, Germany), and IL-13 (eBioscience, San Diego,
Calif) in the supernatant was performed by means of ELISA. For real-time
analysis, DCs were cultured with the indicated additives with or without
a-CD3/a-CD28–activated TH2 cells in transwell plates for 6 hours.
Real-time quantitative PCR
Total RNA was extracted from in vitro–cultured DCs or from ears after
adoptive transfer by using the RNAKit (Machery &Nagel, D€uren, Germany).
RNA was reverse transcribed to cDNA with the iScript cDNA Synthesis Kit
(Bio-Rad Laboratories, Munich, Germany), according to the manufacturer’s
instruction. Quantitative real-time PCR was carried out with a LightCycler
LC480 (Roche, Basel, Switzerland) by using SYBRGreen Supermix (Roche).
Data were presented normalized to the housekeeping gene b-actin and
calculated as the difference from the value obtained after transfer of OVA
alone, which was set as 1.
Statistical analysis
All data are presented as means 6 SEMs and representative of at least 2
experiments. Statistical analysis was performed with the unpaired Student
t test (2-tailed) or with 2-way repeated-measures ANOVA and the Bonferroni
posttest. P values of less than .05 were considered statistically significant.
Additional information can be found in theMethods section in this article’s
Online Repository at www.jacionline.org.
RESULTS
Self-limited allergen-induced dermatitis is
mediated by IL-4
Early immune reactions in AD skin are dominated by TH2
cells and cytokines and are believed to predispose the AD skin
for colonization by bacteria, such as S aureus. As a model for
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the early phase of AD inflammation, OVA-specific IL-4–
producing TH2 cells were intracutaneously transferred with or
without OVA into the ears of naive mice. Ear swelling was
determined as the change in skin thickness to quantify dermatitis.
Transfer of TH2 cells with OVA provoked strong but self-limiting
cutaneous inflammation, with a peak at 24 hours in both
TH2-prone BALB/c (Fig 1, A) and C57BL/6 mice (Fig 1, B).
OVA-specific TH2 cells from wild-type (WT) or IL-4–deficient
mice were generated to identify the underlying mechanisms.
TH2 polarization of Il4
2/2 T cells was determined based on
IL-13 production, which was identical to cytokine secretion by
WT TH2 cells, whereas IL-4 production was lacking, as expected
(see Fig E1 in this article’s Online Repository at www.jacionline.
org). Intracutaneous transfer of WT TH2 cells and antigen
resulted in a significant increase in ear thickness in WT mice
that was dependent on TH2 cell–derived IL-4 and host IL-4R.
Il42/2 TH2 cells did not induce dermatitis in WT mice, and simi-
larly, WT TH2 cells did not induce cutaneous inflammation in
mice lacking the IL-4 receptor (Il4ra2/2; Fig 1, C). Importantly,
IL-4–mediated dermatitis was also strictly dependent on MHCII
on recipient cells because it was completely abrogated in
recipients deficient for MHCII (Fig 1, D). Thus our data demon-
strate that antigen-activated TH2 cells induce self-limited
cutaneous inflammation, which is dependent on IL-4 signaling.
TLR2 ligands enhance and sustain TH2-mediated
dermatitis through activation of skin-resident cells
S aureus is a dominant trigger of AD, providing high levels of
different TLR2 ligands. One such ligand, LTA, was recently
isolated from AD skin lesions and identified as a PAMP that
correlates with AD severity.17 Therefore we analyzed the role
of innate immune sensing of S aureus–derived PAMPs by
exposing the skin to those TLR2 ligands. LTA significantly
enhanced dermatitis induced by OVA-specific TH2 cells in
BALB/c (Fig 2, A) and C57BL/6 (Fig 2, B) mice, indicating
that innate immune sensing of S aureus–derived LTA contrib-
utes to AD inflammation. LTA was initially described as a
ligand for TLR2,22 although it now appears that lipoproteins
in LTA preparations mediate the TLR2-dependent effects of
LTA.23,24 Therefore we next exposed the skin to the lipoprotein
Pam2, another TLR2 ligand.25 Like LTA, Pam2 significantly
enhanced and sustained TH2-mediated dermatitis in BALB/c
and in C57BL/6 mice, as shown by ear swelling (Fig 2, C
and D, respectively). In addition, hematoxylin and eosin
staining of skin sections at 48 hours demonstrated epidermal
thickening (Fig 2, E, yellow arrow) and a massive dermal
cellular infiltrate in these Pam2 conditions, exceeding findings
in self-limited TH2 dermatitis (Fig 2, E, white arrows).
Interestingly, IFN-g mRNA was upregulated in skin undergoing
Pam2-exposed exacerbated inflammation, although not in self-
limited TH2 dermatitis skin (Fig 2, F). This upregulation could
be due to endogenous T-cell bystander recruitment in addition
to the transfer of TH2 cells. Therefore we extended our analyses
to a model in which endogenous TH2 cells induced by OVA
sensitization are recruited to the skin after antigen challenge.19
In this model, OVA-activated TH2 cells led to short-lived derma-
titis as well. In agreement with the results obtained with Pam2
in the transfer model, a single exposure to Pam2 in actively
sensitized mice also induced severe and ongoing dermatitis, as
assessed by measuring the increase in ear thickness (Fig 2, G)
and by epidermal thickness and cellular infiltrates in histology
(Fig 2, H). Next, we adopted our transfer model, in which
TH2 cells and OVA were administered first followed by
exposure to Pam2 24 hours later because this might be closer
to the situation in human AD. Exposure to Pam2 24 hours after
TH2 cell activation also significantly enhanced and prolonged
FIG 1. TH2-mediated dermatitis is self-limited and dependent on IL-4 and MHCII. A and B, Intracutaneous
OVA-specific TH2 cells mediate dermal inflammation in the ears of naive BALB/c (Fig 1, A) or C57BL/6
(Fig 1, B) mice quantified as changes in ear thickness. C, Transfer of WT or Il42/2 OVA-activated TH2 cells
in WT or Il4ra2/2 mice (BALB/c background) demonstrated a strict dependence on IL-4. D, Complete
abrogation of inflammation in MHCII2/2 mice (C57BL/6 background). n 5 4-10. #*P < .05, **P < .005, and
***P < .0005.
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cutaneous inflammation, followed by significantly increased
recruitment of CD451 leukocytes (see Fig E2 in this
article’s Online Repository at www.jacionline.org). Thus innate
immune sensing through TLR2 enhanced and sustained skin
inflammation caused by IL-4–producing TH2 cells.
One possible target of TLR2 ligands are T cells because
TLR2 can act as a costimulatory molecule for T-cell activa-
tion.26 WT or Tlr22/2 TH2 cells were adoptively transferred into
either WT or Tlr22/2 mice, and skin inflammation was moni-
tored thereafter to identify the dominant target cells for TLR2
ligands. In WT mice Pam2 enhanced and sustained dermatitis
induced by OVA-activated TH2 cells, irrespective of whether
the T cells were TLR2 deficient (Fig 3, A). In contrast, TLR2
ligands completely failed to enhance and sustain TH2-induced
dermatitis in Tlr22/2 mice, and the ear-swelling pattern in these
mice was indistinguishable from the control transfer without
TLR2 ligands (Fig 3, B). These data demonstrate that TLR2
ligands most likely target skin-resident antigen-presenting cells.
Among these, the most important are DCs, which function as
crucial sentinels of the immune system and link innate and
adaptive immunity also in patients with AD.11 Accordingly,
we modified our protocol and transferred OVA-pulsed DCs
with (Pam2-DCOVA) or without (DCOVA) Pam2 exposure
together with OVA-specific TH2 cells. Indeed, the transfer of
OVA-pulsed DCs resulted in a limited antigen-induced derma-
titis, whereas Pam2-DCOVA caused significantly enhanced and
prolonged inflammation (Fig 3, C). Aggravated skin inflamma-
tion was dependent on TLR2 activation of DCs because WT but
not Tlr22/2 Pam2-DCOVA exacerbated dermatitis in C57BL/6
mice (Fig 3, D) and BALB/c mice (see Fig E3 in this article’s
Online Repository at www.jacionline.org). Together, these
data demonstrate that activation of DCs through TLR2
converts limited TH2-mediated dermatitis to an aggravated and
persisting inflammation.
IL-4–induced suppression of IL-10 causes
exacerbation and persistence of TH2-mediated
dermatitis by TLR2 ligands
Given the critical role of IL-4 during early skin inflammation at
the time of Pam2 encounter and of DCs for Pam2-induced
dermatitis exacerbation, we next investigated the combined
immune sensing of IL-4 and the TLR2 ligand Pam2 by DCs. To
this end, DCs were activated with Pam2 with or without
additional exposure to IL-4, as in AD skin. Cytokine levels
were analyzed 24 hours later. The quality and functional
consequences of immune responses are determined by the
cumulative effect of differentially acting cytokines. Therefore
we analyzed the main representatives of the proinflammatory and
anti-inflammatory cytokines IL-12 and IL-10, respectively, to
anticipate the immune consequences of such DCs. We found that
Pam2-mediated activation of DCs induced IL-12 and IL-10.
However, when mimicking the TH2-dominant milieu of early AD
by adding IL-4, IL-12p70 levels were upregulated further in
activated DCs, as expected.14,27 More importantly, IL-10 levels
were significantly suppressed (Fig 4, A). This resulted in a
proinflammatory shift of the cytokine milieu, as represented by
the IL-10/IL-12 ratio (Fig 4, B). This suppression of IL-10 was
indeed mediated by IL-4 because it was completely abolished
in DCs with defective IL-4 signaling (see Fig E4 in this article’s
Online Repository at www.jacionline.org).
On the basis of these in vitro data, we askedwhether this change
of cytokine expression was also associated with the observed con-
version of self-limited dermatitis into aggravated inflammation
in vivo (Fig 2). To do this, we performed quantitative real-time
PCR of ear skin 12 and 24 hours after the initiation of AD-like
inflammation. As expected, Pam2 exposure upregulated IL-12
levels in the skin of recipient mice, with the highest levels
detected 24 hours after challenge (Fig 5, A). Remarkably, and
consistent with our in vitro results, cutaneous IL-10 expression
FIG 2. TLR2 ligands convert TH2-mediated acute dermatitis into exaggerated and persistent inflammation.
A-D, Progression of TH2-induced dermatitis after exposure to TLR2 ligands in BALB/c (Fig 2, A and C) and
C57BL/6 (Fig 2, B and D) mice is shown. LTA temporarily enhanced dermatitis (Fig 2, A and B). Pam2
converted dermatitis into persistent inflammation (Fig 2, C and D). E, Representative hematoxylin and eosin
staining of histologic sections from C57BL/6 mice 48 hours after intracutaneous transfer. F, Relative IFN-g
mRNA level in ear skin 12 hours after transfer. G and H, OVA-sensitized DO11.10 mice (BALB/c background)
challenged intracutaneously with OVA with or without Pam2. Cutaneous inflammation after OVA activation
of endogenous TH2 cells is shown in Fig 2, G, and histology (day 6) is shown in Fig 2, H. n 5 4-20. *P < .05,
**P < .005, and ***P < .0005.
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appeared earlier and was highest 12 hours after Pam2 exposure
(Fig 5, A). This opposing regulation is best reflected by the
cutaneous IL-10/IL-12 mRNA ratio: in mice with self-limited
TH2-mediated dermatitis, IL-10 dominated skin inflammation at
24 hours (Fig 5, B, left). In contrast, the IL-10/IL-12 mRNA ratio
was markedly reduced in dermatitis lesions that showed enhanced
and sustained inflammation after TLR2 ligand exposure (Fig 5, B,
right). Importantly, amplified IL-4 production, as detected by
means of cutaneous IL-4 mRNA expression, was found in both
self-limited TH2 dermatitis and enhanced and sustained
inflammation after Pam2 exposure (see Fig E5 in this article’s
Online Repository at www.jacionline.org). Therefore after innate
immune sensing of TLR2 ligands, TH2-derived IL-4 suppressed
IL-10 levels, allowing TLR2 ligands to enhance and sustain AD
inflammation. Indeed, IL-10 expression in Pam2-treated DCs
was significantly reduced on coculture with IL-4–secreting TH2
cells comparable with the suppression seen after direct addition
of IL-4 (Fig 5, C). Intracutaneously transferred TH2 cells and
Pam2-DCOVA were reconstituted with IL-10 to prove that IL-10
is indeed critical for the IL-4–mediated conversion of acute AD
flares into persistent AD-like inflammation. Supplementation
with IL-10 completely abrogated Pam2-induced dermatitis,
which decreased to the level of inflammation without Pam2
activation (Fig 5, D). This demonstrated IL-10 to be a key
regulator in the orchestration of adaptive TH2-mediated
immune responses. Next, we carried out long-term analyses
of Pam2-exposed dermatitis. Impressively, after a single
exposure to Pam2, TH2-induced dermatitis increased over 5
days and remained significantly enhanced for more than 3 weeks
(Fig 5, E). In summary, our data demonstrate that TLR2 ligands
convert acute self-limited inflammation to chronic and persistent
dermatitis through IL-4–mediated suppression of IL-10.
DISCUSSION
AD is based on a complex genetic trait, with skin barrier defects
being among the most frequent functional abnormalities.3,28 The
majority of patients with AD have increased IgE levels toward
environmental antigens and TH2-biased T-cell immunity,
which is based on both cutaneous barrier defects and an inherent
immune bias toward TH2 immunity.
2 A prerequisite for the
FIG 4. Suppression of TLR2 ligand–induced IL-10 by IL-4.A,DCs exposed to
Pam2 produced intermediate levels of IL-12p70 and high levels of IL-10
(left). Coactivation of Pam2-exposed DCs with IL-4 significantly suppressed
IL-10 secretion (Fig 4, A, right), resulting in a low IL-10/IL-12p70 ratio
(B; average of 4 experiments). **P < .005.
FIG 3. TLR2 activation of skin cells converts TH2-mediated acute dermatitis to enhanced and prolonged
inflammation. A and B, Crossover experiment for persistent inflammation. Fig 3, A, shows Pam2-induced
aggravated dermatitis in BALB/c mice after intracutaneous activation of either WT or Tlr22/2 TH2 cells.
Fig 3, B, shows self-limited acute dermatitis, as in OVA-treated control animals, despite exposure to
Pam2 in Tlr22/2 recipients (done in parallel with Fig 3, A). C, Exacerbation and prolongation of dermatitis
after transfer of TH2 cells and Pam2-exposed OVA-pulsed DCs in C57BL/6 mice. D, Pam2-exposed WT but
not Tlr22/2 DCs promote exacerbated inflammation in Tlr22/2-C57BL/6 mice. n 5 4-10. **P < .005 and
***P < .0005.
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development of AD inflammation is the initial recruitment of
IL-4–producing TH2 cells to the skin on acute triggering factors,
among them exposure to environmental allergens.29-31 However,
the switch from acute AD flares to chronic cutaneous inflamma-
tion is not understood, and functional human in vivo studies are
difficult to perform. Cutaneous colonization or infections with S
aureus are found in almost all patients with AD, demonstrating
a positive correlation between bacterial density and the severity
of AD.32 Moreover, this correlation with AD severity is also valid
for TLR2 ligands found on the skin.17 Therefore we hypothesized
that TLR2 ligands play a major role in the conversion of acute AD
inflammation to chronic dermatitis.
TLR2 has been associated with AD pathogenesis,2 with the
most recent work demonstrating that TLR2 contributes to skin
barrier repair when acting on the epithelium.33 To investigate
howTLR2 ligands orchestrate cutaneous inflammation in patients
with AD, we used a mouse model in which IL-4 is the dominant
and functionally relevant cytokine, as in early AD. This allowed
us to specifically focus on the effect of innate TLR2 signals in a
TH2-dominant adaptive immune response in the skin. Previous
analyses concentrated on the role of TLR2 ligands for cutaneous
TH1 responses,
34 for which IFN-g had been shown to mediate
dermal thickening.35 We showed that TLR2 ligands, as provided
by S aureus, convert TH2-mediated self-limited skin dermatitis
into persistent and aggravated chronic inflammation. These
analyses provide a rationale for the conversion of acute AD flares
to chronic skin inflammation, which is observed in patients with
AD. This conversion was driven by innate and adaptive signals
that simultaneously activated immune sentinels of the skin. In
general, TLR2 ligands are known to coinduce rather high levels
of IL-10.36 This, under homeostatic conditions, might contribute
to microbiota tolerance because gram-positive bacteria persist on
the skin in the absence of inflammation. However, in the setting of
IL-4–dominated inflammation, this upregulation is counterregu-
lated by IL-4, which suppresses IL-10, leading to TLR2-
mediated exacerbation of inflammation. Thus the combinative
sensing of adaptive IL-4 together with innate TLR2 signals
directly drives skin inflammation by suppressing IL-10. These
newly identified consequences of coactivating signals shed light
onto a hitherto neglected effect of combinatorial immune
sensing.15 Moreover, the identification of IL-10 as a target
cytokine of this immune orchestration confirms its dominant
role as an important anti-inflammatory cytokine with immuno-
modulatory properties, limiting otherwise excessive immune
responses.37 It is well established that IL-10 regulates a variety
of immune cells, including TH2 cells.
38 Furthermore, IL-10 has
even been used as a therapeutic agent for inflammatory diseases
of the skin, such as psoriasis,39 and the gut, such as Crohn
disease.40 Interestingly, an AD-like skin disease in NcNgA
mice was effectively treated with IL-10,41 and IL-10 was also
relevant for the amelioration of canine AD.42 These analyses
support the concept that the adaptive cytokine IL-4 suppresses
innately induced IL-10, which is responsible for the conversion
of acute dermatitis to chronic and persistent inflammation.
These findings are highly relevant to patients with AD because
S aureus is found on the skin of almost all such patients.32 In
addition to S aureus, Malassezia species have been shown to be
triggers of head-and-neck variants of AD, and herpes virus
infections lead to severe AD complications.43-45 Importantly, in
the context of our findings, innate signals from Malassezia
FIG 5. Suppression of IL-10 by coactivation of IL-4R and TLR2 converts acute dermatitis to chronic
inflammation. A and B, Quantitative real-time PCR of cutaneous cytokines during conversion to persistent
Pam2-induced dermatitis. Fig 5, A, shows Pam2-induced IL-12p40 and IL-10 expression. Fig 5, B, shows
reduced IL-10/IL-12p40 ratio in persistent dermatitis. C, Suppression of IL-10 mRNA in Pam2-exposed
DCs by means of coculture with activated TH2 cells or the addition of IL-4. D, Reconstitution of IL-10
abrogated Pam2-induced aggravation of dermatitis after intracutaneous transfer of TH2 cells, DCs, and
OVA in Il4ra2/2 mice. E, A single Pam2 exposure converted TH2-mediated dermatitis into exacerbated
chronic inflammation in C57BL/6 mice. n 5 6-10. ***P < .0005.
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species and herpes viruses activate TLR2.46,47 This indicates that
our findings on S aureus–derived TLR2 ligands might be of
general importance and also functional in other settings in
patients with AD.
Our findings also further emphasize that IL-4 is a promising
target for AD therapy. It has long been known that IL-4 is the
hallmark cytokine of TH2 cells and early AD and that IL-4
downregulates antimicrobial peptides and cutaneous barrier
function.6,7,48 We have now added a crucial new role for IL-4 in
AD pathogenesis: IL-4 suppresses cutaneous IL-10 induced by
innate signals and therefore promotes chronic AD. Until recently,
however, IL-4 was targeted in patients with severe asthma49 but
not in those with AD. Now clinical trials report significant
improvement of AD-related inflammation by subcutaneous appli-
cation of a human mAb directed against IL-4Ra.50-53 Together
with our data, this indicates that inhibiting IL-4R signaling also
prevents IL-4–mediated suppression of IL-10, which is pivotal
for persistent and chronic inflammation in patients with AD after
the simultaneous activation of IL-4R and TLR2.
We thank Ulrike Schmidt, Stefanie M€uller, Synia Haub, and Natalie Mucha
for their excellent technical assistance.
Key messages
d TH2 cell–mediated dermatitis is self-limiting and strictly
depends on IL-4.
d TLR2 ligands convert self-limited TH2-mediated derma-
titis to chronic inflammation by activating skin-resident
sentinels.
d TLR2 ligand–induced chronic dermatitis results from
IL-4–mediated suppression of IL-10.
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METHODS
Skin cell analysis
Mouse ear tissue was incubated with Dispase II (Sigma-Aldrich) for 2
hours at 378C. The dermis and epidermis were separated; digested for 30
minutes at 378C in collagenase A (Serva, Heidelberg, Germany) or trypsin-
EDTA (Biochrom Berlin, Germany), respectively; and pooled again. Samples
were given twice through a cell strainer to obtain single-cell suspension. After
washing, cells were counted, stained for 30 minutes at 48C, and analyzed by
means of flow cytometry with an LSRII flow cytometer and FACSDiva
Software (BD Biosciences, Heidelberg, Germany).
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FIG E1. Phenotypic characterization of TH2 cells. Characterization ofWT and IL-4–deficient TH2 cells used for
intracutaneous transfer, as shown in Fig 2. Secretion of IL-4 (A), IL-13 (B), and IFN-g (C) was determined by
means of ELISA. For comparison, cytokine secretion by TH1 cells is shown. n.d., Not detectable.
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FIG E2. Pam2-induced exacerbated inflammation after TH2 cell activation. A, TH2 cells and OVA were
transferred into the skin of BALB/c mice. Twenty-four hours later, some mice were additionally exposed
to Pam2, which resulted in aggravated inflammation comparable with that seen after simultaneous
application of TH2, OVA, and Pam2 (see Fig 2, C; n 5 8). B, Ear skin analysis from the experiment
depicted in Fig E2, A, showing increased numbers of CD451 cells in the Pam2-exposed condition.
*P < .05 and ***P < .0005.
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FIG E3. TLR2 activation of DCs converts TH2-mediated acute dermatitis to
enhanced and prolonged inflammation. Comparable with Fig 3, D, TH2 cells
and OVA-pulsed WT or Tlr22/2 DCs with or without Pam2 exposure
were transferred into Tlr22/2 BALB/c mice, and ear swelling was measured
thereafter. Pam2-exposed WT but not Tlr22/2 DCs promoted exacerbated
dermatitis (n 5 10). ***P < .0005.
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FIG E4. Suppression of IL-10 by IL-4 in Pam2-activated DCs. IL-10 secretion by bone marrow–derived DCs
either from a BALB/c background (A and B) or a C57BL/6 background (C and D), as determined by means of
ELISA. Addition of IL-4 significantly suppressed Pam2-induced IL-10 in WT DCs (Fig E4, A and C) but not in
DCs with defective IL-4 signaling pathways (Fig E4, B and D). n.d., Not detectable. *P < .05 and ***P < .0005.
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FIG E5. IL-4 expression in mouse ear skin. Relative IL-4 mRNA levels in
mouse ear skin 12 and 24 hours after transfer of TH2 cells and OVA with or
without Pam2, corresponding to expression shown in Fig 5,A and B. Values
were determined by using real-time PCR, normalized to b-actin, and shown
relative to values obtained after transfer of OVA alone (n56).
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Nonpathogenic Bacteria Alleviating Atopic Dermatitis
Inflammation Induce IL-10-Producing Dendritic Cells
and Regulatory Tr1 Cells
Thomas Volz1, Yuliya Skabytska1, Emmanuella Guenova1, Ko-Ming Chen1, Julia-Stefanie Frick2,
Carsten J. Kirschning3, Susanne Kaesler1, Martin Ro¨cken1 and Tilo Biedermann1
The beneficial effects of nonpathogenic bacteria are increasingly being recognized. We reported in a placebo-
controlled study with atopic dermatitis (AD) patients that cutaneous exposure to lysates of nonpathogenic
bacteria alleviates skin inflammation. To now unravel underlying mechanisms, immune consequences of sensing
nonpathogenic bacterium Vitreoscilla filiformis lysate (Vf) were characterized analyzing (1) differentiation of
dendritic cells (DCs) and, consecutively, (2) effector functions of DCs and T helper (Th) cells in vitro and in a
murine model of AD in NC/Nga mice in vivo. Topical treatment with Vf significantly reduced AD-like
inflammation in NC/Nga mice. Importantly, cutaneous exposure to Vf in combination with the allergen FITC
significantly also reduced subsequent allergen-induced dermatitis indicating active immune modulation. Indeed,
innate sensing of Vf predominantly induced IL-10-producing DCs, which was dependent on Toll-like receptor
2 (TLR2) activation. Vf-induced IL-10þ DCs primed naive CD4þ T helper cells to become regulatory IFN-glow
IL-10high Tr1 (type 1 regulatory T) cells. These IL-10high Tr1 cells were also induced by Vf in vivo and strongly
suppressed T effector cells and inflammation. In conclusion, we show that innate sensing of nonpathogenic
bacteria by TLR2 induces tolerogenic DCs and regulatory Tr1 cells suppressing T effector cells and cutaneous
inflammation. These findings indicate a promising therapeutic strategy for inflammatory skin diseases like AD.
Journal of Investigative Dermatology advance online publication, 25 July 2013; doi:10.1038/jid.2013.291
INTRODUCTION
Atopic dermatitis (AD) is a chronic inflammatory skin disease
with increasing prevalence rates, affecting up to 10–20% of
the children in western countries (Bieber, 2008; Boguniewicz
and Leung, 2010). Although the detailed mechanisms under-
lying inflammation of AD skin are not fully understood, a
defect in skin barrier function as well as an immune
dysbalance play a crucial role, leading to T helper cell type 2
(Th2)–biased immune responses (Palmer et al., 2006; Bieber,
2008; Irvine et al., 2011). Increased hygiene standards, less
infectious diseases, and lowered family sizes are claimed to
lead to microbial deprivation during early years of life that
facilitate misdirected effector immune responses rather than
the induction of immune tolerance (‘‘hygiene hypothesis’’),
contributing to increase and development of allergies and
atopic diseases (Strachan, 1989; Bach, 2002; von Mutius and
Vercelli, 2010). Surface organs like the skin are constantly
colonized with bacteria in the absence of detectable
inflammation, but the mechanisms that inhibit inflammation
or even induce tolerance to the local microbiota are still
enigmatic (Grice et al., 2009). A reduced genetic diversity of
Gram-negative gammaproteobacteria in the environment of
atopic individuals was observed that profoundly influenced
the skin microbiota, leading to a decrease in Gram-negative
bacterium Acinetobacter and the anti-inflammatory cytokine
IL-10, demonstrating that resident microbes shape cutaneous
immune homoeostasis (Hanski et al., 2012). These data ideally
complement analyses in mouse models that first demonstrated
the potential of Gram-negative bacterium Acinetobacter to
prevent allergies (Debarry et al., 2007; Conrad et al., 2009). In
contrast to prevention of allergic sensitizations, most thera-
peutic strategies reporting the oral use of nonpathogenic or the
so-called ‘‘probiotic’’ bacteria failed to show significant effects
in the treatment of AD (Lee et al., 2008; Boyle et al., 2009).
Recently, we performed a proof-of-concept study in patients
demonstrating that immune recognition of the nonpathogenic
microbe Vitreoscilla filiformis is a promising strategy to treat
AD when directly applied onto patients’ skin and not orally
(Gueniche et al., 2008). Based on these clinical findings we
hypothesized that immune recognition of Gram-negative
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nonpathogenic bacterium V. filiformis exploits an important
mechanism of microbial immune sensing, finally alleviating
inflammation by induction of tolerance.
Pattern recognition receptors such as Toll-like receptors
(TLRs) play a key role in detecting ‘‘pathogen-associated
molecular patterns’’ (Takeuchi and Akira, 2010; Volz et al.,
2010; Volz et al., 2012). Especially within surface organs,
dendritic cells (DCs) are equipped with numerous pattern
recognition receptors and act as sentinels to sense micro-
bes, leading to DC maturation and cytokine production
(Reis e Sousa, 2004; Joffre et al., 2009). Activated DCs are
the most potent directors of immune phenotypes in T cells,
determining T-cell polarization to the different Th subtypes.
During this process of Th cell differentiation, DC cytokines are
most important possibly also shaping regulatory T cells
(Kapsenberg, 2003; Bettelli et al., 2008; Volz et al., 2012).
Intriguing studies demonstrated that these pathways are also
critical for induction of tolerance to the microbiota (Round
and Mazmanian, 2010; Geuking et al., 2011).
Given the positive results from our proof-of-concept study
in AD patients, we investigated the underlying mechanisms.
AD-prone NC/Nga mice with Th2-dominated cutaneous
hypersensitivity to FITC showed, similar to AD patients,
alleviated dermatitis when their skin was exposed to
V. filiformis signals. Importantly, this therapeutic effect was
even more pronounced when the skin was exposed to
V. filiformis signals previous to allergen challenge, indicating
effective immune modulation. Indeed, V. filiformis signals
induced high levels of IL-10 in DCs via TLR2. These DCs
orchestrated the induction of IL-10high, IFN-glow-producing Tr1
(type 1 regulatory T) cells. This regulation was also detected in
AD mice after cutaneous exposure to Vf with dominant IL-10
production by T cells from skin-draining lymph nodes and
consecutively reduced T-cell proliferation and proinflamma-
tory cytokine production.
Thus, immune recognition of the Gram-negative nonpatho-
genic bacterium V. filiformis by DCs induces IL-10-producing
DCs and regulatory Tr1 cells. This pathway may generally be
functional when discriminating between ‘‘pathogenic’’ and
‘‘nonpathogenic’’ bacteria and could be exploited to alleviate
cutaneous inflammation such as in AD.
RESULTS
Exposure to nonpathogenic bacteria attenuates cutaneous
inflammation in a murine model of AD
We recently reported effective treatment of AD lesions by
topical treatment of V. filiformis lysate (Vf) in a double-blind,
placebo-controlled clinical trial (Gueniche et al., 2008). Thus,
we first asked whether Vf solely suppressed cutaneous
inflammation in AD at the time and site of application. To
this end, mice of the NC/Nga strain that have been shown to
develop AD-like skin lesions and clinical features most closely
resembling human AD were investigated (Matsuda et al.,
1997). NC/Nga mice sensitized to the allergen FITC clearly
developed dermatitis lesions as measured by a strong increase
in ear thickness following allergen challenge (Figure 1a). All
appropriate controls without sensitization and subsequently
challenged with FITC with or without Vf exposure showed ear
swelling responses that were always o0.03 mm. Dermatitis
was reduced by 425% in mice that received topical treatment
of ear skin with Vf during FITC challenge, indicating direct
anti-inflammatory properties of Vf (Figure 1a). However, these
effects remained somewhat limited. Therefore, we next asked
whether exposure to Vf could also orchestrate immune
modulation or tolerance mediating long-term effects in addi-
tion. Therefore, one group of FITC-sensitized mice was
exposed to Vf in combination with FITC and the effects of
this exposure were determined 1 week later by challenge with
the allergen only. Compared with the FITC-sensitized control
group, mice previously exposed to Vf together with FITC
showed significantly reduced ear swelling after allergen
challenge alone (Po0.01), with almost 50% reduction at the
peak of skin inflammation (Figure 1b). Importantly, we
determined antigen-specific immunoglobulin levels in all
mice sensitized to FITC with or without exposure to Vf and
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Figure 1. Cutaneous exposure to Vitreoscilla filiformis (Vf) attenuates skin
inflammation. (a) FITC-sensitized NC/Nga mice showed ear swelling responses
peaking at 24 hours after challenge and declining thereafter. Cutaneous
exposure of mice to Vf exclusively during challenge significantly reduced ear
swelling at 24 and 48 hours. Not sensitized but FITC-challenged mice
(gray lines) did not display marked ear swelling responses irrespective of
exposure to Vf. Percentage of reduction of ear swelling of FITC-sensitized
Vf-exposed mice compared with FITC-challenged mice not receiving Vf is
shown at the right. (b) Cutaneous exposure of mice to FITC together with Vf
only previous to the final challenge significantly reduced ear swelling 24 and
48 hours after FITC challenge compared with the positive control group.
Reduction of ear swelling was up to 50% compared with mice not being
exposed to Vf, as depicted in the right panel. One out of two independent
experiments is shown, mean±SEM, n¼ 5 mice per group. NS, not significant.
*Po0.05 and **Po0.01.
T Volz et al.
Nonpathogenic Bacteria Induce Tr1 Cells
2 Journal of Investigative Dermatology
found elevated antigen-specific immunoglobulin levels when
compared with naive control mice. We detected no difference
in FITC-specific IgG1 and IgG2a levels when comparing Vf
exposed with unexposed mice and only a slight reduction in
antigen-specific IgE (Supplementary Figure S1 online). Thus,
Vf attenuated cutaneous T cell–mediated inflammation in a
murine model of AD by modes of immune modulation,
indicating that innate sensing of nonpathogenic V. filiformis
regulates even already established adaptive immunity.
Signals from nonpathogenic bacterium V. filiformis induce
maturation of human and murine DCs
Immune modulation or tolerance can be induced by immature
or semimature DCs not fully activated. To investigate DC
activation, murine bone marrow–derived dendritic cells
(BMDCs) and human monocyte-derived dendritic cells were
stimulated with either lipopolysaccharide (LPS) as positive
control or Vf for 24–48 hours. DC maturation was assessed by
FACS analysis.
Both Vf and LPS unequivocally induced maturation of
BMDCs as detected by upregulation of maturation markers
such as CD80, CD86, CD83, and major histocompatibility
complex class II as compared with untreated cells (Figure 2a).
After activation of human monocyte-derived dendritic cells
with Vf or LPS, CD83, the most reliable surface marker for
detection of human DC maturation, was also clearly upregu-
lated (Supplementary Figure S2a online). This shows that
signals of V. filiformis orchestrate the development of pheno-
typically mature DCs as determined by FACS analysis.
Signals from nonpathogenic bacterium V. filiformis orchestrate
the induction of IL-10high DCs
Next we analyzed cytokine production of DCs after activation
with either Vf or LPS. As expected, LPS induced high amounts
Unstim
LPS
(1 μg ml–1)
Vf
(5% v/v)
CD83MHC IICD86CD80
2.5
2.0
1.5
1.0
IL
-1
2p
70
 (n
g m
l–1
)
IL
-1
0 
(ng
 m
l–1
)
0.5
0
2.5
2.0
1.5
1.0
0.5
0
Unstim Vf
(5% v/v)
LPS
(1μg ml–1)
Unstim Vf
(5% v/v)
LPS
(1μg ml–1)
Ce
ll c
ou
nt
Figure 2. Signals of Vitreoscilla filiformis (Vf) predominantly induce IL-10-producing mature dendritic cells (DCs). DCs were exposed to Vf or lipopolysaccharide
(LPS). (a) Vf and LPS unequivocally stimulated murine bone marrow–derived dendritic cells (BMDCs) to upregulate CD80, CD86, major histocompatibility
complex class II (MHC II), and CD83 (filled area) compared with untreated cells indicating full DC maturation. Gray lines indicate isotype controls. Unstim,
unstimulated. (b) BMDCs activated with Vf produced high levels of IL-10 but only low amounts of IL-12p70, characteristic for IL-10þ DCs. In contrast and, as
expected, LPS induced high IL-12p70 but only low IL-10 levels in BMDCs. Representative data from one out of four independent experiments are shown.
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of IL-12p70 and low levels of IL-10. In sharp contrast,
stimulation with Vf led to a DC cytokine profile dominated
by the anti-inflammatory cytokine IL-10, whereas IL-12p70
levels remained low for all V. filiformis strains investigated
(Figure 2b and Supplementary Figure S3 online). This IL-10
production induced by Vf was dose dependent in both human
and mouse DCs, indicating ligand(s) that trigger pattern
recognition receptors (Supplementary Figure S2b online).
Moreover, investigating numerous synthetic and bacterial-
derived TLR2 ligands, Vf was always superior in the induction
of IL-10 in DCs (Supplementary Figure S4 online). These data
demonstrate that innate immune sensing of nonpathogenic
bacteria governs DCs to predominantly produce the anti-
inflammatory and potentially tolerogenic cytokine IL-10.
Innate immune pathways for DC activation and IL-10 production
following encounter of signals from nonpathogenic bacterium
V. filiformis
To gain further insight into innate immune pathways activated
by Vf, we first investigated WT and MyD88 / DCs. DC
maturation was induced in WT DCs in response to TLR2
ligand Pam2Cys (data not shown), TLR4 ligand LPS, and Vf as
detected by upregulation of major histocompatibility complex
class II, CD80, CD83, and CD86 (Figure 3a). In contrast, but
as expected, Pam2Cys was unable to induce maturation of
MyD88 / DCs (data not shown) and DC maturation in
response to LPS was partially hampered. Strikingly, lack of
MyD88 did not affect DC maturation in response to Vf,
indicating that MyD88-independent pathways are at least in
part functional for DC maturation induced by nonpathogenic
bacteria (Figure 3a).
In sharp contrast to DC maturation, production of IL-10 and
IL-12p70 was almost completely abolished in MyD88 /
DCs (data not shown). Thus, DC maturation and cytokine
production operate via distinct innate immune pathways.
To investigate the pathways that lead to DC cytokine
production following contact to nonpathogenic bacteria, the
consequences of Vf exposure were investigated in BMDCs
lacking either TLR2 or TLR4. Strikingly, IL-10 production
was almost completely dependent on TLR2, as IL-10 was
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Figure 3. Distinct innate immune pathways control dendritic cell (DC) maturation and cytokine production induced by Vitreoscilla filiformis lysate (Vf).
(a) Exposure to Vf also induced DC maturation in DCs lacking Toll-like receptor (TLR) adaptor protein MyD88, whereas it partially reduced lipopolysaccharide (LPS)-
induced DC maturation. (b) Vf-induced IL-10 secretion was significantly reduced in TLR2 / but only marginally affected in TLR4 / DCs. In contrast, IL-12p70
production is almost completely abrogated in TLR4 / . (c) Sustained Vf-induced IL-10 production in wild-type (WT) or TLR4 / DCs following pretreatment with
LPS-scavenger Polymyxin B but reduced Vf-induced IL-12p70 production in WT and TLR2 / DCs. Representative data (mean±SD) from one out of three
independent experiments are shown. MHC II, major histocompatibility complex class II; NS, not significant; Unstim, unstimulated. **Po0.01 and ***Po0.001.
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significantly reduced in TLR2 / DCs (Figure 3b). This
indicates that ligand(s) of TLR2 within Vf is/are respon-
sible for induction of high IL-10 levels. In sharp contrast to
TLR2 / DCs, IL-10 production was only marginally reduced
in TLR4 / DCs (Figure 3b). The low IL-12p70 levels induced
by Vf were also further investigated. Lack of TLR2 significantly
increased IL-12p70 production, presumably because of the
diminished IL-10 levels, whereas the absence of TLR4 abro-
gated the induction of the proinflammatory cytokine IL-12p70.
Thus, we conclude that during DC exposure to Vf, at least two
different dominant pathogen associated molecular patterns are
functional: TLR2 ligand(s) inducing high IL-10 levels and TLR4
ligand(s) responsible for induction of IL-12p70. The latter is
presumably LPS.
To further characterize the nature of the different pathogen
associated molecular patterns inducing either IL-10 or
IL-12p70 WT, TLR2 / , and TLR4 / DCs were activated
in the presence or absence of Polymyxin B that neutralizes
LPS. Low IL-12p70 levels that were detected in WT and
TLR2 / DCs following exposure to Vf were nearly com-
pletely suppressed after preincubation of Vf with Polymyxin B,
demonstrating that V. filiformis LPS is responsible for IL-12p70
induction (Figure 3c). Importantly, Polymyxin B treatment
did not alter IL-10 production in WT, TLR2 / , and
TLR4 / DCs compared with DCs stimulated with Vf only
(Figure 3c). Thus, we conclude that innate immune signals
from nonpathogenic bacteria like V. filiformis activate TLR2
and induce high IL-10 levels independently from LPS and the
TLR4 pathway.
Priming of IL-10-producing CD4þ Tr1 cells by Vf-activated DCs
To assess the consequences on the adaptive immune system of
the innate immune sensing of Vf, cocultures of DCs with Th
cells were set up. First, DCs were activated with different
doses of Vf, pulsed with ovalbumin, and subsequently cocul-
tivated with naive CD4þ CD62Lþ OT-II Th cells. Increasing
concentrations of Vf in the previous DC culture reduced Th
cell proliferation as determined by [3H]-thymidine incorpora-
tion in a dose-dependent manner. This indicates direct
suppressive effects on Th cells mediated by DCs activated
with Vf (Figure 4a), which is in accordance to the observed
direct immunosuppressive effect in vivo (Figure 1a). To
determine immunomodulatory consequences on Th cell
polarization, DCs were activated with either LPS or Vf and
subsequently cocultivated for priming with Th cells as
described before. Primed Th cells were then expanded with
IL-2 for 10 days, stimulated, and analyzed for cytokine
production. Th cells primed by DCs that were activated with
LPS produced high IFN-g levels and no IL-4, indicating Th1
polarization (Figure 4b). In contrast, IFN-g levels secreted by
Th cells primed with Vf-exposed DCs were markedly reduced
compared with LPS-DCs and, again, IL-4 production was
undetectable (Figure 4b). Most importantly, Vf-exposed DCs
primed Th cells to secrete several fold higher levels of IL-10
compared with controls (Figure 4b). IL-10 production in T
cells was dependent on DC-derived IL-10 and TLR2 signaling
as both IL-10 / and TLR2 / DCs failed to induce high
IL-10 levels in T cells (Figure 4c). Thus, innate immune
sensing of Vf induced IL-10high, IFN-glow IL-4 Th cells
in an IL-10-dependent manner, indicating the induction of
Tr1 cells.
Regulatory function of Tr1 cells induced by Vf-exposed DCs
To assess the regulatory function of Tr1 cells primed by
Vf-exposed DCs, suppression assays with proliferating CD4þ
effector T cells were carried out. To this end, effector CD4þ
Th cells were labeled with carboxyfluorescein succinimidyl
ester (CFSE) and activated with anti-CD3/28 in the presence of
unlabeled Tr1 cells previously primed with Vf-exposed DCs.
To balance cell numbers, control experiments were performed
by adding unlabeled unpolarized CD4þ Th cells to CFSE-
labeled CD4þ effector Th cells. CFSE dilution was analyzed
72 hours after activation. Although addition of unpolarized Th
cells could not alter proliferation of CFSE-labeled effector Th
cells, Tr1 cells previously primed with Vf-exposed DCs
suppressed Th cell proliferation in a cell number–dependent
manner (Figure 4d and e).
Cutaneous exposure to signals of nonpathogenic bacterium
V. filiformis leads to enhanced T-cell IL-10 and inhibits T-cell
proliferation in vivo
To assess functional consequences of innate immune sensing
of nonpathogenic bacterium V. filiformis and consecutive
shaping of the adaptive immune system in vivo, NC/Nga mice
were again investigated. As described in Figure 1b, NC/Nga
mice were sensitized to FITC and were or were not exposed to
Vf. At 1 week after the last application, mice were challenged
at the ear skin with FITC alone. Whole lymph node cells from
the ear-draining lymph nodes isolated 8 hours after challenge
were restimulated with antigen (FITC) or anti-CD3/CD28
antibodies ex vivo. Only T cells from mice previously exposed
to Vf displayed antigen-specific production of IL-10, whereas
control mice failed to do so (Figure 5a). Using anti-CD3/CD28
antibodies, immune modulation and induction of IL-10 pro-
duction in T cells in vivo by previous exposure to V. filiformis
signals was confirmed (Figure 5b). Consistently, exposure to
V. filiformis signals reduced T-cell proliferation in draining
lymph nodes in vivo as measured by [3H]-thymidine uptake
ex vivo following FITC restimulation (Figure 5c). To analyze
the effect of enhanced IL-10 production on effector T-cell
responses in vivo, IFN-g, the hallmark cytokine of chronic AD,
was analyzed ex vivo (Grewe et al., 1995; Biedermann, 2006).
Consistent with the reduced T-cell proliferation, antigen-
specific IFN-g production by T cells was significantly
reduced in mice previously exposed to V. filiformis signals
(Figure 5d).
Together, these data show that signals of nonpathogenic
bacterium V. filiformis induce IL-10high T cells in vivo and
inhibit antigen-specific T-cell proliferation and cytokine pro-
duction, thus demonstrating the immunomodulatory role of
nonpathogenic innate immune signals in vivo.
DISCUSSION
Modulating immune responses at surface organs using non-
pathogenic bacteria is a promising strategy to treat inflamma-
tory diseases as reported in clinical trials on inflammatory
T Volz et al.
Nonpathogenic Bacteria Induce Tr1 Cells
www.jidonline.org 5
bowel disease (Rembacken et al., 1999). We recently
demonstrated that nonpathogenic bacteria are also
functional when applied to the skin, alleviating cutaneous
inflammation in AD patients (Gueniche et al., 2008). To
analyze the underlying mechanism and to elucidate how
nonpathogenic bacteria may shape and modulate immune
responses, we investigated consequences of innate immune
sensing of V. filiformis in vitro and in vivo. NC/Nga mice
sensitized to FITC are characterized by a predominance of Th2
cells and high IgE levels and develop AD-like skin
inflammation as measured by increase of ear thickness after
FITC challenge (Matsuda et al., 1997; Dearman and Kimber,
2000; Matsuoka et al., 2003). Cutaneous treatment of these
NC/Nga mice with Vf during elicitation of skin inflammation
significantly decreased allergen-specific dermatitis, indicat-
ing direct immunosuppressive effects of Vf. Importantly,
cutaneous exposure to Vf and FITC antigen before the final
allergen challenge resulted in even more pronounced
suppression of cutaneous inflammation demonstrating
immunomodulatory properties of Vf. This indicates that
cutaneous treatment with Vf in AD patients is effective by
direct and immunomodulatory pathways (Gueniche et al.,
2008). Indeed, in vitro analyses demonstrated that signals of
V. filiformis induced a DC phenotype dominated by IL-10
already suggesting regulatory and tolerogenic properties
(Lutz and Schuler, 2002; Frick et al., 2010). In fact, DCs
activated by signals of V. filiformis effectively induced
regulatory T cells.
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It was known that IL-10 production by DCs contributes to
the induction of tolerance in various settings (Akbari et al.,
2001; Corinti et al., 2001; Yu et al., 2009). However, we
demonstrate according to our knowledge the previously
unreported finding that nonpathogenic Gram-negative
bacteria induce this tolerogenic DC phenotype characterized
by acquisition of a mature phenotype and a cytokine profile
dominated by the production of IL-10, and Tr1 induction. The
Gram-negative pathogen Bordetella pertussis has been shown
to exploit a similar strategy to subvert host immunity and
protective immune responses by induction of IL-10 and Tr1
cells (McGuirk et al., 2002). In accordance with previously
published results, we show that TLR adaptor molecule MyD88
is required for induction of both IL-10 and IL-12p70
production (Boonstra et al., 2006). Surprisingly, however,
DC maturation was independent of MyD88, indicating
activation of other innate immune pathways (Medzhitov,
2009; Takeuchi and Akira, 2010). The dependence of IL-10
production on TLR2 confirms and extends data from previous
reports demonstrating a dominant role for this pattern
recognition receptor in the induction of IL-10 in DCs (Dillon
et al., 2006; Depaolo et al., 2008). Lipoproteins have been
isolated and identified from Gram-negative E. coli initially and
lipopeptides derived thereof have been shown to activate
TLR2 (Braun and Wu, 1994; Buwitt-Beckmann et al., 2005).
TLR2 activation by bacterial or synthetic ligands can result in
either inflammatory or tolerogenic immune responses, but
detailed mechanisms are still to be deciphered (Oliveira-
Nascimento et al., 2012). Lipoproteins from Staphyloccocus
aureus binding to TLR2 have been shown to be crucial in
induction of inflammation and clearance of bacteria (Schmaler
et al., 2009). In contrast, host immunity is subverted by
Yersinia pestis inducing Tr1 cells triggered by TLR2/6
binding of LcrV subsequently inducing IL-10 production
(Depaolo et al., 2008). Porin B from Neisseria meningitidis
is also a TLR2 ligand inducing DC activation (Singleton et al.,
2005). As both V. filiformis and N. meningitidis are Gram-
negative bacteria belonging to the family of Neisseriaceae, it is
tempting to speculate that the TLR2-activating ligand of
V. filiformis is a bacterial porin with predominant anti-
inflammatory properties (Strohl, 2005). In contrast to Gram-
negative pathogenic bacteria such as Salmonella spp. eliciting
proinflammatory immune responses, innate immune sensing
of nonpathogenic Gram-negative bacteria like V. filiformis is
not dominated by TLR4 signaling over TLR2 signaling and
induction of inflammation, but is characterized by a more
dominant TLR2 signaling and the induction of tolerance. One
may speculate that the functional dominance of tolerogenic
signals may be a general principle of how nonpathogenic
bacteria and their hosts organize their coexistence in the
absence of inflammation. Previously, it has been shown
that the exposure to Gram-negative gammaproteobacterium
Acinetobacter prevents allergic disease in mouse models and
correlates with IL-10 production from healthy but not from AD
individuals (Debarry et al., 2007; Conrad et al., 2009; von
Mutius and Vercelli, 2010; Hanski et al., 2012). This already
demonstrates that contact to Gram-negative nonpathogenic
bacteria leads to active immune recognition resulting in
tolerogenic cytokine production (Hanski et al., 2012).
Strikingly, atopic individuals harbor significantly lower
amounts of Acinetobacter on the skin and show diminished
IL-10 production (Hanski et al., 2012). In light of these findings
and our data, the pathways utilized by nonpathogenic Gram-
negative bacteria to induce tolerance seem to be promising
targets for therapeutic strategies.
DCs have been shown to play a central role in transmitting
innate immune signals into various types of adaptive immune
responses (Kapsenberg, 2003; Joffre et al., 2009). ‘‘Tolerogenic
DCs’’ can prime Th cells to become regulatory T cells. Among
these, Tr1 cells are characterized by the production of low
amounts of IFN-g but high levels of IL-10 (Groux et al., 1997;
O’Garra and Vieira, 2004; Shevach, 2006). Moreover, it has
been reported that immune modulation by Tr1 cells reduces
antigen-specific IgE but not antigen-specific IgG1 and IgG2a
levels, which is similar to our findings following exposure to
Vf (Cottrez et al., 2000), but in contrast to, e.g., low-zone
tolerance that has been reported to tremendously reduce
specific immunoglobulin levels (Steinbrink et al., 1996).
We could demonstrate that DCs activated by signals of
nonpathogenic V. filiformis are potent inducers of Tr1 cells
producing these signature cytokines. Moreover, these Tr1 cells
strongly inhibited Th cell responses demonstrating function-
ality. This is in accordance with previously published results
demonstrating that Tr1 cells are equally potent to FoxP3pos
natural regulatory T cells in controlling effector T-cell
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Figure 5. Cutaneous exposure to signals of Vitreoscilla filiformis (Vf)
enhances T-cell IL-10 and inhibits T-cell proliferation in vivo. Induction of
antigen-specific IL-10 production in draining lymph nodes was only detected
in (a) mice previously exposed to Vf and (b) could be mapped to T helper (Th)
cells as detected following anti-CD3/CD28 activation. (c) Vf-mediated immune
modulation in previously Vf-exposed mice also reduced antigen-specific T-cell
proliferation and (d) IFN-g production as detected in lymph node cells 72 hours
after in vivo challenge.
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responses (Vieira et al., 2004). However, in contrast to
FoxP3pos natural regulatory T cells, Tr1 cells are inducible,
indicating a feasible therapeutic strategy.
Identifying nonpathogenic bacteria with tolerogenic poten-
tial, crucial active microbial components within these bac-
teria, and activation pathways mediating active tolerance—
such as TLR2 signaling—points to very promising therapeutic
strategies in the treatment of inflammatory and allergic
diseases, especially of the surface organs such as AD.
MATERIALS AND METHODS
FITC induced antigen-specific contact hypersensitivity
NC/Nga mice (5 mice per group) were sensitized by administration of
0.25% FITC solution (dissolved in 1:1 acetone/dibutyl phthalate) on
the shaved abdomen on days 0, 7, and 14. At 7 days after the last
sensitization, mice were challenged by application of 0.25% FITC
solution on both sides of the ears. To determine the direct immuno-
suppressive effects of Vf, one group of mice was treated with Vf (20%
v/v) on the ear skin during the allergen challenge period. Ear thickness
was measured with a micrometer (Oditest; Kroeplin, Germany) and
data are expressed as change in ear thickness as compared with that
before treatment. The immunomodulatory effects of Vf were investi-
gated by coadministration of Vf (20% v/v) on the abdominal skin at
days  1, 7, 14, and 21, and not during challenge. At 7 days after the
last FITC contact, all mice were challenged by application of 0.25%
FITC solution onto the ears in the absence of Vf. Draining lymph
nodes were collected either 8 or 72 hours after challenge and whole
lymph node cells were cultivated with FITC or anti-CD3/CD28
antibodies for another 3 days. Cell culture supernatants were
subjected to ELISA.
Generation and activation of human monocyte-derived DCs
DCs were generated from adherent peripheral blood mononuclear
cells as previously described (Guenova et al., 2008). To induce DC
maturation, day 6 immature DCs (CD11cþ CD14 HLA-DRþ
CD86þ CD83 ) were cultured for an additional 24 or 48 hours in
the presence of LPS R595 or Vf.
Generation and stimulation of murine BMDCs
Murine BMDCs were generated as described previously (Lutz et al.,
1999). At day 8, cells were collected, washed, and seeded in
1 106 ml per well in 24-well-plates. DCs were stimulated with
LPS (1mg ml 1) or Vf (5% v/v) for 24 hours unless otherwise specified.
DC/T-cell coculture
Immature BMDCs were activated in the presence of ovalbumin
(50mg ml 1) with LPS or Vf. Subsequently, DCs were washed
extensively and cultivated together with naive CD4þCD62Lþ OT-II
Th cells in a ratio of 1:5 for 3 days. CD4þ T cells were then
expanded using IL-2 (50 U ml 1) for another 12 days. Resting T cells
were washed and restimulated with plate-bound anti-CD3
(2mg ml 1) and anti-CD28 (5mg ml 1) in 96-well plates. Cell culture
supernatants were harvested after 72 hours and subjected to ELISA.
Proliferation assays
Naive OT-II CD4þCD62Lþ T cells (2 105) were activated
with ovalbumin-pulsed and Vf-stimulated DCs (4 104) in 96-well
flat-bottom plates in a total volume of 200ml. After 5 days 0.25mCi
[3H]-thymidine was added and cells were harvested after another
10 hours. Incorporated [3H]-thymidine was measured using a micro
beta counter (Perkin Elmer, Wiesbaden, Germany).
To asses suppressive capacity of Vf-induced IL-10þ Tr1 cells,
unprimed CD4þ Th cells were isolated using magnetic cell isola-
tion as described. These CD4þ cells were labeled with 1mM CFSE
(Molecular Probes, Eugene, OR) according to the manufacturer’s
protocol and 2 105 CFSEþ CD4þ T cells were activated with
plate-bound anti-CD3 (2mg ml 1) and soluble anti-CD28 (5mg ml 1)
in the presence of activated Vf-induced IL-10þ Tr1 cells at the
indicated cell ratios. Controls were set up using CFSEþ CD4þ cells
cultivated together with unlabeled Th cells to ensure balanced cell
numbers. Proliferation was determined 72 hours after activation.
All mice were maintained under specific pathogen free conditions
at the animal facilities of the University of Tu¨bingen according to
local and federal guidelines.
Additional methods concerning animals, reagents, antibodies,
bacterial lysates, Th cell isolation, and description of FACS analysis
can be found online.
Statistical analysis
All data are presented as means±SD or SEM (where indicated) of one
representative experiment. Experiments were repeated at least three
times if not indicated otherwise and revealed comparable results.
Statistical analysis was performed with Student’s t-tests (two tailed).
Values of Po0.05 were considered as statistically significant.
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Staphylococcus aureus skin colonization is promoted by barrier
disruption and leads to local inflammation
Ines Wanke1, Yuliya Skabytska1, Beatrice Kraft1, Andreas Peschel2, Tilo Biedermann1 and Birgit Schittek1
1Department of Dermatology, Eberhard-Karls-University T€ubingen, T€ubingen, Germany; 2Interfaculty Institute of Microbiology and Infection
Medicine, Cellular and Molecular Microbiology, Eberhard-Karls-Universit€at T€ubingen, T€ubingen, Germany
Correspondence: Birgit Schittek, Tilo Biedermann, Liebermeisterstr. 25, 72076 Tu¨bingen, Germany. Tel.: 0049 7071 2980832; Fax: 0049 7071 295187;
e-mails: birgit.schittek@med.uni-tuebingen.de; tilo.biedermann@med.uni-tuebingen.de
Abstract: Experimental mouse models of bacterial skin infections
that have been described show that pathogenic microorganisms
can readily invade the epidermis and dermis to produce localized
infections. We used an epicutaneous mouse skin infection model
to determine how the level of barrier disruption by tape-stripping
correlates with persistence of Staphylococcus aureus skin
colonization, concomitant induction of cutaneous inflammation
and infection. Furthermore, we investigated how murine skin
responds to S. aureus colonization in a physiologic setting by
analysing proinflammatory cytokines and antimicrobial peptides
in mouse skin. We show that previous cutaneous damage allows
skin inflammation to develop and favours S. aureus persistence
leading to cutaneous colonization, suggesting an interdependence
of cutaneous bacteria and skin. Our study suggests that skin
barrier defects favour S. aureus skin colonization, which is
associated with profound cutaneous inflammation.
Key words: antimicrobial peptides – inflammation – mouse model –
S. aureus – skin colonization
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Background
In vivo skin infection models in which the pathogens need to be
injected subcutaneously into the skin of mice have the limitations
that this does not resemble the natural way of skin infection.
Moreover, they are not suited to investigate processes underlying
skin colonization such as Staphylococcus aureus colonization on
skin of atopic dermatitis patients. Therefore, we used a mouse
model of staphylococcal skin infection based on the epicutaneous
inoculation of S. aureus onto mouse skin whose integrity was pre-
viously affected by tape-stripping. In previous studies, this model
was used to analyse the degree of subsequent bacterial invasion
into subcutaneous tissues and the dissemination of the microor-
ganisms to other organs or to determine the effectiveness of topi-
cal antibiotic treatment for pathogen infection in skin wounds
induced by extensive tape-stripping (1–3).
Questions addressed
We extended this model system for a new experimental approach
determining how the extent of barrier disruption by tape-stripping
correlates with the efficiency of infection, pathogen persistent skin
colonization, concomitant induction of cutaneous inflammation
and induction of antimicrobial peptide (AMP) expression in
mouse skin.
Experimental design and results
The experimental model is based on epicutaneous application of
the S. aureus strain 113 onto shaved skin of C57BL/6 mice. Before
application, we either left the skin untreated or disrupted the skin
barrier to different levels by either mild tape-stripping (3 times)
or strong tape-stripping (7 times). Mild and strong tape-stripping
left part of the epidermis intact and did not create a wound in
contrast to another published study (1) (Figs 1a, b, S1). An inocu-
lum of 107 S. aureus 113 in 0.015 ml of phosphate-buffered saline
(PBS) or PBS control was added to 7-mm filter paper discs placed
onto the prepared skin and covered by Finn Chambers on Scan-
por (Smart Practice, Phoenix, AZ, USA). Fixation occurred via
Fixomull stretch plaster as in patients undergoing epicutaneous
patch testing (Fig. 1a).
After overnight occlusion, Finn Chambers and plasters were
removed in all experimental groups, and one to 6 days after
S. aureus application, the number of colony-forming units (CFUs)
on mouse skin was quantified. In addition, biopsy samples from
the application site were taken for further molecular analyses.
Time titration experiments revealed that at least 1 9 106 bacteria
were recovered 1 day after inoculation using epidermal scrapes to
gather bacteria colonizing the epidermis. We detected 1 9 105
bacteria in the skin wash fraction, which harvests bacteria loosely
attached to the skin surface (Fig. 1b, c). Interestingly, in strongly
tape-stripped skin, the infection efficiency (day 1) as well as the
persistence of S. aureus 113 as detected by scrapes was significantly
higher compared with non- or mildly tape-stripped skin. This sug-
gests that epithelial barrier defects facilitate cutaneous S. aureus
colonization, probably by allowing bacterial adhesion, providing
enhanced nutrition, possibly supported by an inflammatory
response or reduced antibacterial defense.
Indeed, in strongly tape-stripped skin, S. aureus application
induced high expression of IL-1b and IL-6 in mouse epidermis 1
and 3 days later and low but significant levels of TNF-a at 1 day
after infection persisting until day 6. In contrast, S. aureus applica-
tion in non- or mildly tape-stripped skin led to only mild, but sig-
nificant, induction of IL-1-b 1 day after infection, but failed to
induce IL-6 (Fig. 2). IFN-c was only slightly induced in all cases,
but started to become upregulated specifically in the experimental
group with strong barrier disruption on day 6 after infection,
indicating possible sensitization and migration of IFN-c-producing
lymphocytes under this condition (Fig. 2). Strong tape-stripping
ª 2013 John Wiley & Sons A/S
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alone induced only low expression of IL-1b and IL-6 one day after
cutaneous damage, but failed to regulate TNF-a or IFN-c at any
time point. These data indicate that S. aureus application and
persistence on barrier-disrupted skin induce an inflammatory
cytokine response lasting at least 3–6 days.
Staphylococcus aureus infection of human keratinocytes grown
in vitro and experimental barrier disruption in humans and mice
are known to induce AMPs (4–7). Interestingly, in our mouse
model of cutaneous bacterial persistence, we found that S. aureus
induced the expression of the mouse b-defensins mBD3, mBD4
(both are murine orthologs of human HBD-2) and mBD14 (mur-
ine ortholog of human HBD-3) in the epidermis. The highest
induction levels of mBD3, mBD4 and mBD14 were seen 1 day
after S. aureus application in the strongly tape-stripped skin,
which lasted at least 3 days (Figure S2). Strong tape-stripping alone
induced only a transient induction of these AMPs at day 1. Further-
more, mBD2 expression was only transiently induced 3 days after
S. aureus application in strongly tape-stripped skin (Figure S2).
Conclusions
We describe a mouse model for cutaneous colonization and per-
sistence of bacteria such as S. aureus, which resembles the natural
route of how skin colonization and infection take place. Staphylo-
coccus aureus colonizes nasal epithelia, is found on skin in high
amounts, mainly in the case of skin barrier defects as in atopic
dermatitis, and is thought to contribute actively to skin inflamma-
tion (6,8,9). Our study confirms these assumptions by demon-
strating that skin barrier defects favour S. aureus skin colonization
and that prolonged colonization is associated with profound cuta-
neous inflammation, suggesting an interdependence of cutaneous
bacteria and skin. Thus, this mouse model is ideally suited for
unravelling the role and molecular mechanisms of barrier disrup-
tion and skin inflammation in pathogen infection and for evaluat-
ing strategies to prevent skin inflammation and infection.
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Figure 1. Epicutaneous application of Staphylococcus aureus onto barrier-
disrupted skin leads to cutaneous bacterial persistence. (a) Shown are 8-week-old
female C57BL/6 mice directly after epicutaneous S. aureus 113 application. The
Finn Chambers on Scanpor adaptors are shown in the increment. (b) HE staining of
S. aureus 113-challenged mouse skin reveals bacteria on the uppermost layer of
infected mouse skin, but not on uninfected mouse skin (arrows mark the bacteria).
(c) CFU assay shows the persistence of viable S. aureus 113 over 6 days after the
application of the bacteria onto mouse skin without or after mild or strong tape-
stripping (TS) in scraped or washed skin samples. We do not find significant
differences in the colonization efficiency one day after infection between the three
different S. aureus strains 113, Newman and ATCC 25923 (data not shown).
Control: Without S. aureus application but with tape-stripping. Four skin samples
were plated in duplicate for scraped skin (n = 8) or on a single plate for washed
skin (n = 4). Asterisks mark significant differences (P-values  0.05 in Student’s
t-test). There is a statistically significant difference between strong and mild tape-
stripping and between strong and no tape-stripping in the scrapes. The efficiency
of skin colonization is defined by the recovery of viable colony-forming units (CFU)
from scraped skin of previously mild or strong tape-stripped skin compared with
untaped skin.
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Figure 2. Epicutaneous application of Staphylococcus aureus induces mRNA
expression of inflammatory cytokines especially in strongly tape-stripped skin.
Shown is the relative RNA expression of the proinflammatory cytokines Il-1b, Il-6,
TNF-a and IFN-c in skin biopsies 1, 3 and 6 days after application of S. aureus 113
bacteria onto mouse skin without or after mild or strong tape-stripping (TS).
Effects of tape-stripping alone are shown in the PBS + TS group. mRNA expression
levels were analysed by real-time PCR. PBS-treated skin without tape-stripping was
used as a control and set as 1. Four samples were analysed in duplicate (n = 8).
Asterisks mark significant differences to the control or between labelled groups
(P-values  0.05 in Student’s t-test).
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Photoprotective effect of libanoridin isolated from Corydalis
heterocarpa on UVB stressed human keratinocyte cells
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Abstract: Ultraviolet-B (UVB) irradiation acts primarily on the
epidermal basal cell layer of the skin, inducing harmful biological
effects. In this study, we have investigated the effect of libanoridin
isolated from Corydalis heterocarpa against UVB-induced damage
in human keratinocyte (HaCaT) cells and the molecular
mechanism underlying those effects. Treatment with libanoridin
inhibited the cell cytotoxicity and LDH induced by UVB exposure
at 40 mJ/cm2. Additionally, expression levels of type IV
collagenases (MMP-2, MMP-9) were decreased by libanoridin.
Furthermore, MMP tissue inhibitors were enhanced followed by
treatment with libanoridin. Moreover, UVB-induced activation of
phosphorylation of three MAPKs such as JNK, ERK, p38 and
AP-1 transcription factor were decreased by treatment with
libanoridin.Our present study demonstrates that libanoridin has
the abilities to inhibit UVB-induced cellular damage via ASK1-
MAPK and AP-1 signalling pathways. Therefore, libanoridin may
be used as an effective natural compound to prevent skin damage
due to UVB exposure.
Key words: AP-1 – libanoridin – MAPK – MMP – UVB exposure
Accepted for publication 28 December 2012
Background
Recent studies have indicated that various physical phenomena
are caused by exposure to UVB irradiation (1,2). Thus, searching
for sun-blocking agents may be a basic step in the prevention of
skin damage by UVB irradiation. UVB (290–320 nm) irradiation
is known to be a major cause for the epidermal damage in
human skin (3). Keratinocytes constitute for 90% of the cells
found in the epidermis and are capable of producing cytokines
in response to external stimuli (4). Human keratinocyte (Ha-
CaT) cells were reported to be the appropriate experimented
model to study the biological changes in human epidermis (5).
Therefore, to study the inhibitory effects of libanoridin on cell
damage induced by UVB exposure, HaCaT keratinocytes were
chosen.
Halophytes are salt-tolerant plants that are adapted primarily to
an ionic imbalance and hyperosmotic stress. The effect of imbalance
or disruption in homoeostasis occurs at the cell level that causes
molecular damage and growth arrest. Moreover, these plants com-
monly suffer from serious in vivo photodynamic damage (6).
Although their cells are equipped with protective mechanisms to
reduce photodynamic damage, biological activities of their second-
ary metabolites have been little investigated to date (7).
A kind of halophyte, Corydalis heterocarpa, has been used as a
traditional medicine for dysentery in Korea. It has been reported
ª 2013 John Wiley & Sons A/S
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IL-4 abrogates TH17 cell-mediated inﬂammation by
selective silencing of IL-23 in antigen-presenting cells
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Interleukin (IL-) 4 can strongly suppress delayed type hypersensi-
tivity reactions (DTHR), including organ-speciﬁc autoimmune dis-
eases in mice and in humans. Despite the broadly documented
anti-inﬂammatory effect of IL-4 the underlying mode of action
remains unknown, as IL-4 promotes IL-12 production by dendritic
cells (DC) and interferon-γ-producing TH1 cells in vivo. Studying
the impact of IL-4 on the polarization of human and mouse DC,
we surprisingly found that IL-4 exerts strictly opposing effects
on the production of either IL-12 or IL-23. While promoting IL-
12-producing capacity of DC, IL-4 completely abrogates the ca-
pacity of DC to produce IL-23. Bone marrow chimeras directly
proved that IL-4-mediated suppression of DTHR strictly relies on
the STAT6-dependent abrogation of IL-23 in antigen-presenting
cells. In linewith this, IL-4 therapy severely attenuated DTHR by se-
lective, STAT6- and ATF3-dependent suppression of the IL-23/TH17
responses despite simultaneous enhancement of IL-12/TH1 re-
sponses. As IL-4 therapy also improves psoriasis in humans and
selectively suppresses IL-23/TH17 responses, without affecting the
IL-12/TH1 responses, selective IL-4-mediated IL-23/TH17-silencing
is promising as treatment against harmful inﬂammation, while
sparing the IL-12-dependent TH1 responses.
IL-4 j TH17 j IL-23
Introduction
IL-4 is a pleiotropic cytokine produced by CD4+ TH2 cells but
also CD8+ T cells, natural killer T cells, eosinophils, basophils,
innate lymphoid and mast cells (1-6). IL-4 is a canonical type
2 immune cytokine known for its capacity to induce IgE iso-
type switching in B cells and to initiate and sustain TH2 cell
differentiation (2, 7). IL-4 provides protective immune responses
to helminthes (8), and excessive IL-4 production is linked to
TH2-dominated allergic asthma and atopic dermatitis (9). IL-4
produced by malignant T cells further promotes a TH2 bias and T
cell immunosuppression in leukemic cutaneous T cell lymphoma
(10). In vivo, IL-4 can suppress organ-specific autoimmune and
delayed type hypersensitivity reactions (DTHR). In line with this,
IL-4 is absent in naturally occurring DTHR, such as experimental
autoimmune encephalomyelitis (EAE), multiple sclerosis (MS),
rheumatoid arthritis (RA), inflammatory bowel disease (IBD) or
psoriasis (11-15). Systemic IL-4 immunotherapy improves EAE
(16), experimental colitis (5), non-obese diabetes (17), collagen-
induced arthritis (18), and hapten-induced contact hypersensitiv-
ity (19) inmice, and psoriasis in humans (20). The inhibitory effect
of IL-4 on the autoimmuneDTHRhowever failed to be explained
by the redirection of the TH1 immune responses towards IFN-γ-
deficient type 2 immune responses. To the contrary, the number of
peripheral IFN-γ+CD4+ TH1 cells or serum IFN-γ even increases
after IL-4 administration in mice with EAE (16), haemophago-
cytic lymphohistiocytosis (21) or hapten-induced contact hyper-
sensitivity (19), and in humans with psoriasis (20); mice with
transgenic overexpression of IL-4 exhibit TH2-driven allergic-
like inflammatory disease with elevated IFN-γ levels (22), and
IL-4 can even directly instruct protective TH1 immunity in mice
with Leishmania major infection (23). Thus, although IL-4 might
be an important natural inhibitor of many DTHR, the mode
of action by which IL-4 suppresses inflammatory autoimmune
disease and DTHR remains enigmatic. Functional and genetic
data now revealed that a significant number of DTHR that have
long been associated with IFN-γ-producing TH1 cells and IL-
12p70-producing APC, are mediated by IL-17/IL-22-producing
Th17 cells and IL-23-producing APC, rather than by TH1/IL-12
responses (24-28). Consistently, recent reports have correlated
the level of disease activity and the absence of IL-4 with the
Signiﬁcance
IL-4 has been shown to have a highly beneﬁcial clinical out-
come in delayed type hypersensitivity, autoimmune and auto-
inﬂammatory reactions in mice and humans, but its mode
of action has remained controversial and has failed to be
explained solely by redirection of the pathologic Th1/Th17-
towards a Th2-type immune response. Here, we identify a
new immunoregulatory role of IL-4 on cells of the innate
immune system, describe its therapeutic mode of action in
Th17-mediated autoimmune inﬂammation, and a new phys-
iologically highly relevant approach to selectively target IL-
23/Th17-dependent inﬂammation while sparing IL-12 and Th1
immune responses.
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Fig. 1. Strictly opposing effects of IL-4 on either IL-12 or IL-23 secretion
by DC.(A and B) Different subsets of human conventional myeloid DC and
mouse BMDC were pre-incubated with 100ng/ml IL-4 and then stimulated
with LPS. The IL-12 (A) and IL-23 (B) levels in the culture supernatants were
determined by an ELISA. The data shown are from at least three independent
experiments, and the results are expressed as the means ± SD. (C) The expres-
sion levels of transcripts encoding IL23A, IL12A, and IL12B were determined
by quantitative real-time PCR in slanDC treated as described in (A). The
values from three independent experiments were calculated relative to the
expression levels of the housekeeping gene G6PD and were normalized to
the unstimulated control. FC = fold change. (D and E) SlanDC were treated
as described in (A), and IL-12p70 and IL-23 secretion was analyzed at the
indicated time-points (D) or as a function of IL-4 (E). The data are expressed
as means ± SD of triplicates and are representative of ﬁve independent
experiments.
presence of IL-23 producing APC and IL-23-dependent TH17
cells (29-31).
We analyzed the impact of IL-4 on the regulation of IL-
23 and TH17 in DTHR in mice and in human psoriasis. Un-
expectedly, IL-4 abolished the capacity of APC to produce IL-
23, while promoting IL-12p70. This selective inhibition impaired
the induction and maintenance of pathogenic TH17 cells. Bone
marrow chimeras with either STAT6-deficient APC or STAT6-
deficient T cells proved that IL-4 suppressed the development
of TH17 cells by abrogating the IL-23 production in APC. IL-
4 therapy of psoriasis also dose-dependently suppressed IL-23-
production by APC and TH17 cells, while largely preserving IL-12
and TH1-immunity in humans. This may open an entirely new ap-
proach for a targeted abrogation of harmful IL-23/Th17-immune
reactions without affecting potentially protective IL-12/TH1 in
Fig. 2. IL-4 selectively abrogates the TH17 cell-inducing capacity of DC(A) DC
stimulated with LPS in the presence or absence of 100ng/ml IL-4 or control
DC were co-cultured with autologous naïve T cells in the presence of SEB,
and proliferationwas determined by 3H-thymidine uptake. (B) DC stimulated
with LPS in the presence or absence of 100ng/ml IL-4 and control DC were co-
cultured with autologous naïve T cells over 12 days. Cytokine production by
CD4+ T cells was determined by ﬂow cytometry following re-stimulationwith
PMA and ionomycin. (C) T cells co-cultured with DC stimulated as indicated
in (B) were reactivated on day 12 with anti-CD3/CD28 for an additional 48
h, and cytokines were analyzed by ELISA. The results are expressed as means
± SD, and the data shown represent independent experiments from three
different donors.
mycobacteria and parasite immunity (23, 32) and perhaps cancer
(32).
Results
Strictly opposing effects of IL-4 on either IL-12 or IL-23 secretion
by DC
To dissect the pro- and anti-inflammatory effects of IL-4 on
DC, we stimulated, with TLR ligands in the presence or ab-
sence of IL-4, four distinct DC populations: BDCA-1-expressing
DC (MDC1), BDCA-3-expressingDC (MDC2), 6-sulfo-LacNAc-
expressing DC (slanDC), and murine bone-marrow derived DC
(mBMDC). IL-4 strongly and significantly induced IL-12p70
production in all four DC subsets, in human DC 10- to 100-fold
and in murine BMDC about 3-fold (Fig. 1A). Surprisingly, IL-4
simultaneously and almost completely abrogated TLR-triggered
IL-23 production in all human and mouse DC populations (Fig.
1B). The opposing effects of IL-4 on the production of either
IL-12 or IL-23 were transcriptionally regulated. IL-4 significantly
suppressed the TLR-driven induction of il23amRNA (P=0.001),
while strongly inducing il12a mRNA expression (P<0.001; Fig.
1C). IL-4 also suppressed TLR-induced expression of the com-
mon IL-12/23p40 (il12b) subunit in most APC (P<0.003; Fig.
1C). The opposing effects on either IL-12p70 or IL-23 production
seemed to be unique to IL-4, as other TH2 cytokines, including
IL-13, failed to abrogate IL-23 secretion (Fig. S1). To determine
whether IL-4 affects the dynamics of IL-12 or IL-23 induction
rather than the total production, we performed time-course stud-
ies over 12 hours in slanDC. We observed that, following LPS
stimulation, slanDC started to produce IL-12 and IL-23 after 2-4
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Submission PDFFig. 3. IL-4-induced immune-suppression strictly depends on direct suppres-sion of IL-23. (A) Representative H&E stains (x40) from skin inﬂammation
after challenge with TNCB in TNCB- sensitized C57BL/6 mice (B and C). Time
course (B) of the ear swelling and representative H&E stains (x20) (C) after
TNCB-challenge in sensitized C57BL/6 mice, treated intraperitoneally with
either PBS or IL-4 during challenge. The results in (B) are means ± SD. (D)
Expression of transcripts encoding IL23A and IL17A in DTHR ear samples in
mice treated with IL-4 as described in (B). Quantitative real-time PCR was
performed, and the data are expressed in relative units [Δct] compared to the
housekeeping gene. The results are the means ± SD. (E and F) Ear swelling
(E) and representative H&E stains (F) 24 hours after challenge with TNCB
in sensitized C57BL/6 mice. Mice were treated intraperitoneally with either
PBS or IL-4 as in (B). Additionally, IL-23 was applied to some groups where
indicated. The data are expressed as means ± SD.
hours, and IL-23 levels increased more than 100-fold during the
first 12 hours (Fig. 1D). IL-4 simultaneously suppressed IL-23
but enhanced IL-12p70 production over the entire study period,
showing that IL-4 did not alter the dynamics of either IL-12 or
IL-23 production. Moreover, the opposing effects of IL-4 were
dose-dependent and reached saturation at 100 ng IL-4/ml (Fig.
1E). IL-4 also reduced the secretion of other innate cytokines,
such as IL-1β and IL-6 (Fig. S1B).
IL-4 selectively abrogates the TH17 cell-inducing capacity of DC
The hallmark of DC function is their ability to prime naïve
T cells, and steer TH cell differentiation into either TH1, TH17,
or TH2 cells. To address whether IL-4 affects the capacity of
DC to drive proliferation of naïve T cells, we first used either
immature or in vitro-matured DC to stimulate naïve autologous
CD4+CD45RA+ T cells. As expected, immature DC were less
efficient than mature DC in inducing the proliferation of naïve
CD4+ T cells (Fig. 2A). IL-4 did not affect T-cell proliferation
of either DC population (Fig. 2A). Based on our observation
that IL-4 affected the cytokine pattern secreted by DC, we tested
whether IL-4 also affected their capacity to prime naïve T cells for
either TH1, TH17 or TH2 differentiation. To test this, we matured
DC in the presence or absence of IL-4, used them to prime naïve
CD4+ T cells, expanded the cells and re-stimulated such primed
CD4+ T cells for cytokine production. Maturation of DC in the
absence of exogenous IL-4 resulted in a DC phenotype that in-
duced both TH1 and TH17 cells, which produced large amounts of
either IL-17 and IL-22 or IFN-γ (Fig. 2B), as previously reported
(33, 34). Maturation of DC in the presence of IL-4 resulted in a
DC phenotype that failed to induce TH17 cells (≤0.5%) (Fig. 2B);
Fig. 4. IL-4 responsive APC orchestrate IL-4-induced suppression of TH17
responses.(A to C) Ear swelling after TNCB-challenge in sensitized C57BL/6
mice bone marrow (BM) chimeric mice. IL-4 treatment during challenge was
administered in some of the groups as indicated. Data from control CD45.1+-
BM chimericmice onwild type non-hematopoietic background are presented
in (A). Data from STAT6-/-/Tc-/--BM chimeric mice are presented in (B), and
data from STAT6-/-/MHCII-/--BM chimeric mice are presented in (C). Data are
expressed as mean ± SD and represent two independent experiments. At
least six mice per each group have been analyzed (D) Schematic presentation
of the experimental approach for the generation of bone marrow chimeric
mice.
instead the percentage of IFN-γ-producing TH1 cells increased
(Fig. 2C).
IL-4-induced immune-suppression strictly depends on direct
suppression of IL-23
To analyze the biological relevance of this IL-4-mediated
suppression of IL-23 and of the subsequent maintenance of TH17
cells in vivo, we first studied IL-4-induced immune suppression in
2,4,6-trinitrochlorobenzene (TNCB)-inducedDTHR in C57BL/6
mice. Challenging sensitized mice with TNCB resulted in pro-
nounced ear swelling and skin inflammation characterized by
epidermal hyperplasia, sub-corneal neutrophilic infiltrates, and
angiogenesis (Fig. 3A). Systemic administration of IL-4 during
the challenge significantly reduced the ear swelling in TNCB-
sensitized mice (Fig. 3B and C), abrogated the infiltration of
polymorphonuclear (PMN) cells, and normalized skin morphol-
ogy (Fig. 3C). The TNCB challenge caused a strong induction
of il23a and of il17a mRNA in ear tissues of mice challenged
with TNCB (Fig. 3D), and IL-4 treatment during the TNCB
challenge suppressed il23a and of il17amRNAabout 10-fold (Fig.
3D). To directly test whether this IL-4-mediated suppression of
IL-23 also suppressed inflammation, we treated sensitized mice
with recombinant mouse (rm) IL-4 during the TNCB challenge.
Subsequently, we aimed, in half of the IL-4-treated mice, to
prevent suppression of inflammation via systemic administration
of rmIL-23, rmIL-6 or PBS. Neither PBS nor rmIL-6 restored
the rmIL-4-mediated suppression of IL-23 and DTHR to almost
background levels (Fig. S2A and B). In contrast, rmIL-23 fully
rescued the cutaneous DTHR, as determined by the ear swelling
responses (Fig. 3E and F).
IL-4-responsive APC orchestrate IL-4-induced suppression of
TH17 responses
Wenext determinedwhether IL-4 suppresses T cell-mediated
inflammation by its action on CD4+ T cells or through the
suppression of IL-23-production of APC in vivo. Therefore we
first generated bone marrow (BM) chimeric (BMC) mice with
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Submission PDFFig. 5. IL-4 mediated suppression of IL-23 is partly mediated throughactivating transcription factor 3 (ATF3).(A) Representative data from a semi-
quantitative PCR for ATF3 mRNA expression in murine RAW264.7 cells, ana-
lyzed as a function of IL-4. (B and C) Quantiﬁcation of ATF3 mRNA expression
in LPS-stimulated human (B) and murin (C) DC. Data are expressed in relative
units [Δct] compared to the housekeeping gene. The results are the means
± SD. (D) Human DC and BMDC from either C57BL6wt mice or ATF3-/- mice
were pre-incubatedwith IL-4 and then stimulatedwith LPS. ATF3 protein was
analyzed semi-quantitatively by western blotting. Representative data from
three independent experiments are shown. (E) BMDC from either C57BL6wt
mice or ATF3-/- mice were treated as in (D). IL-12 and IL-23 levels in the
culture supernatants were determined by ELISA. The data shown are from
three independent experiments, and the results are expressed as the means
± SD. (F and G) Ear swelling (F) and representative H&E stains (G) 48 hours
after challenge with TNCB in sensitized C57BL/6 and ATF3-/- mice. Mice were
treated intraperitoneally with either PBS or IL-4 as in Fig. 3B. The data are
expressed as means ± SD.
CD45.1+ hematopoiesis on a CD45.2+ background (CD45.1+→
CD45.2+ mice). Eight weeks after transplantation, engraftment
efficiency and lineage reconstitution were >90%, and residual
host CD45.2+ BMC was <3% (Fig. S3 and S4). The chimeric
mice developed a typical DTHR showing that the BMC mice
could be sensitized normally; in addition, rmIL-4 suppressed
cutaneousDTHR in suchCD45.1+→CD45.2+mice as in previous
experiments (Fig. 4A). To distinguish the effects of IL-4 on either
APC or on T cells, we selectively blocked IL-4 signaling in either
T cells or APC of the BMC mice. This was achieved first by
generating BMC chimeric mice deficient for STAT6 in the T cell
lineage (STAT6-/-/Tc-/-→WTmice). In detail, by transplanting BM
of STAT6-/- mice into lethally irradiated recipient mice, the T cell
repertoire of STAT6-/- mice was established in BMC mice. By co-
transplantation of BM devoid of any T cells from Tc-/- mice into
these BMC mice, those chimeric mice had normal IL-4 sensitive
STAT6 expressing APC from the Tc-/- donor organism, but only
harbored STAT6neg T cells unresponsive to IL-4 therapy from the
STAT6-/- mice. A TNCB challenge in sensitized STAT6-/-/Tc-/-→
WT chimeric mice resulted in a similar ear swelling response as
compared to the control chimeric mice (CD45.1+→WTCD45.2+
mice) (Fig. 4A and B). Of note, IL-4 significantly reduced ear
swelling and abrogated cutaneous inflammation in these sensi-
tized STAT6-/-/Tc-/-→ WT chimeric mice (Fig. 4B), highlighting
a key role for APC in mediating the beneficial effect of IL-4
therapy. Next, to study the exclusive role of APC in this pro-
Fig. 6. IL-4 therapy of psoriasis abrogates intralesional IL-23 and IL-17
in human skin. (A) Representative H&E stains from co-localized biopsies
of psoriatic skin before (A) and after systemic IL-4 treatment. (B and C)
Visualization of co-localized IL-23 (red) and MHC II (blue) and IL-17 (red)
and CD3 (blue) in human psoriatic skin lesions before (B) and after (B) IL-
4 therapy. The nuclei are stained with YO-PRO. For colorblind-accessible
images, please refer to Supplementary Fig. 9. (D to G) RT-PCR expression of
transcripts encoding IL23A, ATF3, IL17A, and IL12A in psoriatic skin samples
before and after different doses of IL-4 therapy. The expression of the target
gene within psoriasis tissue before treatment (relative to the housekeeping
gene G6PD) was set to 100%, and the expression after treatment is presented
as a percentage of this value. Each dot represents one pair of specimens from
a single study patient; the horizontal bars indicate the means ± SEM. *P <
0.05. **P < 0.01. (H) Ratio of IL23A [% after treatment] to IL12A [% after
treatment] as detected by quantitative real-time PCR in the skin samples from
the study patients treatedwith different doses of IL-4. The data are expressed
as the means ± SEM. *P < 0.05. **P < 0.01. r = Pearson correlation coefﬁcient.
cess, we extended our experiments and generated BM chimeric
mice with a mixed STAT6-/-/MHCII-/-hematopoiesis on a wild
type background (STAT6-/-/MHC II-/-→WT mice), in which IL-
4 signaling was completely abrogated in functional MHCIIpos
APC. TNCB challenge after sensitization of those chimeric mice
resulted in an increased ear swelling comparable to what we
observed in the other two chimeric mouse models (Fig. 4A to
C). However, when we treated the STAT6-/-/MHC II-/-→WTmice
with IL-4, cutaneous inflammation failed to improve, and the ear
swelling was not reduced but remained comparable to that of
STAT6-/-/MHC II-/-→ WT mice not treated with IL-4 (Fig. 4C).
This demonstrates the indispensable role for APC in the reg-
ulatory anti-inflammatory therapeutic effect of IL-4 in DTHR.
Fig. 4D presents schematically the experimental approach for the
generation of the bone marrow chimeric mice.
IL-4-mediated suppression of IL-23 is partly mediated through
ATF3
ATF3 is a repressor of il6, but also tnf and il23b transcription
in TLR4-stimulated macrophages (35, 36). ATF3 blocks il23b
transcription by binding to repressive promotor elements near
the genes coding for the il23b subunit in macrophages and pos-
sibly other APC, such as DC (35, 37). Because IL-4 significantly
suppresses il23b transcription (Fig. 1C), we assessed whether the
effects of IL-4 could be at least partially mediated through ATF3.
Indeed, IL-4 markedly upregulated ATF3 mRNA expression and
protein production in murine and human dendritic cells, and
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in murine RAW264.7 cells (Fig- 5A to D). To determine the
functional relevance of ATF3 on IL-23 production, we stimulated
DC from either wt or ATF3-/- mice with LPS, and assessedmRNA
expression and production of IL-23. Even in the absence of IL-4,
ATF3-deficient DC produced higher amounts of IL-23 than wt-
DC, and IL-4 significantly further suppressed transcription and
production of IL-23 only in the ATF3-competent, but not in the
ATF3-deficient DC (Fig. 5E). In line with this, IL-4 significantly
reduced the TNCB-mediatedDTHR inwtmice but not inATF3-/-
mice (Fig. 5F).
IL-4 therapy of psoriasis abrogates intralesional IL-23 and IL-
17 in human skin
IL-4 suppresses IL-23 production in mouse and human DC,
and abrogates their capacity to induce/maintain TH17 responses.
Moreover, rmIL-4 suppresses DTHR by suppressing IL-23 and
downstream IL-17 during contact hypersensitivity in mice. We
therefore asked whether this mode of immune suppression also
translates to human autoimmune diseases, namely psoriasis,
which is a disease that is strongly improved by IL-4 therapy or
the mAb-mediated blockade of either IL-17 or IL-23 (38-40).
To this end, we studied a unique population of psoriasis patients
who had successfully been treated with increasing doses of sys-
temically applied IL-4. Consistent with recent data (41, 42), il23a
and il17a mRNA were both increased in psoriasis skin lesions
(Fig. S5A). Confocal laser scanning microscopy co-localized the
abundant IL-23 protein with HLA-DR-expressing APC, and the
IL-17 protein with CD3+ T cells (Fig. S5B and fig. S6A and
B) in psoriasis plaques, but not in healthy skin (Fig. S7 and fig.
S8). In addition to TH1 and TH17 cells, the psoriasis plaques
contained numerous polymorphonuclear cells and, thus, share
many similarities with the TNCB-induced DTHR. Because IL-4
therapy strongly improves psoriasis without suppressing IFN-γ-
expressing T cells in the peripheral blood (20), we asked whether
IL-4 therapy might improve psoriasis by suppressing IL-23- and
IL-17, driving the TH17-response. We examined the effect of IL-
4 therapy on the expression and production of IL-17/IL-23 in
a cohort of 22 psoriasis patients (i.e. 19 patients, 3 drop-outs).
The study was designed as a dose-escalation study, where patients
were treated for psoriasis systemically with increasing doses of
IL-4 over 6 weeks. The therapy was initiated with either 0.05, 0.1,
0.2, 0.3 or 0.5 μg/kg of IL-4, and increased to the next level after
three weeks, except in the last group (20). Systemic IL-4 ther-
apy significantly improved psoriasis in a dose-dependent manner
and normalized the skin morphology (20) (see also Fig. 6A).
Cryopreserved tissue sections of these study patients revealed
that untreated psoriasis plaques contained abundant IL-23 that
co-localized with HLA-DR-expressing APC and abundant IL-17
protein that co-localized with CD3+ T cells (Fig. 6B and fig. S9A).
After 6 weeks of IL-4 therapy, both IL-23 and IL-17 protein were
almost undetectable (Fig. 6C and fig. S9B), suggesting that IL-4
therapy suppressed IL-23 and IL-17 production also in human
skin. We further analyzed the tissue samples from the study pa-
tients for the expression of il17a, atf3, il23a or il12a mRNA. The
dose-escalation design of the study allowed us to correlate local
mRNA changes for each of the three cytokines (i.e. IL17a, IL23a
and IL12a) and of the transcription factor ATF3 with the IL-4
treatment dose. IL-4 therapy suppressed il23amRNA expression
in a dose-dependent manner, with 20% suppression at 0.05 μg/kg
IL-4 and almost 90% suppression at 0.5 μg/kg of IL-4 (Fig. 6D).
Similarly, we detected a dose-dependent upregulation of ATF3
expression in the analyzed tissue (Figure 6E). Consistent with
the il23a mRNA suppression, IL-4 therapy dose-dependently
suppressed il17a mRNA expression (Fig. 6F). As predicted by
the in vitro and animal data shown above, IL-4 therapy increased
il12amRNA expression in human skin during the 6 weeks of IL-4
therapy (Fig. 6G). Finally, at low concentrations, IL-4 induced an
IL23A/IL12A ratio of >1 (1.7 at 0.05 µg/kg IL-4), but at high IL-
4 concentrations, IL-4 therapy induced a very low IL23A/IL12A
ratio (0.05 at 0.5 µg/kg IL-4), a finding that could be important for
the design of future IL-4 treatment regimens in humans (Figure
6H).
Discussion
IL-4 reverts both TH1 and TH17 cell-mediated pathology and that
this effect is associated with the induction of IL-4-producing TH2
cells in mice and humans (5, 16-20). The underlying mechanism
was attributed to inhibition and replacement of pathologic TH1
and TH17 cells and their respective cytokines by TH2 cells and
IL-4. However, this concept fails to completely explain the thera-
peutic effects observed, because IL-4 exerts opposing regulatory
effects on T cells and DC; IL-4 abrogates IFN-γ induction upon
direct interaction with T cells (43-45). In contrast, IL-4 promotes
IL-12 production by DC, thus indirectly promoting IFN-γ pro-
duction in mice and humans (46-48). Importantly, these effects
are not exclusive; IL-4 and IL-4-producing TH2 cells efficiently
improve established TH1/TH17 mediated inflammation in mice
and humans while enhancing both IL-12 and IFN-γ (19, 20).
These phenomena are highly suggestive of a regulatory mech-
anism whereby IL-4 selectively prevents TH17 immunity, while
sparing IL-12/TH1 immunity.
We addressed this question by analyzing in detail the effect
of IL-4 on the regulation of IL-23 and TH17 cells. Starting with
human DC subsets, we found that IL-4 had exactly opposing
effects on IL-12 and IL-23. While IL-4 induced IL-12, it abol-
ished the induction of IL-23 and abrogated the capacity of DC
to maintain TH17 but not TH1 cells. Our observations are in line
with reports suggesting different roles of IL-4 on DC-derived
IL-12 and IL-23 (49-52), but go far beyond the former studies.
We confirmed the biological relevance of this regulation in an
in vivo experimental setting and demonstrated that IL-4 therapy
could abrogate cutaneous inflammation in the elicitation phase
of DTHR. In extensive bone marrow reconstitution experiments
we elucidated the effects of IL-4 on the different immune cells
and could demonstrate the selective mode of action of IL-4 on
APC. This is important because our data show for the first time
that antigen presenting innate immune cells are indispensable
for the immunosuppressive effect of IL-4 therapy. Activation
of APC in an IL-4-deprived or IL-4-dominated inflammatory
milieu dictated their capacity to orchestrate TH17 induction,
which supports previous data suggesting that the amount of IL-
4 ultimately determines whether immune responses promote or
attenuate inflammatory autoimmune diseases (46, 53).
Psoriasis is characterized by the absence of IL-4, and both
TH1 and TH17 cells prevail in the skin (11). However, the exact
roles of either TH1 or TH17 cells remain to be defined. Our
data have identified a sequence of immunological events, trig-
gered by IL-4 that selectively impaired the IL-23/IL-17 axis and
relieved TH17-mediated pathology, while promoting IL-12 and
TH1 cytokines. This is relevant since IL-23, but not IL-12, also
mediates inflammation in the absence of T cells (15), at least
under experimental conditions, and via intracutaneous injection
induces a psoriasis-like skin disease inmice (43). Our data further
showed that IL-4 indirectly prevented the maintenance of IL-17-
producing TH17 cells by abrogating the expression and produc-
tion of the TH17 cell-associated cytokine IL-23 in APC. Together
with our data, the high degree of efficacy of the anti-IL-12/IL-
23p40 monoclonal antibody in the treatment of psoriasis further
emphasizes the crucial role for IL-23 in disease progression (54,
55). These findings do not exclude a role for IL-12, TH1 cells or
TH1 cytokines in psoriasis but rather confirm that the therapeutic
silencing of IL-23 (for example by IL-4 or newly engineered IL-
4 superkines, currently under investigation) (56) is promising for
psoriasis and other TH17/IL-23-associated autoimmune diseases.
Materials and Methods
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Reconstitution experiments.
Tcrb-/-Tcrd-/- (Tc-/-) mice, STAT6-/- mice and CD45.2+C57BL/6 mice were
purchased from the Jackson Laboratory (Bar Harbor, Maine 04609 USA).
MHCII-/-mice were a gift from Ludger Klein, Institute of Immunology, Lud-
wig Maximillian University, Munich, Germany. Recipient mice were lethally
irradiated at 7.0 Gy and bone marrow cells (106 cells per recipient) of donor
mice were intravenously injected into recipient mice. Donor hematopoietic
cells were either bonemarrow cells from CD45.1+ mice, a 1:1 mixture of bone
marrow cells from STAT6-/- and Tc-/- mice, or a 1:1 mixture of STAT6-/- and
MHCII-/-mice. To conﬁrm the chimerism of mice, ﬂow cytometry was made
for analysis of CD45.2+ (recipient mice) and CD45.1+ (donor mice). TNCB
sensitization experiments were performed eight weeks after irradiation.
A detailed description of all experimental procedures and the statistical
analysis is given in SI Materials and Methods.
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Abstract  30 
The interplay between microbes and surface organs such as skin shapes a complex 31 
immune system with several checks and balances. The first line defense is mediated 32 
by innate immune pathways leading to inflammation. The second phase consists of 33 
specific T cells invading the infected organ amplifying inflammation and defense. 34 
Consecutively, termination of inflammation is crucial to avoid chronic inflammation 35 
triggered by microbes such as in atopic dermatitis. Here we aimed to elucidate how 36 
Staphylococcus-derived cell wall component lipoteichoic acid (LTA) governs the 37 
second phase of immune responses when high levels of LTA on a disrupted skin 38 
barrier allow T cells direct exposure to LTA. Surprisingly we found that LTA potently 39 
suppressed T lymphocyte activation in a TLR independent manner. LTA-exposed T 40 
cells failed to proliferate and to produce cytokines. Importantly, these T cells 41 
remained completely viable and were susceptible to consecutive activation signals in 42 
the absence of LTA. Thus, LTA exposure of T cells resulted in temporary functional T 43 
cell paralysis. In vivo experiments revealed that T cell cytokine production and 44 
cutaneous recall responses were significantly suppressed by LTA. Thus, we 45 
identified a new mechanism of how bacterial compounds temporarily and directly 46 
modulate adaptive immune responses.  47 
  
4
Introduction 48 
Surface organs such as the skin developed under the pressure of constant exposure 49 
to microbes and microbial products. As a consequence, a highly complex and 50 
regulated immune system evolved conserving the integrity of both the surface organ 51 
as well as of the whole organism. 52 
Cutaneous infection, on the one hand, was shown to very effectively induce adaptive 53 
immune responses even allowing the first vaccination strategy to successfully 54 
eradicate vaccinia virus (Tian et al., 2009). On the other hand, chronic inflammatory 55 
diseases of the gut such as Crohn’s disease or of the skin such as atopic dermatitis 56 
(AD) are believed to be triggered by microbes (Bieber, 2008; Kaesler et al., 2014; 57 
Lipinski and Rosenstiel, 2013) and to be mediated by T cells, which migrate into the 58 
gut or skin to initiate and maintain the inflammatory process (Akdis et al., 2006; 59 
Boguniewicz et al., 2003; Kapp et al., 2002; Mosli et al., 2014). Interestingly, clinically 60 
unaffected skin of AD patients already contains a sparse perivascular T cell infiltrate 61 
in the absence of detectable signs of dermatitis (Leung et al., 1983; Mihm et al., 62 
1976). In addition, analyses of biopsy samples from clinically unaffected skin of AD 63 
patients, as compared with normal non-atopic skin, demonstrate an increased 64 
number of type 2 helper T cells (Th2) expressing IL-4 and IL-13 mRNA (Hamid et al., 65 
1994).  66 
S. aureus most commonly elicits skin, wound, and also systemic infections being a 67 
major pathogen in both community-acquired and nosocomial infections (Fournier and 68 
Philpott, 2005; Myles and Datta, 2012). These and even minor infections lead to 69 
specific elicitation of S. aureus-specific adaptive immune responses in most people 70 
inducing also long-lived immune memory (Broker et al., 2014). More than 90% of 71 
patients with AD show Staphylococcus aureus colonization or infection, S. aureus 72 
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and S. aureus-derived substances were shown to trigger skin inflammation, and 73 
effective treatment protocols for these patients include antiseptics (Leung and Bieber, 74 
2003). The presence of microbes on the skin may elicit or increase an immune 75 
response and constituents of S. aureus may function as a pro-inflammatory adjuvant. 76 
Pathogen-associated molecular patterns (PAMPs) may activate resident skin cells 77 
such as dendritic cells of the skin (Nakamura et al., 2013; Volz et al., 2012). Such 78 
PAMPs have been identified for S. aureus. Lipoteichoic acid (LTA), lipoprotein, and 79 
peptidoglycan (PG) are part of the bacterial cell wall of S. aureus and bind Toll-like 80 
receptor (TLR) 2, which is expressed by several immune cells also within the skin 81 
(Akira et al., 2006; Biedermann, 2006; Lipinski and Rosenstiel, 2013; Tian et al., 82 
2009). 83 
Recent researches showed that S. aureus found in infected dermatitis lesions leads 84 
to the presence of LTA in the majority of specimens with levels of LTA positively 85 
correlating with the concentration of S. aureus (Travers et al., 2010; Zhang et al., 86 
2005). We recently showed in a mouse model of AD that TLR2 ligands potently 87 
exacerbate inflammation leading to chronic dermatitis (Kaesler et al., 2014). These 88 
findings are in line with data from other models of AD, in which the development of 89 
skin lesions often depends on conventional housing conditions for the animals. 90 
Animals fail to develop dermatitis lesions when kept in specific pathogen free (SPF) 91 
conditions also indicating a role for microbes and PAMPs for AD (Akdis et al., 2006). 92 
On the other hand, we showed that cutaneous microbes were able to ameliorate AD 93 
inflammation by inducing regulatory T cells and IL-10 (Volz et al., 2013). Moreover, 94 
our group discovered recently that activation of TLR2/6 on the skin led to immune 95 
suppression mediated by myeloid-derived suppressor cells (MDSCs) (Skabytska et 96 
al.). Thus, different mechanisms to terminate and limit inflammation can be 97 
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developed to avoid tissue damage or as immune escape of microorganisms. 98 
Interestingly, among TLR2 ligands, exacerbation and persistence of the early phase 99 
of cutaneous inflammation was most potently induced by lipopeptides such as 100 
Pam2Cys with LTA showing significant but much weaker effects on skin inflammation 101 
(Kaesler et al., 2014). LTA is a surface-associated adhesion macroamphiphile 102 
molecule of Gram-positive bacteria. It is released from the bacterial cells after 103 
bacteriolysis and as a consequence of bacterial cell wall turn over (Ginsburg, 2002). 104 
The physiochemical properties of LTA were postulated to be similar to those of 105 
lipopolysaccharide (LPS) in Gram-negative bacteria (Fournier and Philpott, 2005). 106 
Most prominently, concentrations of about 10 g/ml LTA from S. aureus and more 107 
were shown to stimulate the production of multiple pro-inflammatory cytokines and 108 
chemokines in different leukocytes, especially in macrophages and monocytes 109 
(Cleveland et al., 1996; Kapp et al., 2002; Standiford et al., 1994; von Aulock et al., 110 
2003). Peptidoglycan from S. aureus has been shown to provoke secretion of pro-111 
inflammatory cytokines and chemoattractants (TNF-, IL-1, IL-6, and CXCL8) from 112 
monocytes, macrophages as well as dendritic cells (Heumann et al., 1994; 113 
Timmerman et al., 1993; Volz et al., 2010). Thus, it is clear that LTA can activate the 114 
innate immune system, but direct effects on the adaptive immune system were not 115 
studied in detail. The purpose of this research was to study the properties of Gram-116 
positive cell wall component LTA in regard to T lymphocyte function. 117 
In this study, we show that limited exposure to LTA during initial contacts to 118 
fluorescein isothiocyanate (FITC) significantly suppressed lesional T cell cytokine 119 
expression. The proliferation of T cells from the draining lymph nodes of LTA-120 
exposed skin was also significantly reduced. Moreover, LTA also significantly 121 
suppressed T cell proliferation in vitro, which was independent of TLR2 signaling. 122 
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Those LTA-exposed T cells were viable and LTA exposure did not induce T cell 123 
apoptosis. To investigate whether T cell suppression by LTA is a pathway with in vivo 124 
relevance, FITC contact hypersensitivity (CHS) and ovalbumin (OVA)-induced 125 
dermatitis as models for Th2-mediated cutaneous inflammation in AD patients were 126 
investigated. LTA potently suppressed both FITC CHS and OVA-induced dermatitis 127 
independent of TLR2. To summarize, T cell-mediated immune responses are 128 
susceptible to LTA-induced immune suppression. These newly discovered 129 
consequences of LTA exposure may be functional following effective immune 130 
defense of S. aureus allowing the termination of inflammation or represent another 131 
way of immune escape of S. aureus. Importantly, this LTA induced T cell paralysis is 132 
temporary in nature avoiding prolonged periods of immune suppression. 133 
 134 
Results 135 
LTA exposure during mild cutaneous inflammation suppressed T cell cytokine 136 
levels and T cell proliferation 137 
Chronic inflammatory diseases of the skin such as AD are believed to be triggered by 138 
microbes. We wondered whether TLR2 ligands are capable to transform non-lesional 139 
skin with a detectable but sparse T cell infiltrate as found in AD patients (Leung et al., 140 
1983; Mihm et al., 1976) into overt dermatitis. Contact hypersensitivity to the hapten 141 
FITC following up to six repetitive sensitizations with FITC is associated with FITC-142 
specific immunoglobulin (Ig) E and Th2 cells (Supplementary Figure S1). We now 143 
established a model, in which the weak hapten FITC was applied only twice to the 144 
shaved abdomen of mice before a FITC challenge at the ear skin was carried out. In 145 
this model, no obvious ear swelling was detectable following the last FITC challenge 146 
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(Supplementary Figure 2). However, T cell recruitment to the skin can be identified 147 
with T cell cytokines significantly upregulated already 4-8 hours after challenge (data 148 
not shown). Moreover, FITC-specific T cells were readily detectable in these mice. 149 
Thus, this model of mild T cell inflammation is ideal to identify microbial constituents 150 
that trigger and therefore amplify cutaneous inflammation. However and much to our 151 
surprise, exposure to up to 40 µg LTA could not significantly amplify ear swelling in 152 
mildly FITC-sensitized animals. Therefore we investigated the dynamics of T cell 153 
cytokine expression in animals exposed to either LTA or PBS (Figure 1a). At 8 hours 154 
after challenge, cutaneous IL-4 mRNA expression was suppressed by >10 fold 155 
following exposure to LTA, IFN- mRNA levels were reduced by a factor of 3, and IL-156 
10 expression was unchanged compared to controls (Figure 1b). To identify 157 
functional consequences of LTA exposure in vivo, draining lymph nodes were 158 
prepared at several time points following FITC +/- LTA exposure and subjected to 159 
further analyses. Ex vivo stimulation of T cells with anti-CD3 and anti-CD28 160 
antibodies (Abs) as well as with FITC demonstrated significantly reduced T cell 161 
proliferation (Figure 1c) indicating consequences of LTA exposure on both FITC-162 
specific T cells and T cell bystanders. 163 
 164 
LTA directly suppressed CD4+ T cell proliferation and cytokine production in 165 
vitro 166 
In order to identify whether LTA mediated immune suppression by directly targeting T 167 
cells, CD4+ T cells were isolated from untreated BALB/c mice and activated by anti-168 
CD3/anti-CD28 Abs in vitro. These T cells were then treated with TLR2 ligands 169 
Pam2Cys, staphylococcal LTA, or control medium. Pam2Cys dose dependently 170 
acted as potent T cell co-stimulator reaching a maximum at 10 µg/ml confirming data 171 
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previously published (Okusawa et al., 2004) (Figure 2a). In contrast, at the same 172 
concentration of 10 µg/ml LTA significantly suppressed T cell proliferation (Figure 173 
2a). Moreover, increasing LTA concentrations further increased T cell suppression, 174 
almost completely abrogating T cell proliferation at 100 µg/ml (Figure 2a). As these 175 
experiments were performed with murine T cells, we next investigated human T cells. 176 
Human CD4+ T cells were isolated from peripheral blood mononuclear cells (PBMCs) 177 
and then stimulated under several conditions including different concentrations of 178 
staphylococcal LTA for 3 days. LTA most potently inhibited human T cell activation 179 
elicited by TCR activation as with anti-CD3 and anti-CD28 Abs and superantigen 180 
(Figure 2b). Interestingly, LTA also blocked human T cell activation induced by 181 
mitogens albeit with less potency (Figure 2b). Importantly, LTA not only affected T 182 
cell proliferation but most potently also inhibited T cell cytokine production, such as 183 
IFN- and IL-4 in murine (Figure 2c) and human T cells (data not shown). 184 
These data indicate that S. aureus-derived LTA can potently block T cell activation 185 
and thereby represent one mechanism of immune evasion. However, skin microbiota 186 
such as S. epidermidis that is tolerated by the host in most circumstances also 187 
contains large quantities of LTA. Therefore, for comparison, LTA was isolated from 188 
both pathogenic S. aureus and non-pathogenic S. epidermidis and analyzed in 189 
regard to T cell suppression. LTA from both, S. aureus and S. epidermidis potently 190 
suppressed T cell activation indicating a general effect of this class of PAMPs (Figure 191 
2d). 192 
 193 
Paralysis but not apoptosis or necrosis in LTA exposed Th cells 194 
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One possible explanation for LTA-mediated reduction of Th cell cytokine production 195 
or proliferation could be apoptosis of T cells following LTA exposure. To this end, Th 196 
cells were stained with Annexin V and propidium iodide (PI) following exposure to 197 
LTA. Surprisingly, LTA exposed Th cells exhibited even less Annexin V staining and 198 
PI uptake (Figure 3a) and no increase in trypan blue staining (data not shown) 199 
compared to control T cells. Thus, these Th cells seemed to be completely viable 200 
following LTA exposure. To further demonstrate Th cell viability, CD4+ T cells were 201 
activated in vitro by anti-CD3/anti-CD28 and exposed to LTA for 4 days. Thereafter 202 
Th cells were cultured with low concentration of IL-2 until resting and then stimulated 203 
in the absence of bacterial constituents. In contrast to the primary stimulation, Th 204 
cells, previously exposed to LTA, readily responded to anti-CD3/anti-CD28 Abs 205 
treatment. These data demonstrate that these Th cells completely recovered from the 206 
exposure to LTA (Figure 3b). Thus, Th cells exposed to LTA were viable and 207 
remained fully responsive to subsequent stimulation. This indicated that LTA-208 
mediated suppression could be only temporary reflecting a status of transient Th cell 209 
paralysis. 210 
 211 
LTA-induced suppression of Th cell activation independent of TLR2 and MyD88 212 
Next, we analyzed whether LTA functions only during incoming TCR signals as it is 213 
expected for TLR2 ligands acting as T cell costimulators. Therefore, Th cells were 214 
activated by anti-CD3/anti-CD28 Abs and LTA or Pam2Cys were added 215 
subsequently up to 3 days following activation. As expected, the costimulatory role of 216 
Pam2Cys was only functional in parallel to T cell TCR activation (Figure 4a). In sharp 217 
contrast, LTA was functional up to 48 hours following Th cells activation indicating a 218 
mechanism of action independent of TCR signaling (Figure 4a). Consequently, we 219 
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assumed that LTA is functional via structures different from TLRs. To this end, wild 220 
type, TLR2-/-, and MyD88-/- CD4+ T cells were isolated from untreated mice and 221 
analyzed. LTA suppressed activation of Th cells from all three strains, whereas 222 
costimulation by Pam2Cys was dependent on TLR2 and MyD88 (Figure 4b). 223 
 224 
LTA induced cell cycle arrest in activated T cells 225 
Transforming growth factor- (TGF-) inhibits T cell proliferation (Kehrl et al., 1986) 226 
through mechanisms directly targeting cell cycle regulators (Datto et al., 1995; 227 
Hannon and Beach, 1994; Polyak et al., 1994). The normal cell cycle is composed of 228 
the gap 1 phase (G1), the synthesis phase (S), the gap 2 phase (G2), and the mitosis 229 
phase (M). In the S phase, DNA replication occurs and cells at G2 and M phases of 230 
the cell cycle have double the DNA content of those at G0 and G1 phases. DNA 231 
content of cells at S phase is between that of cells in G2/M and G0/G1 phases. To 232 
better understand the underlying mechanisms of LTA mediated Th cell suppression, 233 
consequences of LTA exposure on cell cycle regulation were investigated. In fact, 234 
only 6% of LTA-treated CD4+ T cells were found at the S or G2/M phases (Figure 235 
5a), whereas 25% of the control cells were. In contrast, Pam2Cys-stimulated T cells 236 
were prone to divide. As control, we also treated Th cells with TGF- and most of 237 
these TGF--treated Th cells also remained at G1 phase as previously published 238 
(Kehrl et al., 1986) (Figure 5b). Thus, these data further consolidated the suppressive 239 
effect of LTA exposure on Th cells and provided an explanation why this suppressive 240 
effect of LTA i) was also functional when adding LTA at later time points, ii) was 241 
functional in the absence of apoptosis and necrosis, and iii) was transient allowing 242 
normal activation of T cells following a period of resting. 243 
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 244 
LTA suppressed T cell-mediated FITC-induced inflammation and OVA-245 
dermatitis in vivo 246 
To investigate whether LTA-mediated suppression of T cells is also functionally 247 
relevant in vivo, we next analyzed models of T cell-mediated cutaneous inflammation. 248 
To this end, we adoptively transferred CD3+ T cells from FITC-sensitized mice into 249 
mice treated as indicated in Figure 1a to increase FITC-specific T cells. The next day, 250 
recipients were challenged with FITC or vehicle control and exposed to either LTA or 251 
PBS in addition. Interestingly, when challenged with vehicle only, in the absence of 252 
antigen, LTA elicited an ear swelling response indicating direct pro-inflammatory 253 
effects of LTA, however, in the presence of antigen and T cell activation, LTA 254 
significantly reduced cutaneous inflammation (Figure 6a), confirming our data on 255 
inhibition of T cell activation in vivo. These data indicate that LTA may function as a 256 
TLR2 ligand on skin resident cells activating the innate immune system and leading 257 
to inflammation. In contrast, T cell-dependent contact hypersensitivity is significantly 258 
suppressed, possibly by a TLR2 independent effect. However, pro-inflammatory and 259 
immune suppressive consequences of LTA exposure may partly compensate for 260 
each other in this model. To be able to dissect TLR2-dependent from TLR2-261 
independent effects of LTA and innate from T cell-mediated immune consequences, 262 
we used another AD-like mouse model as recently published (Kaesler et al., 2014). In 263 
this model, we adoptively transferred OVA-specific Th2 cells and antigen to the ear 264 
skin of previously untreated wild type and TLR2-/- mice and monitored the T cell 265 
driven ear swelling response in the presence or absence LTA. Interestingly and 266 
confirming our hypothesis, in the absence of TLR2 LTA profoundly suppressed OVA-267 
specific dermatitis (Figure 6b). These data elucidate how the host immune system 268 
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fine tunes the response to microbial PAMPs. The early innate response is mediated 269 
by pathogen recognition receptors and results in inflammation, whereas the later and 270 
T cell-mediated immune response is susceptible to immune suppression allowing the 271 
termination of inflammation. Importantly, the latter is transient in nature avoiding 272 
prolonged periods of immune suppression. 273 
 274 
Discussion 275 
The concentrations of LTA encountered by host cells during bacterial infections are 276 
likely to be quite high at local sites of infection. For example, the 50% lethal dose of 277 
live S. aureus in an intraperitoneal infection model in mice is 109 CFU (Dziarski et al., 278 
2003), and this amount of S. aureus contains about 200 µg of LTA in the peritoneal 279 
cavity fluid that is <0.1 ml. While LPS in the ng/ml range is sufficient to trigger even 280 
severe inflammatory responses (Hoetzenecker et al., 2011; Kusunoki et al., 1995), it 281 
has been shown that relatively large amounts of LTA (about 1~10 g/ml) are required 282 
to elicit cellular responses in vitro (Fournier and Philpott, 2005). However, LTA is a 283 
major component of Gram-positive bacterial cell wall, whereas bacterial cell walls of 284 
Gram-negative harbor much less LPS. The active concentrations of LTA (10 µg or 285 
107 to 108 CFU) as well as of LPS (20 ng or 107 CFU) are comparable when they are 286 
transposed to bacterial cell equivalents (von Aulock et al., 2003). 287 
LTA from Staphylococcus aureus is a potent stimulus for neutrophil recruitment 288 
through stimulating the production of cytokines and chemokines in macrophages and 289 
monocytes (Standiford et al., 1994; von Aulock et al., 2003). Following the induction 290 
of innate immune signals activation of the adaptive immunity is functional (Medzhitov, 291 
2007). Previous studies showed that LTA merely played the pro-inflammatory role on 292 
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the host immune system, especially on the innate immunity, and thus the notion that 293 
LTA was the ‘’LPS’’ of Gram-positive bacteria was proposed. However, as a result of 294 
thousands of years of coexistence with human, S. aureus is a well adapted pathogen 295 
that has developed several evasion mechanisms. This organism secretes proteins 296 
that inhibit complement activation and neutrophil chemotaxis or that lyse neutrophils, 297 
neutralizes antimicrobial defensin peptides, and its cell surface is modified to reduce 298 
effectiveness of immune responses (Lowy, 2011). S. aureus can survive in 299 
phagosomes, express polysaccharides and proteins that inhibit opsonization by 300 
antibody and complement, and its cell wall is resistant to lysozyme. Moreover, S. 301 
aureus expresses several types of superantigen, which disturb the normal humoral 302 
immune response, resulting also in anergy, apoptosis, and immunosuppression 303 
(Foster, 2005; Kaesler et al., 2012; Rooijakkers et al., 2006). It has also been 304 
reported that bacterial components from S. aureus inhibited fibroblast proliferation in 305 
vitro (Edds et al., 2000). In addition, LTA isolated from S. aureus was demonstrated 306 
to inhibit platelet function and platelet-monocyte aggregation (Sheu et al., 2000). Not 307 
only pathogens like S. aureus, but also parts of the normal microbiome like S. 308 
epidermidis contain LTA. Furthermore, S. aureus sometimes lives as a commensal of 309 
the human skin. Recently, it was shown that a unique LTA produced by S. 310 
epidermidis inhibits uncontrolled skin inflammation during skin injury (Lai et al., 2009). 311 
After skin injury, the host RNA from damaged cells activates TLR3 in the 312 
keratinocytes, which accounts for the release of inflammatory cytokines, resulting in 313 
inflammation. Staphylococcal LTA inhibits both inflammatory cytokine release from 314 
keratinocytes and inflammation triggered by injury through a TLR2-dependent 315 
mechanism (Lai et al., 2010). However, how the known pro-inflammatory 316 
macroamphiphile molecule works directly on adaptive immune cells was still 317 
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unknown. Functional TLR2 expression on T cells were demonstrated by other groups 318 
(Komai-Koma et al., 2004; Reynolds et al., 2010), and Bacteroides fragilis signals 319 
through TLR2 on Foxp3+ regulatory T cells promoting immunologic tolerance (Round 320 
et al., 2011). It is therefore reasonable to postulate that LTA can exert its modulatory 321 
effect directly on adaptive immunity. 322 
In our current study, we demonstrate that the application of Staphylococcus aureus 323 
derived cell wall component LTA most potently suppressed T lymphocyte activation, 324 
the late phase of defense. This suppression was independent of TLR signaling and 325 
functional by means of transient cell cycle arrest. Thus, we identified a novel 326 
mechanism of how bacterial compounds temporarily directly modulate the adaptive 327 
immune system. This new mechanism of T cell paralysis may be functional to 328 
terminate inflammation such as in Gram-positive infection or during immune evasion 329 
of pathogenic bacteria representing another level of regulation of the complex 330 
interplay between microbes and the host. 331 
 332 
Materials and Methods 333 
Animals 334 
Pathogen-free, 6- to 12-week-old wild type BALB/c mice and C57BL/6 mice were 335 
purchased from Charles River (Sulzfeld, Germany). MyD88-/- BL/6 were from Akira’s 336 
group (Osaka, Japan), TLR2-/- mice were from C. Kirschning (Institute of Medical 337 
Microbiology, University Duisburg-Essen). All wild type and knockout mice were kept 338 
and bred under specific pathogen free conditions in accordance with the guidelines of 339 
FELASA (Federation of European Laboratory Science Association) in the animal 340 
facility of Eberhard Karls University. Age-matched female mice were used in all 341 
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experiments. All animal experiments were in compliance with both European Union 342 
and German law and approved by the local authorities (HT1/10). 343 
 344 
Reagents 345 
Fluorescein isothiocyanate (FITC), 2-mercaptoethanol, phorbol 12-myristate 13-346 
acetate (PMA), ionomycin, concanavalin A (con A), and staphylococcal enterotoxin B 347 
(SEB) were purchased from Sigma-Aldrich (Taufkirchen, Germany). Purified LTA 348 
from Staphylococcus aureus was obtained from InvivoGen (San Diego, USA). 349 
Purified LTA from Staphylococcus epidermidis was a gift from Porf. Hartung 350 
(Konstanz, Germany). Pam2Cys and Pam3Cys were from EMC microcollections 351 
(Tübingen, Germany). DMEM, RPMI 1640, penicillin/streptomycine, L-glutamine, 352 
sodium-pyruvate, MEM-amino acids (50X) and HEPES were from Biochrom (Berlin, 353 
Germany). Fetal calf serum (FCS) was from PAA (Cölbe, Germany). PBS (w/o Ca2+, 354 
Mg2+) were from Gibco/Invitrogen (Karlsruhe, Germany). ACK lysis buffer was from 355 
Cambrex (Walkersville, USA). Endotoxin-free ovalbumin was purchased from Hyglos 356 
(Bernried, Germany). Streptavidin-horseradish peroxidase and TMB-substrate 357 
solution were from BD Biosciences (Heidelberg, Germany). 358 
 359 
FITC-induced antigen-specific contact hypersensitivity 360 
6- to 12-week-old wild type female BALB/c mice (5 to 6 mice per group) were 361 
sensitized by administration of 0.5% FITC solution (dissolved in 1:1 acetone:dibutyl 362 
phthalate) on the shaved abdomen on days 0, 1. Six days after the last sensitization 363 
all mice were challenged by application of 0.5% FITC solution on both sides of the 364 
ears. Ear thickness was measured thereafter with a micrometer (Kroeplin, Germany) 365 
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and data are expressed as change in ear thickness compared to before treatment. 366 
Draining lymph node cells were cultured with FITC or anti-CD3 and anti-CD28 367 
antibodies for another 3 days. Cell culture supernatants were collected and subjected 368 
to ELISA. 369 
 370 
Real-time reverse transcriptase polymerase chain reaction (RT-PCR) analysis 371 
Total RNA from mouse ears was isolated using the Macherey-Nagel isolation kit 372 
(Düren, Germany). Total RNA was reverse-transcribed to cDNA by using the iScript 373 
cDNA Synthesis Kit (Bio-Rad, Munich, Germany). The oligonucleotide primer 374 
sequences were as follows: IFN- forward primer, 5’- 375 
CTCTGAGACAATGAACGCTAC-3’, and IFN- reverse primer, 5’- 376 
TCTTCCACATCTATGCCACTT-3’; IL-4 forward primer, 5’-377 
GACGGCACAGAGCTATTGATG-3’, and IL-4 reverse primer, 5’-378 
ACCTTGGAAGCCCTACAGACG-3’; IL-10 forward primer, 5’-379 
CAACATACTGCTAACCGACTC-3’, and IL-10 reverse primer, 5’- 380 
CATTCATGGCCTTGTAGACAC-3’. Real-time PCR assay was carried out with 381 
iCycler (Bio-Rad) by using iQ SYBR Green Supermix (Bio-Rad). Data are presented 382 
as normalized to housekeeping gene hypoxanthine phosphoribosyl transferase 383 
(HPRT). 384 
 385 
Proliferation assays 386 
Whole lymph node cells or CD4+ T cells (250000 cells/well) were activated with 387 
different antigens/antibodies in 96 well flat bottom plates (Greiner, Frickenhausen, 388 
Germany) in a total volume of 200 µl. After 3-4 days 0.25µCi [3H] thymidine (GE 389 
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Healthcare, Freiburg, Germany) was added per well and cells were harvested after 390 
another 16 hours. Incorporated [3H] thymidine was measured using a microbeta 391 
counter (Perkin Elmer, Wiesbaden, Germany). 392 
 393 
CD4+ T cell isolation and stimulation for in vitro experiments 394 
Lymph nodes and spleens of untreated mice were isolated and lymphocytes were 395 
prepared by homogenizing organs through a nylon mesh cell strainer. Red blood 396 
cells were lyzed by incubating with ACK lysis buffer for 5 minutes. Cells were washed 397 
twice and CD4+ T cells were purified using a CD4+ isolation kit from Miltenyi Biotech 398 
(Bergisch Gladbach, Germany). Human CD4+ cells were isolated from peripheral 399 
blood mononuclear cells, which were obtained from heparinized blood samples from 400 
healthy volunteers by density gradient centrifugation (800 g for 30 min). CD4+ T cells 401 
were resuspended in DMEM containing 10% heat-inactivated FCS, penicillin (100 402 
U/mL), streptomycine (100 µg/mL), 0,5 mM sodium-pyruvate, 5 mM HEPES, 1% 403 
MEM-amino acids (50X) and 2-mercaptoethanol (50 µM). T cell were stimulated with 404 
presence of 4 µg/ml (murine) or 0.5µg/ml (human) anti-CD3 and 2 µg/ml (murine) or 405 
0.5µg/ml (human) anti-CD28 (Biolegend, San Diego, USA). For some assays 406 
PMA/Iono (1 ng/ml; 500 ng/ml), Con A (2 µg/ml), SEB (4 µg/ml) or TGF- (2ng/ml) 407 
were added. 408 
 409 
Measurement of cytokines 410 
IFN- and IL-4 (BD Biosciences) levels in culture supernatants were assayed using 411 
ELISA kits according to the manufacturer’s instructions. 412 
 413 
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Apoptosis detection 414 
Detection of apoptotic cells and necrotic cells was performed by using the Annexin V 415 
Apoptosis Detection Kit (BD Biosciences). 416 
 417 
Cell cycle analysis 418 
Cell cycle analyses were performed by using the APC BrdU Flow Kits (BD 419 
Biosciences) according to the manufacturer’s instructions. 420 
 421 
Adoptive transfer 422 
FITC CHS model: Naïve mice serving as donors were sensitized by FITC on day -15, 423 
-14, -8, -7, -1, and 0, and on day 6, axillary lymph nodes (LNs), inguinal LNs, and 424 
spleens of these mice were isolated. CD3+ cells were then isolated from secondary 425 
lymphoid organs with Pan T Cell Isolation Kit (Miltenyi Biotec) and transferred into 426 
recipient mice, which were previously sensitized twice with FITC. The next day (day 427 
7) recipients were injected with LTA or PBS and challenged with FITC or vehicle 428 
control. 429 
OVA-dermatitis model: OVA-specific T cells were harvested from OVA-sensitized 430 
mice and expanded in vitro under Th2-promoting conditions. For adoptive transfer 431 
1x106 OVA-specific Th2 cells and 5 µg OVA protein with or without 10 µg S. aureus  432 
LTA were intracutaneously injected into the ear skin of wild type and TLR2-/- BL/6 433 
recipient mice. 434 
Ear thickness was measured with a micrometer and expressed as change in ear 435 
thickness following treatment. 436 
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 437 
Statistical analysis 438 
All experiments were performed at least twice. The data shown are means ± 439 
standard deviations. Statistical analyses were performed with student t-tests (two-440 
tailed) using Microsoft Excel. Differences were considered to be statistically 441 
significant when the p value was less than 0.05. 442 
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Figure legends 644 
Figure 1. Effects of cutaneous LTA exposure on mild cutaneous inflammation. 645 
(a) Mice were sensitized with 80 µl 0.5% FITC onto the shaved abdomen at day 0 646 
and1, and on day 7 mice were challenged by applying FITC onto the ears. Shortly 647 
prior to challenge, LTA or PBS (control) was applied intracutaneously. (b) 8 hours 648 
after FITC challenge cytokine mRNA expression was compared between LTA-649 
exposed and PBS-exposed skin by quantitative RT-PCR (normalized to a 650 
housekeeping gene HPRT, (mean +/- SD of triplicates???). (c) Ear skin draining 651 
lymph nodes were isolated at several different time points after challenge. Cells were 652 
either stimulated ex vivo by FITC or anti-CD3/anti-CD28 Abs for 3 days  and their 653 
proliferation was analyzed as counts per minute (cpm) of 3H-thymidine incorporation 654 
(mean +/- SD of triplicates),  (**: p<0.01, ***: p<0.001). 655 
 656 
Figure 2. LTA exposure suppressed murine and human T cell proliferation and 657 
cytokine production. 658 
(a, b) Proliferation of murine CD4+ T cells isolated from untreated mice (a) or  human 659 
CD4+ T cells isolated from PBMCs (b) was analyzed (mean +/- SD of triplicates) after 660 
stimulation under several conditions: (a) anti-CD3/anti-CD28 Abs and different 661 
concentrations of Pam2Cys or LTA; (b) anti-CD3/anti-CD28 Abs, PMA/Iono, Con A, 662 
SEB and different concentrations LTA. (c) T cell cytokines was analyzed 72 hours 663 
following activation and exposure to LTA. (d) Murine CD4+ T cells were stimulated by 664 
anti-CD3/anti-CD28 Abs and S. aureus LTA, S. epidermidis LTA, or TGF- were 665 
added and the cell proliferation was analyzed (as cpm) (mean +/- SD of triplicates) (*: 666 
p<0.05, **: p<0.01, ***: p<0.001, NS: p>0.05). 667 
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 668 
Figure 3. Unequivocal viability of LTA exposed and control T cells and restored 669 
responsiveness upon re-stimulation in the absence of LTA. 670 
(a) CD4+ T cells exposed to LTA were stained with Annexin V and PI and analyzed 671 
by flow cytometry. LTA-exposed T cells showed Annexin V- and PI-staining 672 
comparable to controls (mean +/- SD of triplicates). (b) CD4+ T cells were primarily 673 
activated by anti-CD3/anti-CD28 Abs and exposed to LTA. These cells were then 674 
washed and rested with 10 U/ml IL-2. Secondary activation was done with anti-675 
CD3/anti-CD28 Abs alone and their proliferation was analyzed (as cpm) (NS: 676 
p>0.05). 677 
 678 
Figure 4. LTA-mediated suppression of CD4+ T cells independent of TLR2 and 679 
MyD88. 680 
(a) CD4+ cells were polyclonally activated for 96 hours. LTA or Pam2Cys was added 681 
on indicated days. Pam2Cys acted as costimulator solely during the phase of T cell-682 
activation. In contrast, LTA exposure suppressed T cell proliferation for up to two 683 
days following T cell activation. (b) CD4+ T cells from wild type, TLR2-/-, and MyD88-/- 684 
mice were polyclonally activated and incubated with different concentrations of 685 
staphylococcal LTA or Pam2Cys for 4 days. Cell proliferation was analyzed (as cpm) 686 
(mean +/- SD of triplicates). The proliferation of the control group of all three strains 687 
was normalized as 100% (*: p<0.05, **: p<0.01). 688 
 689 
Figure 5. Consequences of LTA exposure for cell cycling of T cells. 690 
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CD4+ T cells were stimulated in vitro by anti-CD3/anti-CD28 Abs and different 691 
concentrations of Pam2Cys or staphylococcal LTA were added. Cell cycle analysis 692 
was performed by DNA staining and the amount of DNA was determined by flow 693 
cytometry. A representative FACS plot (a) and means +/- SD (n=3???) (b) is shown. 694 
 695 
Figure 6. LTA exposure suppressed contact hypersensitivity reactions in vivo. 696 
(a) Donor mice were sensitized with FITC 6 times and thereafter CD3+ T cells were 697 
isolated from axillary and inguinal LNs, and spleens. 7.5 x 106 T cells were then 698 
adoptively transferred into recipient mice pre-treated as described for Figure 1a. The 699 
next day, LTA or PBS was intracutaneously applied to the recipient mice, which were 700 
then challenged by FITC or vehicle control. Ear swelling as the consequence of T cell 701 
mediated dermatitis was monitored at 24 hours (mean +/- SD, n=5). (b) OVA-specific 702 
Th2 cells were adoptively transferred together with OVA antigen into naïve recipient 703 
wild type and TLR2-/- BL/6 mice with or without LTA (mean +/- SD, n=5). (*: p<0.05, 704 
**: p<0.01, ***: p<0.001). 705 
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